Funding Opportunities Monthly Edition
May 2020 Due Dates
Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in May 2020. The opportunities are organized in the following order:

1. National Institutes of Health (NIH)
2. National Science Foundation (NSF)
3. Other Federal
4. Non Federal

Use the bookmarks to navigate to each section.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Sponsor</th>
<th>PA or PAR</th>
<th>Date</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>064981</td>
<td>Using Small Molecules and Molecular Genetics to Identify Novel Targets and Mechanisms Contributing to Tumor Immune Evasion (R01)</td>
<td>National Cancer Institute/NIH/DHHS</td>
<td>PA-17-330</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td>R. Allan Mufson, Ph.D.</td>
<td>Contact Telephone: 240-276-6231</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email: <a href="mailto:am214t@nih.gov">am214t@nih.gov</a></td>
<td>Sponsor Website: <a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL): 07-May-2020, 05-Jun-2020, 07-Sep-2020</td>
<td>National Cancer Institute (NCI) offers this funding opportunity with the purpose of stimulating research on the identification of new and novel targets and mechanisms involved in tumor immune evasion, that may be amenable to analysis by small molecule or molecular genetics approaches. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 067401 | Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional) | National Cancer Institute/NIH/DHHS                                      | PAR-18-307 | 07-May-2020   | 1,025,000 USD |
|      | Frank Perna, Ed.D., Ph.D.                                             | Contact Telephone: 240-276-6782                                        |           |               |        |
|      | Contact Email: pernafm@mail.nih.gov                                   | Sponsor Website: [Link to program URL](#)                                |           |               |        |
|      | Deadline Dates (ALL): 07-May-2020, 16-Oct-2020, 07-Jan-2021           | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for highly innovative and promising research aimed at developing multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for optimizing the intervention and conducting larger-scale feasibility studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. This program will use the NIH R21/R33 Phased Innovation Award award mechanism. |

| 070784 | National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | National Cancer Institute/NIH/DHHS                                      | PAR-18-560 | 07-May-2020   | 2,499,995 USD |
|      | Lori A. Henderson, Ph.D.                                              | Contact Telephone:                                                    |           |               |        |
|      | Contact Email:                                                        | Sponsor Website:                                                     |           |               |        |
|      | Deadline Dates (ALL): 07-May-2020                                     | National Cancer Institute (NCI) offers this funding opportunity with the purpose of stimulating research on the identification of new and novel targets and mechanisms involved in tumor immune evasion, that may be amenable to analysis by small molecule or molecular genetics approaches. This FOA will use the NIH Research Project (R01) award mechanism. |
Synopsis

National Cancer Institute (NCI) invites applications for research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD). Applicants are strongly encouraged to consult the NCI DCTD website at https://dctd.cancer.gov/ to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>070540</th>
<th>Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>PAR-18-530</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
</table>

Synopsis

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one
academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or straight clinical trials that lack translation as the primary motivation. This FOA will use the NIH Research Project (R01) award mechanism.

**Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)**

- **Contact Name**: Tanya Agurs-Collins, Ph.D
- **Contact Telephone**: 240-276-6956
- **Contact Email**: collinsta@mail.nih.gov
- **Sponsor Website**: [Link to program URL](#)

**Synopsis**

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum.

**Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)**

- **Contact Name**: Shobha Srinivasan, Ph.D.
- **Contact Telephone**: 240-276-6938
- **Contact Email**: ss688k@nih.gov
- **Sponsor Website**: [Link to program URL](#)
- **Deadline Dates (ALL)**: 14-May-2020

**Synopsis**

[Details of the synopsis related to this FOA]
**Deadline Dates (ALL)**

14-May-2020

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities. For the purposes of this FOA, the term 'Native Americans' includes the following populations: Alaska Native, American Indian, and Native Hawaiian. The term 'Native Hawaiian' means any individual whose ancestors were natives, prior to 1778, belonging to the area that now comprises the State of Hawaii. Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>061512</th>
<th>Innovative Research in Cancer Nanotechnology (IRCN) (R01)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>PAR-17-240</th>
<th>21-May-2020</th>
<th>2,250,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Dr. Piotr Grodzinski</td>
<td><strong>Contact Telephone</strong></td>
<td>301-451-8983</td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:grodzinp@mail.nih.gov">grodzinp@mail.nih.gov</a></td>
</tr>
</tbody>
</table>
### RFA-OD-19-022 -- Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)

**Contact Name:** Rachel Grana Mayne, PhD  
**Contact Telephone:** 240-276-5899  
**Contact Email:** granar@nih.gov  
**Sponsor Website:**  
**Program URL:** Link to program URL  
**Deadline Dates (ALL):** 21-May-2020 [Optional] [LOI/Pre-App], 20-Jul-2020, 07-Jan-2021 [Optional] [LOI/Pre-App], 08-Mar-2021

**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the United States (U.S.). The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA’s regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).

---

### Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)

**Contact Name:** Frank Perna, Ed.D., Ph.D.  
**Contact Telephone:** 240-276-6782  
**Contact Email:** pernafm@mail.nih.gov  
**Sponsor Website:**  
**Program URL:** Link to program URL  
**Deadline Dates (ALL):** 07-May-2020, 05-Oct-2020, 07-Jan-2021

**Synopsis:** Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)
### Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)

**Synopsis**
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This program will use the NIH R01 Research Project Grant award mechanism.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Frank M. Perna, Ed.D., Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>240-276-6782</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:pernafm@mail.nih.gov">pernafm@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

### Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)

**Synopsis**
National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Gabriela Riscuta, MD, CNS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>240-276-7118</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:gabriela.riscuta@nih.gov">gabriela.riscuta@nih.gov</a></td>
</tr>
</tbody>
</table>
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. The purpose of this funding opportunity announcement (FOA) is twofold: 1) to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2) to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA will use the NIH Research Project (R01) award mechanism.

080575
RFA-CA-19-034 -- Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional)
National Cancer Institute/NIH/DHHS
RFA-CA-19-034
20-May-2020 [Optional][LOI/Pre-App]
800,000 USD

Contact Name: Tiffany Wallace, Ph.D.
Contact Telephone: 240-276-5114
Contact Email: wallaceti@mail.nih.gov
Sponsor Website: Link to program URL
Program URL: Link to program URL

This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed. All the proposed P20 programs must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Sponsor</th>
<th>Type</th>
<th>Deadline Dates (ALL)</th>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>076579</td>
<td>Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Not Allowed)</td>
<td>National Cancer Institute/NIH/DHHS</td>
<td>PA-18-876 07-May-2020 Not Specified</td>
<td>07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021, 05-Feb-2021, 07-May-2021, 05-Jun-2021, 07-Sep-2021</td>
<td>Dr. Roberto Flores</td>
<td>240-276-7119</td>
<td><a href="mailto:floresr2@mail.nih.gov">floresr2@mail.nih.gov</a></td>
<td></td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other 'omic' sciences, biotechnology, and bioinformatics. This FOA will use the NIH Research Project (R01) award mechanism.

085268 Neural Regulation of Cancer (R21 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

PAR-19-354 27-May-2020 275,000 USD

Synopsis

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

085265 Neural Regulation of Cancer (R01 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

PAR-19-353 27-May-2020 Not Specified

Synopsis

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.
Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

### 085422 Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>National Cancer Institute/NIH/DHHS</th>
<th>PA-19-363</th>
<th>07-May-2020</th>
<th>499,999 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Anne Menkens, Ph.D.</td>
<td>240-276-6510</td>
<td><strong><a href="mailto:menkensa@mail.nih.gov">menkensa@mail.nih.gov</a></strong></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td></td>
<td><a href="#">Link to program URL</a></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td></td>
<td></td>
<td><a href="#">Link to program URL</a></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 085441 RFA-CA-19-051 -- Revision Applications for Mechanisms of Cancer Drug Resistance (U54 Clinical Trial Not Allowed)

<table>
<thead>
<tr>
<th>National Cancer Institute/NIH/DHHS</th>
<th>RFA-CA-19-051 [Optional][LOI/Pre-App]</th>
<th>24-May-2020</th>
<th>750,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Laurence (Austin) Doyle, MD</td>
<td>240-276-6112</td>
<td><strong><a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a></strong></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td></td>
<td><a href="#">Link to program URL</a></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td></td>
<td></td>
<td><a href="#">Link to program URL</a></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded U54 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RFA-CA-19-050 -- Revision Applications for Mechanisms of Cancer Drug Resistance (U01 Clinical Trial Not Allowed)</td>
<td>National Cancer Institute/NIH/DHHS</td>
<td>RFA-CA-19-050</td>
<td>24-May-2020 [Optional][LOI/Pre-App]</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Contact Name</strong></td>
<td>Laurence (Austin) Doyle, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>240-276-6112</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded U01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Laurence (Austin) Doyle, MD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>240-276-6112</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded P50 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)

Contact Name: Erica S. Breslau, PhD, MPH
Contact Telephone: 240-276-6773
Contact Email: breslaue@mail.nih.gov
Sponsor Website: 
Program URL: Link to program URL

Synopsis:
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan. In this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed disease in asymptomatic populations. Research supported by this initiative should enhance the screening process related to use: (1) in diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, non-traditional and/or allied health care providers. This FOA will use the NIH Research Project (R01) award mechanism.

RFA-CA-19-049 -- Revision Applications for Mechanisms of Cancer Drug Resistance (R01 Clinical Trial Not Allowed)

Contact Name: Laurence (Austin) Doyle, MD
Contact Telephone: 240-276-6112
Contact Email: Doylela@mail.nih.gov
Sponsor Website: 
Program URL: Link to program URL

Synopsis:
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded R01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synopsis</strong></td>
<td>The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>18-May-2020 [Optional][LOI/Pre-App], 17-Jul-2020, 15-Dec-2020 [Optional][LOI/Pre-App], 13-Feb-2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Early-life Factors and Cancer Development Later in Life (R01 - Clinical Trial Not Allowed)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>PA-18-529</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synopsis</strong></td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>Date</th>
<th>Program URL</th>
<th>Sponsor Website</th>
<th>PA-18-532</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>070405</td>
<td>Early-life Factors and Cancer Development Later in Life (R21 Clinical Trial Not Allowed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>Somdat Mahabir, Ph.D., M.PH</td>
<td><a href="mailto:mahabir@mail.nih.gov">mahabir@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>240-276-6941</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Synopsis

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

<table>
<thead>
<tr>
<th>Date</th>
<th>Program URL</th>
<th>Sponsor Website</th>
<th>PA-18-531</th>
<th>07-May-2020</th>
<th>100,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>070406</td>
<td>Early-life Factors and Cancer Development Later in Life (R03 Clinical Trial Not Allowed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>Somdat Mahabir, Ph.D., M.PH</td>
<td><a href="mailto:mahabir@mail.nih.gov">mahabir@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>240-276-6941</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention. This FOA will use the NIH R03 Small Grant Program award mechanism.

RFA-CA-19-052 -- Revision Applications for Mechanisms of Cancer Drug Resistance (P01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded P01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.
This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.
<table>
<thead>
<tr>
<th>ID</th>
<th>Program Description</th>
<th>Sponsor</th>
<th>PAR</th>
<th>Deadline Dates</th>
<th>Contact Name</th>
<th>Telephone</th>
<th>Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Funding Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>064983</td>
<td>Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)</td>
<td>National Cancer Institute/NIH/DHHS</td>
<td>17-331</td>
<td>07-May-2020</td>
<td>Sundar Venkatachalam, Ph.D.</td>
<td>240-276-7304</td>
<td><a href="mailto:sundarv@nih.gov">sundarv@nih.gov</a></td>
<td></td>
<td><a href="#">Link to program URL</a></td>
<td>0 Not Specified</td>
</tr>
<tr>
<td></td>
<td>National Cancer Institute (NCI) offers this funding opportunity with the purpose of promoting the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technology, medicinal chemistry, and pharmacology) are encouraged to establish collaborative teams to discover and develop novel small molecule immunomodulators for cancer therapy. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>086964</td>
<td>NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)</td>
<td>National Cancer Institute/NIH/DHHS</td>
<td>20-052</td>
<td>24-Feb-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100,000 USD</td>
</tr>
</tbody>
</table>
This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

RFA-CA-20-020 -- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)

National Cancer Institute/NIH/DHHS

RFA-CA-20-020

28-Apr-2020

[Optional][LOI/Pre-App]

300,000 USD

Contact Name

Tony Dickherber, Ph.D., Program Director

Contact Telephone

301-547-9980

Contact Email
dickherberaj@mail.nih.gov

Sponsor Website

Link to program URL

Program URL

Link to program URL

Deadline Dates (ALL)

28-Apr-2020 [Optional][LOI/Pre-App], 28-May-2020, 30-Aug-2020 [Optional][LOI/Pre-App], 29-Sep-2020

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical
diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this FOA and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

<table>
<thead>
<tr>
<th>RFA-CA-20-017 -- Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>RFA-CA-20-017</th>
<th>28-Apr-2020</th>
<th>400,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Tony Dickherber, Ph.D., Program Director</td>
<td>Contact Telephone</td>
<td>301-547-9980</td>
<td>Contact Email</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>28-Apr-2020 [Optional][LOI/Pre-App], 28-May-2020 , 30-Aug-2020 [Optional][LOI/Pre-App], 29-Sep-2020</td>
<td>Synopsis</td>
<td>This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</td>
<td></td>
</tr>
</tbody>
</table>
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

RFA-CA-20-020 -- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)

**Synopsis**

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing...
or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this FOA and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

<table>
<thead>
<tr>
<th>RFA-CA-20-025-- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>RFA-CA-20-025</th>
<th>28-Apr-2020 [Optional][LOI/Pre-App]</th>
<th>150,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Tony Dickherber, Ph.D.</td>
<td>301-547-9980</td>
<td><a href="mailto:dickherberaj@mail.nih.gov">dickherberaj@mail.nih.gov</a></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>28-Apr-2020 [Optional][LOI/Pre-App], 28-May-2020 , 30-Aug-2020 [Optional][LOI/Pre-App], 29-Sep-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called &quot;competing revisions&quot;) from currently funded NCI P50 specialized centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress of the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RFA-CA-20-026-- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>RFA-CA-20-026</th>
<th>28-Apr-2020 [Optional][LOI/Pre-App]</th>
<th>150,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Tony Dickherber, Ph.D.</td>
<td>301-547-9980</td>
<td><a href="mailto:dickherberaj@mail.nih.gov">dickherberaj@mail.nih.gov</a></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Program URL</td>
<td>Deadline Dates (ALL)</td>
<td>Synopsis</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------</td>
<td>----------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Link to program URL</td>
<td>28-Apr-2020 [Optional][LOI/Pre-App], 28-May-2020, 30-Aug-2020 [Optional][LOI/Pre-App], 29-Sep-2020</td>
<td>The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called &quot;competing revisions&quot;) from currently funded NCI U2C Resource-Related Multi-Component Projects and Centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>Contact Telephone</td>
<td>Contact Email</td>
<td>Sponsor Website</td>
<td>Program URL</td>
</tr>
<tr>
<td>Tony Dickherber, Ph.D.</td>
<td>301-547-9980</td>
<td><a href="mailto:dickherberaj@mail.nih.gov">dickherberaj@mail.nih.gov</a></td>
<td>Link to program URL</td>
<td>28-Apr-2020 [Optional][LOI/Pre-App], 28-May-2020, 30-Aug-2020 [Optional][LOI/Pre-App], 29-Sep-2020</td>
</tr>
<tr>
<td>RFA-CA-20-021</td>
<td>National Cancer Institute/NIH/DHHS</td>
<td>RFA-CA-20-023</td>
<td>28-Apr-2020 [Optional][LOI/Pre-App]</td>
<td>150,000 USD</td>
</tr>
<tr>
<td>087849</td>
<td>RFA-CA-20-021 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)</td>
<td>087854</td>
<td>RFA-CA-20-023 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trial Optional)</td>
<td>087854</td>
</tr>
</tbody>
</table>
The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U54 Resource-Related Research Projects. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress of the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.
<table>
<thead>
<tr>
<th>FOA ID</th>
<th>FOA Title</th>
<th>Sponsor</th>
<th>RFA ID</th>
<th>Deadline Date</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>RFA-CA-20-022</td>
<td>Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)</td>
<td>National Cancer Institute/NIH/DHHS</td>
<td>RFA-CA-20-022</td>
<td>28-Apr-2020 [Optional][LOI/Pre-App]</td>
<td>150,000 USD</td>
</tr>
<tr>
<td>087852</td>
<td>Contact Name: Tony Dickherber, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone: 301-547-9980</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email: <a href="mailto:dickherberaj@mail.nih.gov">dickherberaj@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL: Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL): 28-Apr-2020 [Optional][LOI/Pre-App], 28-May-2020, 30-Aug-2020 [Optional][LOI/Pre-App], 29-Sep-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called &quot;competing revisions&quot;) from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>070783</td>
<td>Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)</td>
<td>National Cancer Institute/NIH/DHHS</td>
<td>PAR-18-559</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>070783</td>
<td>Contact Name: Brandy Heckman-Stoddard, Ph.D., M.P.H.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone: 240-276-7048</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email: <a href="mailto:heckmanbm@mail.nih.gov">heckmanbm@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL: Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis: National Cancer Institute (NCI) invites applications for investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences as based on their scientific missions. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>067252</th>
<th>Research to Improve Native American Health (R21 Clinical Trials Optional)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>PAR-17-464</th>
<th>14-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Shobha Srinivasan, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>240-276-6938</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:ss688k@nih.gov">ss688k@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>14-May-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Synopsis:
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities. For the purposes of this FOA, the term 'Native Americans' includes the following populations: Alaska Native, American Indian, and Native Hawaiian. The term 'Native Hawaiian' means any individual whose ancestors were natives, prior to 1778, belonging to the area that now comprises the State of Hawaii. Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life. This FOA will use the NIH R21 Exploratory/Developmental Research award mechanism.

<table>
<thead>
<tr>
<th>088454</th>
<th>RFA-CA-20-010 -- Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>RFA-CA-20-010</th>
<th>10-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Juli Klemm, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-480-5778</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020 , 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

088452 | RFA-CA-20-009 -- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | National Cancer Institute/NIH/DHHS | RFA-CA-20-009 | 10-May-2020 [Optional][LOI/Pre-App] | 3,000,000 USD |

Contact Name | Juli Klemm, Ph.D. |
Contact Telephone | 301-480-5778 |
Contact Email | juli.klemm@nih.gov |
Sponsor Website |  |
Program URL | Link to program URL |
Deadline Dates (ALL) | 10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020 , 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020 |
Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed |
and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion FOAs listed above.

### RFA-CA-20-008 -- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

**National Cancer Institute/NIH/DHHS**

**RFA-CA-20-008**

10-May-2020 [Optional][LOI/Pre-App]

900,000 USD

**Contact Name**: Juli Klemm, Ph.D.

**Contact Telephone**: 301-480-5778

**Contact Email**: juli.klemm@nih.gov

**Sponsor Website**: [Link to program URL](#)

**Program URL**: [Link to program URL](#)

**Deadline Dates (ALL)**: 10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020, 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020

**Synopsis**: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

### RFA-CA-20-007 -- Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)

**National Cancer Institute/NIH/DHHS**

**RFA-CA-20-007**

10-May-2020 [Optional][LOI/Pre-App]

275,000 USD

**Contact Name**: Juli Klemm, Ph.D.

**Contact Telephone**: 301-480-5778

**Contact Email**: juli.klemm@nih.gov

**Sponsor Website**: [Link to program URL](#)

**Program URL**: [Link to program URL](#)
Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Potential applicants who are interested in downstream technology development, from prototyping to hardening and adaptation, should consult the other companion FOAs.

RFA-CA-20-012 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)

Contact Name: Juli Klemm, Ph.D.
Contact Telephone: 301-480-5778
Contact Email: juli.klemm@nih.gov
Sponsor Website: [Link to program URL]

Deadline Dates (ALL):
10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020, 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020

Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.
<table>
<thead>
<tr>
<th>Title</th>
<th>Agency</th>
<th>RFA-CA-20-011</th>
<th>Deadline Dates (ALL)</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)</td>
<td>National Cancer Institute/NIH/DHHS</td>
<td>10-May-2020 [Optional][LOI/Pre-App]</td>
<td>10- May-2020 [Optional][LOI/Pre-App], 09-Jun-2020, 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020</td>
<td>200,000 USD</td>
</tr>
</tbody>
</table>

**Synopsis**

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.

---

<table>
<thead>
<tr>
<th>Title</th>
<th>Agency</th>
<th>PAR-20-077</th>
<th>Deadline Dates (ALL)</th>
<th>Cost</th>
</tr>
</thead>
</table>

**Synopsis**

With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application
submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

<table>
<thead>
<tr>
<th>088464</th>
<th>RFA-CA-20-013 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trial Optional)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>RFA-CA-20-013</th>
<th>10-May-2020</th>
<th>200,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Juli Klemm, Ph.D.</td>
<td><strong>Contact Telephone</strong></td>
<td>301-480-5778</td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020 , 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called &quot;competing revisions&quot;) from currently funded NCI U24 resource-related research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>067445</th>
<th>Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2018, 2019, and 2020 (P50 Clinical Trial Required)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>PAR-18-313</th>
<th>25-May-2020</th>
<th>7,000,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Toby T. Hecht, Ph.D, Associate Director</td>
<td><strong>Contact Telephone</strong></td>
<td>240-276-5683</td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:hechtt@mail.nih.gov">hechtt@mail.nih.gov</a></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>25-May-2020 , 25-Sep-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>National Cancer Institute (NCI) and National Institute of Dental and Craniofacial Research (NIDCR) invite applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers. For the purpose of this FOA,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
cancers derived from the same organ system (i.e., a group of organs that perform a common function) are considered related. Examples of such organ systems include gastrointestinal, endocrine and other biological systems. Other programatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers sustained and promoted by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant. This FOA will utilize the NIH specialized center grant (P50) mechanism.

<table>
<thead>
<tr>
<th>070133</th>
<th>Cancer Research Education Grants Program - Research Experiences (R25)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>PAR-18-478</th>
<th>07-May-2020</th>
<th>1,500,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Contact Name: Jeannette F. Korczak, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone: 240-276-5630</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email: <a href="mailto:korczakj@mail.nih.gov">korczakj@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL: <a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Synopsis: National Cancer Institute (NCI) invites applications for creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients. This program will use the NIH Research Education Grant (R25) award mechanism.

<table>
<thead>
<tr>
<th>070127</th>
<th>Cancer Research Education Grants Program - Curriculum or Methods Development (R25)</th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>PAR-18-476</th>
<th>07-May-2020</th>
<th>300,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Contact Name: Jeannette F. Korczak, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone: 240-276-5630</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email: <a href="mailto:korczakj@mail.nih.gov">korczakj@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL: <a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>070129</td>
<td><strong>Cancer Research Education Grants Program - Courses for Skills Development (R25)</strong></td>
<td>National Cancer Institute/NIH/DHHS</td>
<td>PAR-18-477</td>
<td>07-May-2020</td>
<td>1,500,000 USD</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Contact Name</strong></td>
<td>Jeannette F. Korczak, Ph.D.</td>
<td><strong>Contact Telephone</strong></td>
<td>240-276-5630</td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:korczakj@mail.nih.gov">korczakj@mail.nih.gov</a></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td><strong>Program URL</strong></td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>082215</th>
<th><strong>Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)</strong></th>
<th>National Cancer Institute/NIH/DHHS</th>
<th>PAR-19-275</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Gila Neta, Ph.D.</td>
<td><strong>Contact Telephone</strong></td>
<td>240-276-6785</td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td><strong>Program URL</strong></td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

National Cancer Institute (NCI) invites applications for creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in accordance with the overall mission of the NCI. This program will use the NIH Research Education Grant (R25) award mechanism.
The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.

### Contact Information
- **Name:** Gila Neta, Ph.D.
- **Telephone:** 240-276-6785
- **Email:** gila.neta@nih.gov
- **Website:** [Link to program URL](#)

### Deadline Dates (ALL)

### Synopsis
The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.
low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

067448  **Fundamental Science Research on Mind and Body Approaches (R01 Clinical Trial Optional)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Wen G. Chen, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-451-3989</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**
National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH Research Project (R01) award mechanism.

069919  **Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Lanay M. Mudd, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-594-9346</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:lanay.mudd@nih.gov">lanay.mudd@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 16-Jun-2020, 07-Sep-2020</td>
</tr>
</tbody>
</table>

**Synopsis**
National Center for Complementary and Integrative Health (NCCIH) invites applications for early phase clinical trials of mind and body approaches for conditions that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent controlled cohort study, clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: adapting an intervention to a specific population; refining the intervention to
determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; examining acceptability of the intervention and control conditions. This FOA will not support randomized clinical trials to test or determine efficacy or effectiveness. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. The subsequent larger trial should have the potential to make a significant impact on public health. This FOA will use the NIH R34 Planning Grant award mechanism.

### 067449 Fundamental Science Research on Mind and Body Approaches (R21 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Wen G. Chen, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-451-3989</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
</tr>
</tbody>
</table>

### 068150 Center of Excellence for Research on Complementary and Integrative Health (P01 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Craig Hopp, Ph.D.D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-5825</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:hoppdc@mail.nih.gov">hoppdc@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
</tr>
</tbody>
</table>
National Center for Complementary and Alternative Medicine (NCCAM) invites applications that require multi-project, synergistic collaboration between outstanding scientists that blends multiple research approaches by multi-disciplinary research teams. This Center of Excellence for Research on Complementary and Integrative Health (CERCIH) program is designed to support three or more highly meritorious projects that can offer significant scientific advantages and "synergy" that could not be achieved by supporting the same projects as individual research grants. Each CERCIH must be focused on questions of high relevance to the mission of NCCIH. Applications in response to this FOA may propose to involve human participants in mechanistic studies, but this FOA will not support clinical trials of efficacy or effectiveness. This FOA will utilize the NIH P01 Research Program Projects award mechanism.

### 081084 NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Donald Everett, MA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-451-2020</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.

### 081744 NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Donald Everett, MA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-451-2020</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a></td>
</tr>
</tbody>
</table>

The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.
This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.
National Eye Institute (NEI) invites applications for investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research. This FOA will use the NIH UG1 Clinical Research Cooperative Agreements - Single Project award mechanism.

National Eye Institute (NEI) invites applications for investigator-initiated complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research. This FOA will use the NIH UG1 Clinical Research Cooperative Agreements - Single Project award mechanism.

National Eye Institute (NEI) invites applications for investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chair’s Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this FOA encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high risk clinical trial. This FOA will use the NIH UG1 Clinical Research Cooperative Agreements - Single Project award mechanism.
National Eye Institute (NEI) invites applications for investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chair’s Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this FOA encourages applications for the Chair's grant, which includes the scientific rationale, study aims and significance of the research project. This FOA will use the NIH UG1 Clinical Research Cooperative Agreements - Single Project award mechanism.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Sponsor</th>
<th>PA</th>
<th>Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>079552</td>
<td>Implementation of Shared Decision Making for HLBS Diseases and Conditions (R01 Clinical Trial Optional)</td>
<td>National Heart, Lung, and Blood Institute/NIH/DHHS</td>
<td>19-166</td>
<td>07-May-2020</td>
<td>2,499,995 USD</td>
</tr>
</tbody>
</table>
|       | **Contact Name**: Susan T. Shero, BSN, MS  
|       | **Contact Telephone**: 301-496-1051  
|       | **Contact Email**: sheros@nih.gov  
|       | **Sponsor Website**:  
|       | **Program URL**: Link to program URL  
|       | **Synopsis**: The purpose of this initiative is to support research that uses evidence-based, practical approaches to increase the uptake of shared decision making (SDM) into routine clinical practice. Objectives are to improve patient-centered care for heart, lung, blood, and sleep (HLBS) diseases and conditions; and to address barriers and facilitators related to SDM strategies used to improve quality of care, adherence, and informed consent; reduce health disparities; and deliver treatments best suited for individual patients. Investigators and multidisciplinary research teams with expertise in clinical implementation research, health information technology, behavioral science, behavioral economics, workflow design, and organizational engineering are encouraged to apply. |
| 074657| The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed) | National Heart, Lung, and Blood Institute/NIH/DHHS | 18-784 | 07-May-2020 | Not Specified |
|       | **Contact Name**: Lis Caler, Ph.D.  
|       | **Contact Telephone**: 301-435-0222  
|       | **Contact Email**: lis.caler@mail.nih.gov  
|       | **Sponsor Website**:  
|       | **Program URL**: Link to program URL  
|       | **Synopsis**: National Heart, Lung, and Blood Institute (NHLBI) invites applications for functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their components in the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translational
approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiology, pulmonology, hematology, sleep science, circadian biology, immunology, ‘-omic’ sciences, microbiology, microbial ecology, biotechnology, and bioinformatics. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>David Goff, M.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Heart, Lung, and Blood Institute (NHLBI) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also address implementation science, health disparities, and translation research that addresses the mission of the Institute. Each application submitted in response to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective. Higher budgets may be requested for applications that include at least four projects, one of which has an Early Stage Investigator as Project Leader. This FOA will utilize the NIH Program Project (P01) grant mechanism.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Erin Iturriaga, RN, BS, MSN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td>11-May-2020 [Optional][LOI/Pre-App], 10-Jun-2020</td>
</tr>
</tbody>
</table>
| Synopsis        | National Heart, Lung, and Blood Institute (NHLBI) invites applications for Small Business Innovation Research (SBIR) from small business concerns (SBCs) for the design and development of technologies to monitor health or deliver care in a
real-time, accessible, effective, and minimally obtrusive way for older adults with a chronic heart, lung, blood, or sleep (HLBS) condition. These technologies may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems and should have the goal of fostering healthy and independent living for aging adults with HLBS conditions. The development of such technologies should incorporate specific human factors for aging adults including disabilities, mild impairments, as well as chronic HLBS conditions. Technology usability for these populations must be incorporated early in the development of the design. Usability considerations include but are not limited to patient-facing displays, hearing and visual impairments, tactile limitations, literacy, and design preferences between men and women. These improvements in technology design could yield more accurate and earlier detection of changes that may interfere with healthy and independent living for older adults. This FOA will utilize the R43 Small Business Innovation Research (SBIR) Grant - Phase I mechanism.

**Synopsis**

National Heart, Lung, and Blood Institute (NHLBI) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training award mechanism.
<table>
<thead>
<tr>
<th>RFA-HL-19-025 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Required)</th>
<th>National Heart, Lung, and Blood Institute/NIH/DHHS</th>
<th>RFA-HL-19-025</th>
<th>06-May-2020</th>
<th>750,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Jane D. Scott, ScD, MSN, FAHA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-435-0535</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:scottj2@nhlbi.nih.gov">scottj2@nhlbi.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>06-May-2020, 09-Oct-2020, 08-Jan-2021, 11-Feb-2021, 06-May-2021</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

National Heart, Lung, and Blood Institute (NHLBI) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training award mechanism.

<table>
<thead>
<tr>
<th>Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)</th>
<th>National Heart, Lung, and Blood Institute/NIH/DHHS</th>
<th>PAR-19-329</th>
<th>11-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Nancy DiFronzo, PhD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-435-0065</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:difronzon@nhlbi.nih.gov">difronzon@nhlbi.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (DCC) (PAR-19-330). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating DCC application must be submitted on the same application due date for consideration by NHLBI.
<table>
<thead>
<tr>
<th>RFA-HL-18-023--Stimulating Access to Research in Residency (StARR) (R38)</th>
<th>National Heart, Lung, and Blood Institute/NIH/DHHS</th>
<th>RFA-HL-18-023</th>
<th>12-May-2020</th>
<th>884,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Neil Aggarwal, M.D.</td>
<td>Contact Telephone</td>
<td>301-827-7820</td>
<td>Contact Email</td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td>Deadline Dates (ALL)</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to recruit and retain outstanding, postdoctoral-level health professionals who have demonstrated potential and interest in pursuing careers as clinician-investigators. To address the growing need for this critical component of the research workforce, this funding opportunity seeks applications from institutional programs that can provide outstanding mentored research opportunities for Resident-Investigators and foster their ability to transition to individual career development research awards. The program will support institutions to provide support for up to 2 years of research conducted by Resident-Investigators in structured programs for clinician-investigators with defined program milestones. This FOA will use the NIH R38 Education Projects award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Kathleen Rousche, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-827-7981</td>
<td>Contact Email</td>
</tr>
<tr>
<td>Synopsis</td>
<td>This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical...</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

<table>
<thead>
<tr>
<th>Program Title</th>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>085480 RFA-HL-20-022 -- Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)</strong></td>
<td>Margaret Ochocinska, PhD</td>
<td>301-827-8285</td>
<td><a href="mailto:ochocinm@mail.nih.gov">ochocinm@mail.nih.gov</a></td>
<td>Link to program URL</td>
<td>09-Mar-2020, 11-May-2020, 09-Jun-2020, 09-Jul-2020, 11-Aug-2020, 09-Feb-2021, 09-Jul-2021, 11-Aug-2021</td>
<td>This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption.</td>
<td></td>
</tr>
<tr>
<td><strong>085481 RFA-HL-20-023 -- Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)</strong></td>
<td>Kathleen Rousche, Ph.D.</td>
<td>301-827-7981</td>
<td><a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></td>
<td>Link to program URL</td>
<td>09-Mar-2020, 11-May-2020, 09-Jun-2020, 09-Jul-2020, 11-Aug-2020, 09-Feb-2021, 09-Jul-2021, 11-Aug-2021</td>
<td>This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the...</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>----------------</td>
<td>-------------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>Kathleen Rousche, Ph.D.</td>
<td>301-827-7981</td>
<td><a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></td>
<td>Link to program URL</td>
<td>09-Mar-2020 , 11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td></td>
<td></td>
<td></td>
<td>This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>085483</th>
<th>RFA-HL-20-027 -- Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)</th>
<th>National Heart, Lung, and Blood Institute/NIH/DHHS</th>
<th>RFA-HL-20-027</th>
<th>09-Mar-2020</th>
<th>700,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Kathleen Rousche, Ph.D.</td>
<td>301-827-7981</td>
<td><a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></td>
<td>Link to program URL</td>
<td>09-Mar-2020 , 11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td></td>
<td></td>
<td></td>
<td>This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the</td>
<td></td>
</tr>
</tbody>
</table>
entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Lisbeth Welniak, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-435-0050</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:welniakla@mail.nih.gov">welniakla@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>02-Mar-2020, 08-May-2020</td>
</tr>
</tbody>
</table>

The purpose of the NHLBI Career Pathway to Independence in Blood Science Award for Physician Scientists (K99) is to increase and maintain a strong cohort of new and talented, NHLBI supported, independent investigators in blood science. This program is designed to facilitate a timely transition of outstanding blood science researchers with a clinical doctorate degree from mentored research positions to independent, tenure-track or equivalent faculty positions. This K99 award is intended for individuals who require at least three and up to five years of mentored research training and career development before transition to the R00 phase. At the conclusion of this K99, awardees are expected to continue research activity with support from a separate NHLBI-funded FOA, the Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional), described in NOT-HL-18-657, which will require updated research plans and a limited competition review. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial, or a separate ancillary clinical trial as lead investigator, should apply to the companion FOA (RFA-HL-20-002 SPIN # 78836).
The purpose of the NHLBI Career Pathway to Independence in Blood Science Award for Physician Scientists (K99) is to increase and maintain a strong cohort of new and talented, NHLBI supported, independent investigators in blood science. This program is designed to facilitate a timely transition of outstanding blood science researchers with a clinical doctorate degree from mentored research positions to independent, tenure-track or equivalent faculty positions. This K99 award is intended for individuals who require at least three and up to five years of mentored research training and career development before transition to the R00 award. At the conclusion of the K99, awardees are expected to continue research activity with support from a separate NHLBI-funded FOA, the Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional), described in NOT-HL-18-657, which will require updated plans and a limited competition review. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (RFA-HL-20-001, SPIN # 78837).
methodology; and development of new research technology. For current and previous K23 awardees, research proposed in the R03 application may or may not include patient-oriented research. The R03 is therefore intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support a subsequent R01, or equivalent, application.

### NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

- **FOA Number:** 079353
- **Contact Name:** Patrice Desvigne-Nickens, MD
- **Contact Telephone:** 301-435-0504
- **Contact Email:** gweinmann@nih.gov
- **Sponsor Website:** [Link to sponsor website](#)
- **Program URL:** [Link to program URL](#)

**Synopsis:**

This Funding Opportunity Announcement (FOA) is to support studies that are scientifically essential, yet also sufficient, for investigators to make definitive decisions that inform the final designs of important Phase II and beyond clinical trials within NHLBI’s mission; that is, clinical trials with the primary intent of testing the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and treatment of heart, lung, blood, and sleep disorders. This mechanism may be used to test the feasibility of novel and efficient (pragmatic) trial designs, as well as determine the feasibility of an intervention, intervention parameters, subject availability, or other information essential to complete the design of a trial. Applications should demonstrate that the proposed studies are both necessary and sufficient to permit definitive decisions about the final design of the subsequent clinical trial. Applicants who propose solely to write a protocol or manual of operations, to develop infrastructure for a clinical trial, or implement a fully designed trial will not be considered appropriate for this announcement. Please note that NHLBI supports other funding opportunities for clinical trials—see [https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization](https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization) for information on other NHLBI clinical trial funding opportunity announcements. In contrast to the planning or study start up phase of other NHLBI clinical trial FOAs, the R34 mechanism is intended to provide new information that answers a scientific question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial.

### Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)

- **FOA Number:** 081248
- **Contact Name:** Andrei Kindzelski, MD, PhD
- **Contact Telephone:** 301-435-0050
- **Contact Email:** kindzelskial@nhlbi.nih.gov

**Synopsis:**

National Heart, Lung, and Blood Institute/NIH/DHHS

RFA-HL-20-014 [Optional][LOI/Pre-App] 18-May-2020 [Optional][LOI/Pre-App] 3,977,000 USD
<table>
<thead>
<tr>
<th>Sponsor Website</th>
<th>Link to program URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program URL</td>
<td>18-May-2020 [Optional][LOI/Pre-App], 17-Jun-2020</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>May 20-2020 [Optional][LOI/Pre-App], 17-Jun-2020</td>
</tr>
</tbody>
</table>

**Synopsis**

The purpose of this FOA is to fund centers that will establish longitudinal cohorts in rare HLBS diseases to investigate unaddressed research questions using epidemiologic study designs and methods that are appropriate for conditions affecting fewer than 200,000 persons in the US. These observational cohort studies should be designed to provide an evidence base for future interventional studies, including clinical trials; for developing better diagnostics than those that are currently available; for answering early translational questions; or for broader implementation of guidelines for managing these diseases. This program will provide opportunities to advance rare disease research using genetics and deep phenotyping to characterize the disease and to identify disease sub-types; to use data science methods that integrate clinical and patient-reported outcomes with laboratory, imaging, environmental and -omics data to understand the natural history of disease; to generate data that differentiate patients with the same morphological phenotype but different genetic mutations and severity of outcomes; to elucidate genotype-phenotype interactions and multisystem phenotyping to develop reliable and valid predictive tools to determine who will respond to which treatments and when to intervene; and to encourage innovative methods such as telemedicine to include participants with rare diseases located in remote locations. This initiative will allow applicants to study rare or related rare diseases, disorders, conditions or syndromes together based on pathogenesis, affected biochemical, cellular or physiological features or organ system involvement. Studying related rare diseases within the same cohort could help understand the nuances, and knowledge gained from one disease could accelerate the advances in related diseases. For example, investigators may propose to study hemoglobin disorders rather than only sickle cell anemia or thalassemia.

<table>
<thead>
<tr>
<th>RFA-HL-21-011 -- Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required)</th>
<th>National Heart, Lung, and Blood Institute/NIH/DHHS</th>
<th>RFA-HL-21-011</th>
<th>01-Apr-2020 [Optional][LOI/Pre-App]</th>
<th>2,425,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Rebecca A. Roper, MS, MPH</td>
<td>Contact Telephone</td>
<td>301-496-1051</td>
<td>Contact Email</td>
</tr>
</tbody>
</table>
that will increase the use of evidence-based practices (EBP), i.e., evidence-based guidelines or other well-accepted evidence-based interventions, for preventing and/or managing heart, lung, and blood diseases and/or sleep (HLBS) disorders. Clinical trials for this FOA must meet the NIH definition of a clinical trial (see NOT-OD-15-015). Applicants will be expected to address a planning phase (R61) of up to one year, and an implementation research phase (R33) of up to four years for the clinical trial. During the planning phase awardees will be expected to: finalize selection of the EBP; recruit participating organization(s); prepare the implementation protocol; develop milestones and a project timeline; and develop plans for data collection and management, and participant recruitment and retention. Robust plans for the implementation research clinical trial and the supporting implementation strategy dissemination package are required for the R33 phase of the application. Upon administrative review by the NHLBI, only meritorious R61 projects that meet the predetermined scientific milestones will be selected to transition to the R33 phase. Investigators with expertise in T4 clinical trials and hybrid studies for heart, lung, blood, or sleep conditions are expected to be part of the research team. In addition, applications proposing collaborative investigative teams combining expertise in qualitative methods, administration of T4 implementation clinical trials as appropriate at various levels (e.g., individual, clinical practice, facility, etc.), quality improvement, health economics, implementation of skills development programs, and robust experience in the adaptation and implementation of other established EBP will be encouraged. Personnel involved in the proposed strategy, e.g., nurse practitioners, patient, family members, respiratory therapists, pharmacists, hospital intensivists, etc., should be meaningfully engaged in the conceptualization and the planned execution of the proposed project. Applications proposing to establish a new EBP are not within the scope of this FOA.

**Synopsis**

This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement.
mechanism of award and runs in parallel with a companion FOA (PAR-19-329) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.

| FOA ID | FOA Title | Agency | PA Code | Application Due Date | Amount
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>057259</td>
<td>Genomics of HIV/AIDS Drug Response and Co-Morbidities (R01)</td>
<td>National Human Genome Research Institute/NIH/DHHS</td>
<td>PA-16-435</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>065312</td>
<td>Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R03)</td>
<td>National Human Genome Research Institute/NIH/DHHS</td>
<td>PA-17-445</td>
<td>07-May-2020</td>
<td>100,000 USD</td>
</tr>
</tbody>
</table>

**Synopsis**

**Genomics of HIV/AIDS Drug Response and Co-Morbidities (R01)**

National Human Genome Research Institute (NHGRI) invites applications to expand the use of high-throughput genotyping, genomic sequencing, and related genomic technologies, and generate resulting data resources widely available for research use, to improve the efficacy and safety and ease of use of HIV/AIDS therapies and of non-HIV drugs used to treat HIV/AIDS patients, and to reduce HIV/AIDS-related comorbidities, coinfections, and complications. This FOA will use the NIH Research Project (R01) award mechanism.

**Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R03)**

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or
emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. This program will use the NIH R03 Small Grant Program award mechanism.

<table>
<thead>
<tr>
<th>065308</th>
<th>Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21)</th>
<th>National Human Genome Research Institute/NIH/DHHS</th>
<th>PA-17-446</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Joy Boyer</td>
<td>Contact Telephone: 301-402-4997</td>
<td>Contact Email: <a href="mailto:boyerj@mail.nih.gov">boyerj@mail.nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL: <a href="https://...">Link to program URL</a></td>
<td>Deadline Dates (ALL): 07-May-2020, 07-Sep-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>065298</th>
<th>Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01)</th>
<th>National Human Genome Research Institute/NIH/DHHS</th>
<th>PA-17-444</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Joy Boyer</td>
<td>Contact Telephone: 301-402-4997</td>
<td>Contact Email: <a href="mailto:boyerj@mail.nih.gov">boyerj@mail.nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL: <a href="https://...">Link to program URL</a></td>
<td>Deadline Dates (ALL): 07-May-2020, 07-Sep-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders. This program will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiative to Maximize Research Education in Genomics: Diversity Action Plan (R25)</td>
<td>National Human Genome Research Institute/NIH/DHHS</td>
<td>PAR-19-380</td>
<td>25-May-2020</td>
<td>1,500,000 USD</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>Tina Gatlin, Ph.D.</td>
<td>301-480-2280</td>
<td><a href="mailto:gatlincl@nih.gov">gatlincl@nih.gov</a></td>
<td><strong>Synopsis</strong> The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI Diversity Action Plan (DAP) R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral, social and clinical research workforce in genomics. This funding opportunity announcement seeks to expose students at the undergraduate, post-baccalaureate and graduate levels who are from diverse backgrounds, including those from underrepresented groups, to the foundational sciences relevant to genomics to enable them to pursue careers that span all areas of interest to NHGRI - genome sciences, genomic medicine and genomics and society. For the purposes of this FOA, the term “genomics” encompasses issues and activities in these three areas.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Initiative to Maximize Research Education in Genomics: Courses (R25 Clinical Trial Not Allowed)</th>
<th>National Human Genome Research Institute/NIH/DHHS</th>
<th>PAR-19-185</th>
<th>25-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Bettie J. Graham, Ph.D.</td>
<td>301-496-7531</td>
<td><a href="mailto:bettie_graham@nih.gov">bettie_graham@nih.gov</a></td>
<td><strong>Synopsis</strong> The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NIAID Physician-Scientist Pathway to Independence Award (K99/R00)</th>
<th>National Institute of Allergy and Infectious Diseases/NIH/DHHS</th>
<th>PAR-17-329</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Shawn Drew Gaillard, Ph.D.</td>
<td></td>
<td></td>
<td><strong>Synopsis</strong> This FOA will support creative educational activities with a primary focus on Courses for Skills Development.</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Chao Jiang, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-761-7802</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:chao.jiang@nih.gov">chao.jiang@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Contact Name | Greg Deye, M.D. |
| Contact Telephone | 240-627-3371 |
| Contact Email | gregory.deye@nih.gov |

### Synopsis

National Institute of Allergy and Infectious Diseases (NIAID) invites applications for the Pathway to Independence Award (K99/R00). The primary purpose of the Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This FOA will utilize the NIH K99/R00 Career Transition Award/Research Transition Award mechanism.

| FOA Number | 081206 |
| National Institute of Allergy and Infectious Diseases (NIAID) invites applications for the Pathway to Independence Award (K99/R00). The primary purpose of the Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This FOA will utilize the NIH K99/R00 Career Transition Award/Research Transition Award mechanism. |

| Program URL | Link to program URL |
| Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation. |

| Contact Name | Greg Deye, M.D. |
| Contact Telephone | 240-627-3371 |
| Contact Email | gregory.deye@nih.gov |

### Synopsis

National Institute of Allergy and Infectious Diseases (NIAID) invites applications for the Pathway to Independence Award (K99/R00). The primary purpose of the Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This FOA will utilize the NIH K99/R00 Career Transition Award/Research Transition Award mechanism.

| Program URL | Link to program URL |
| Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation. |
This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).

### Theraupetic Strategies for the Converging TB/T2DM/HIV Epidemics (R01)

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>062648</td>
<td>Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R01)</td>
<td>National Institute of Allergy and Infectious Diseases/NIH/DHHS</td>
<td>PA-17-283</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

Contact Name: Daniel Frank, Ph.D.
Contact Telephone: 301-761-6256
Contact Email: Daniel.Frank@nih.gov

Synopsis:
National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications for innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection. This FOA will use the NIH Research Project (R01) award mechanism.

### Imaging the Persistent HIV Reservoir (R01)

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>063563</td>
<td>Imaging the Persistent HIV Reservoir (R01)</td>
<td>National Institute of Allergy and Infectious Diseases/NIH/DHHS</td>
<td>PA-17-305</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

Contact Name: David McDonald, Ph.D.
Contact Telephone: 301-761-7815
Contact Email: david.mcdonald@nih.gov

Synopsis:
National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications for innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection. This FOA will use the NIH Research Project (R01) award mechanism.
<table>
<thead>
<tr>
<th>Program URL</th>
<th>Link to program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>07-May-2020</td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the development of imaging approaches to identify and characterize persistent HIV reservoirs in patients undergoing suppressive antiretroviral therapy (ART) and to quantify the nature and size of these reservoirs in response to therapeutic interventions. This FOA will use the NIH Research Project (R01) award mechanism.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Daniel Frank, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-761-6256</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Daniel.Frank@nih.gov">Daniel.Frank@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 05-Jun-2020, 07-Sep-2020</td>
</tr>
</tbody>
</table>

| Synopsis | National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications for innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism. |

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Usha Sharma, Ph.D., M.P.H.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>240-292-4809</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:usharma@niaid.nih.gov">usharma@niaid.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 07-Sep-2020, 07-Jan-2021, 07-May-2021</td>
</tr>
</tbody>
</table>

| Synopsis | National Institute of Allergy and Infectious Diseases (NIAID) invites applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections. This FOA will use the NIH Research Project (R01) award mechanism. |
### Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R01 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Usha Sharma, Ph.D., M.P.H.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>240-292-4809</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:usharma@niaid.nih.gov">usharma@niaid.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>[Link to program URL]</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 07-Sep-2020, 07-Jan-2021, 07-May-2021</td>
</tr>
</tbody>
</table>

**Synopsis**
National Institute of Allergy and Infectious Diseases (NIAID) invites applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections. This FOA will use the NIH Research Project (R01) award mechanism.

### Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Rosemary McKaig, M.P.H, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>240-627-3214</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:rm434n@nih.gov">rm434n@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>[Link to program URL]</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 07-Sep-2020, 07-Jan-2021, 07-May-2021</td>
</tr>
</tbody>
</table>

**Synopsis**
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles. This FOA will use the NIH Research Project (R01) award mechanism.

### Research to Advance Vaccine Safety (R21 Clinical Trial Not Allowed)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Barbara Mulach, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>240-627-3322</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:bmulach@niaid.nih.gov">bmulach@niaid.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
</tbody>
</table>

**Synopsis**
This FOA will support research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles. This FOA will use the NIH Research Project (R01) award mechanism.
The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) and their participating Institutes and Centers invite applications to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

Synopsis

The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) and their participating Institutes and Centers invite applications to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.
research goals and objectives outlined in the U.S. National Vaccine Plan. This program will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>Program Title</th>
<th>National Institute of Allergy and Infectious Diseases/NIH/DHHS</th>
<th>PAR</th>
<th>Deadline Dates (ALL)</th>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed)</td>
<td>National Institute of Allergy and Infectious Diseases/NIH/DHHS</td>
<td>PAR-19-351</td>
<td>07-May-2020</td>
<td>Shawn Drew Gaillard, Ph.D.</td>
<td>240-627-3857</td>
<td><a href="mailto:Shawn.Gaillard@nih.gov">Shawn.Gaillard@nih.gov</a></td>
<td>Link to program URL</td>
<td>07-May-2020, 16-Jun-2020, 07-Sep-2020</td>
<td>The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and Developmental Research Grant (R21) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R21 is, therefore, intended to support research projects that may provide preliminary data to support a subsequent R01, or equivalent, application.</td>
</tr>
<tr>
<td>NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)</td>
<td>National Institute of Allergy and Infectious Diseases/NIH/DHHS</td>
<td>PAR-19-371</td>
<td>07-May-2020</td>
<td>Shawn Drew Gaillard, Ph.D.</td>
<td>240-627-3857</td>
<td><a href="mailto:Shawn.Gaillard@nih.gov">Shawn.Gaillard@nih.gov</a></td>
<td>Link to program URL</td>
<td>07-May-2020, 12-Jun-2020, 07-Sep-2020, 12-Oct-2020, 07-Jan-2021, 12-Feb-2021, 07-May-2021, 12-Jun-2021, 07-Sep-2021, 12-Oct-2021, 07-Jan-2022</td>
<td>National Institute of Allergy and Infectious Diseases (NIAID) provides support for the NIAID Research Scholar Development Award (RSDA), which is intended to assist postdoctoral fellows' transition to positions of assistant professor or equivalent</td>
</tr>
</tbody>
</table>
and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) will utilize the NIH Career Transition Award (K22) mechanism.

<table>
<thead>
<tr>
<th>FOA Number</th>
<th>Title</th>
<th>Principal Investigator</th>
<th>Institution</th>
<th>PA Number</th>
<th>Start Date</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>078301</td>
<td>Engaging Men in HIV Testing, Prevention, and Care (R21 Clinical Trial Optional)</td>
<td>Adeola Adeyeye, M.D.</td>
<td>National Institute of Allergy and Infectious Diseases/NIH/DHHS</td>
<td>PA-19-050</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td>063627</td>
<td>Optimizing HIV Phyldynamics to Target and Interrogate Clusters (OPTICs) (R21)</td>
<td>Lillian S. Kuo, Ph.D.</td>
<td>National Institute of Allergy and Infectious Diseases/NIH/DHHS</td>
<td>PA-17-306</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td>087001</td>
<td>Transgender People: Immunity, Prevention, and Treatment (R21 Clinical Trial Not Allowed)</td>
<td></td>
<td>National Institute of Allergy and Infectious Diseases/NIH/DHHS</td>
<td>PAR-20-054</td>
<td>11-May-2020</td>
<td>275,000 USD</td>
</tr>
</tbody>
</table>

**Synopsis**

The purpose of this Funding Opportunity Announcement (FOA) is to develop and test strategies to increase the engagement of men in HIV prevention and care within global settings and among US domestic populations who have evidenced lower rates of engagement and retention in HIV prevention and care. The R21 Exploratory/Developmental Grant supports studies that may involve considerable risk but may lead to a breakthrough in a particular area; or to the development of novel techniques, agents, methodologies, models; or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Jim A. Turpin, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-451-2732</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:jturpin@niaid.nih.gov">jturpin@niaid.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>11-May-2020, 11-May-2021</td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).</td>
</tr>
</tbody>
</table>

**Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03)**

National Institute of Allergy and Infectious Diseases/NIH/DHHS

<table>
<thead>
<tr>
<th>PAR-17-439</th>
<th>07-May-2020</th>
<th>100,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Shawn Drew Gaillard, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>240-627-3857</td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Shawn.Gaillard@nih.gov">Shawn.Gaillard@nih.gov</a></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 16-Jun-2020, 07-Sep-2020</td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Allergy and Infectious Diseases (NIAID) provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application. This program will use the NIH R03 Small Grant Program grant mechanism.</td>
<td></td>
</tr>
</tbody>
</table>
National Institute of Allergy and Infectious Diseases (NIAID) invites applications for the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program. The purpose of the program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This FOA will use the NIH K99/R00 Career Transition Award/Research Transition Award mechanism.
<table>
<thead>
<tr>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Link to program URL</td>
<td>13-May-2020, 14-Sep-2020, 13-Jan-2021</td>
<td>National Institute of Allergy and Infectious Diseases (NIAID) invites cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (<a href="https://www.niaid.nih.gov/research/role">https://www.niaid.nih.gov/research/role</a>). Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application. This FOA will use the NIH U01 Research Project – Cooperative Agreements award mechanism.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martin Gutierrez, Ph.D.</td>
<td>240-292-4844</td>
<td><a href="mailto:mgutierrez@niaid.nih.gov">mgutierrez@niaid.nih.gov</a></td>
<td>Link to program URL</td>
<td>07-May-2020, 25-May-2020, 07-Sep-2020, 25-Sep-2020, 07-Jan-2021, 25-Jan-2021, 07-May-2021, 25-May-2021, 07-Sep-2021, 25-Sep-2021, 07-Jan-2022, 25-Jan-2022, 07-May-2022, 25-May-2022, 07-Sep-2022, 25-Sep-2022, 07-Jan-2023</td>
<td>This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate. The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.</td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>Mr. Martin Gutierrez, B.S.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>240-292-4844</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:mgutierrez@niaid.nih.gov">mgutierrez@niaid.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of healthy immune system development and function across the lifespan; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each P01 application submitted to this FOA must include at least two related, synergistic research projects that share a common central theme, focus, and/or overall objective; and an administrative core. A P01 may include scientific cores, if needed for proposed research.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Nancy Lewis Ernst, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>240-669-5076</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:nancyernst@nih.gov">nancyernst@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>08-Apr-2020 [Optional][LOI/Pre-App], 08-May-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>This Funding Opportunity Announcement (FOA) solicits applications to establish Combating Antibiotic-Resistant Bacteria (CARB) Interdisciplinary Research Units (CARBIRUs) focused on improving our understanding of bacterial and host factors important for antibacterial resistance and infection to inform development of new approaches to prevent, diagnose, and treat antibacterial-resistant infections.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Gang Dong, M.D., Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>20-May-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>This Funding Opportunity Announcement (FOA) solicits applications to establish Combating Antibiotic-Resistant Bacteria (CARB) Interdisciplinary Research Units (CARBIRUs) focused on improving our understanding of bacterial and host factors important for antibacterial resistance and infection to inform development of new approaches to prevent, diagnose, and treat antibacterial-resistant infections.</td>
</tr>
</tbody>
</table>
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the NIAID Childhood Asthma in Urban Settings Clinical Research Network Clinical Research Centers (CAUSE-CRCs). The CAUSE-CRCs will conduct both network-wide and site-specific clinical studies and trials with the ultimate goal of developing effective asthma treatment or prevention approaches applicable to children residing in low-income urban settings. For network-wide clinical research projects and other network functions, the CAUSE-CRCs will work closely with the CAUSE Leadership Center (CAUSE-LC).

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the NIAID Childhood Asthma in Urban Settings Clinical Research Network Leadership Center (CAUSE-LC). The CAUSE-LC will provide the overall scientific strategy and organizational structure to the CAUSE Clinical Research Network and will interact closely with the CAUSE Clinical Research Centers (CAUSE -CRCs) to support the conduct of multi-site clinical studies and trials with the ultimate goal of developing effective interventions or asthma prevention approaches applicable to children residing in low-income urban settings.
The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative on-demand, event-driven and long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy, and (HIV/STI) and non-HIV STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.

<table>
<thead>
<tr>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Link to program URL</td>
<td>06-May-2020 , 06-May-2021</td>
<td>The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative on-demand, event-driven and long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy, and (HIV/STI) and non-HIV STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>071816</th>
<th>NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)</th>
<th>National Institute of Allergy and Infectious Diseases/NIH/DHHS</th>
<th>PAR-18-632</th>
<th>13-May-2020</th>
<th>3,000,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Michael Minnicozzi, Ph.D.</td>
<td>Contact Telephone</td>
<td>240-627-3532</td>
<td>Contact Email</td>
<td><a href="mailto:minnicozzim@niaid.nih.gov">minnicozzim@niaid.nih.gov</a></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>13-May-2020 , 14-Sep-2020 , 13-Jan-2021</td>
<td>National Institute of Allergy and Infectious Diseases (NIAID) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID. This program provides support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and can be proposed under this program. This FOA will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Phase II and Fast Track Only.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 088841 | RFA-AI-20-004 -- Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical Trial Not Allowed) | National Institute of Allergy and Infectious Diseases/NIH/DHHS | RFA-AI-20-004 | 30-May-2020 | 2,000,000 USD |
### Synopsis

This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are combined in these studies must already have shown individual immune modulating activity. Understanding the molecular and cellular mechanisms underlying the synergistic enhancement of immune responses by combination adjuvants will facilitate the rational selection of components for vaccines tailored to specific pathogens. The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAID’s overall adjuvant research objectives. The long-term goal is to promote the development of novel adjuvant combinations that will improve the immunogenicity of vaccines while limiting or eliminating reactogenicity.

<table>
<thead>
<tr>
<th>Grant Numbers</th>
<th>Grant Descriptions</th>
<th>Program Identifiers</th>
<th>National Institute of Arthritis &amp; Musculoskeletal &amp; Skin Diseases/NIH/DHHS</th>
<th>Dates</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>067950</td>
<td>Research Grants Using the Resources from the Osteoarthritis Initiative (OAI) (R21 Clinical Trial Not Allowed)</td>
<td>PA-18-408</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
<td></td>
</tr>
<tr>
<td>07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021</td>
<td>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Institute on Aging (NIA) invite applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOA ID</td>
<td>FOA Title</td>
<td>Agency</td>
<td>PA #</td>
<td>Deadline</td>
<td>Budget</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>----------</td>
<td>----------</td>
<td>------------</td>
</tr>
<tr>
<td>067972</td>
<td><strong>Research Grants Using the Resources from the Osteoarthritis Initiative (OAI)</strong> (R01 Clinical Trial Not Allowed)</td>
<td>National Institute of Arthritis &amp; Musculoskeletal &amp; Skin Diseases/NIH/DHHS</td>
<td>PA-18-409</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Gayle E. Lester, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-594-3511</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:lester1@mail.nih.gov">lester1@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Institute on Aging (NIA) invite applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources. This FOA will use the NIH R01 Research Project Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>079367</td>
<td><strong>Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed)</strong></td>
<td>National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS</td>
<td>PAR-19-156</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Seila Selimovic, Ph.D. Program Director</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-451-4577</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:seila.selimovic@nih.gov">seila.selimovic@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding Opportunity</td>
<td>Agency</td>
<td>PAR-Number</td>
<td>Application Date</td>
<td>Contact Name</td>
<td>Contact Telephone</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------</td>
<td>------------</td>
<td>-----------------</td>
<td>---------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Bioengineering Research Partnerships (U01 Clinical Trial Required)</td>
<td>National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS</td>
<td>PAR-19-157</td>
<td>07-May-2020</td>
<td>Seila Selimovic, Ph.D. Program Director</td>
<td>301-451-4577</td>
</tr>
<tr>
<td>Synthetic Biology for Engineering Applications (R01 Clinical Trial Optional)</td>
<td>National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS</td>
<td>PAR-18-434</td>
<td>07-May-2020</td>
<td>David Rampulla, Ph.D.</td>
<td>301-451-4778</td>
</tr>
<tr>
<td>Grant Program</td>
<td>Sponsor</td>
<td>Application Deadline</td>
<td>Budget</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------</td>
<td>--------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)</td>
<td>National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Name: Randy King, Ph.D.</td>
<td>Contact Telephone: 301-451-0707</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email: <a href="mailto:randy.king@nih.gov">randy.king@nih.gov</a></td>
<td>Sponsor Website:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis: National Institute of Biomedical Imaging and Bioengineering (NIBIB) invites applications for exploratory/developmental research programs of interest to the NIBIB (<a href="https://www.nibib.nih.gov/research-funding">https://www.nibib.nih.gov/research-funding</a>). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NIBIB Biomedical Technology Resource Centers (P41 Clinical Trials Optional)</th>
<th>National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS</th>
<th>Application Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name: Antonio Sastre, Ph.D.</td>
<td>Contact Telephone: 301-402-1373</td>
<td></td>
<td>Not Specified</td>
</tr>
<tr>
<td>Contact Email: <a href="mailto:sastrea@mail.nih.gov">sastrea@mail.nih.gov</a></td>
<td>Sponsor Website:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL: Link to program URL</td>
<td>Deadline Dates (ALL): 07-May-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis: National Institute of Biomedical Imaging and Bioengineering (NIBIB) invites applications for Biomedical Technology Resource Centers (BTRCs). BTRCs are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. BTRCs also make their technologies available to other investigators, train members of the research community in the use of the technologies, and disseminate the technologies broadly. This FOA will utilize the NIH P41 Biotechnology Resource Grants award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Program Title</td>
<td>National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS</td>
<td>PA-18-418</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------</td>
<td>---------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>069762</td>
<td><strong>NIBIB Research Project Grant (R01 Clinical Trial Required)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Steven H. Krosnick, M.D.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-594-3009</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:krosnics@mail.nih.gov">krosnics@mail.nih.gov</a></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>NIH invites applications for discrete, specified, circumscribed projects in areas representing the specific interests and competencies of the investigator(s). This NIBIB Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of the NIBIB. For this Funding Opportunity Announcement, NIBIB will only support R01 applications proposing early-stage clinical trials through Phase I, first-in-human, safety, feasibility or other small clinical trials that inform early-stage technology development. NIBIB will not support applications proposing Phase II, III, IV or pivotal clinical trials or trials in which the primary outcome is efficacy, effectiveness or a post-market concern. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
</tr>
<tr>
<td>079361</td>
<td><strong>Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)</strong></td>
<td></td>
<td>PAR-19-158</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Seila Selimovic, Ph.D. Program Director</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-451-4577</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:seila.selimovic@nih.gov">seila.selimovic@nih.gov</a></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.</td>
<td></td>
</tr>
<tr>
<td>078963</td>
<td><strong>HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)</strong></td>
<td>National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS</td>
<td>RFA-EB-18-003</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Contact Name</strong></td>
<td>Michael B. Wolfson</td>
<td>301-451-4778</td>
<td><a href="mailto:Michael.Wolfson@nih.gov">Michael.Wolfson@nih.gov</a></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>079360</th>
<th><strong>Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)</strong></th>
<th>National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS</th>
<th>PAR-19-159</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Seila Selimovic, Ph.D. Program Director</td>
<td>301-451-4577</td>
<td><a href="mailto:seila.selimovic@nih.gov">seila.selimovic@nih.gov</a></td>
<td>07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021, 05-Feb-2021, 07-May-2021</td>
<td>Link to program URL</td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

<table>
<thead>
<tr>
<th>Grant Number</th>
<th>Grant Description</th>
<th>Agency</th>
<th>PAR Number</th>
<th>Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>088092</td>
<td>NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)</td>
<td>National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS</td>
<td>PAR-20-084</td>
<td>07-May-2020</td>
<td>400,000 USD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Randy King, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-451-0707</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:Randy.King@nih.gov">Randy.King@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (<a href="https://grants.nih.gov/policy/early-investigators/index.htm">https://grants.nih.gov/policy/early-investigators/index.htm</a>) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>080488</td>
<td>Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)</td>
<td>National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS</td>
<td>PAR-19-215</td>
<td>28-May-2020</td>
<td>200,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Zeynep Erim, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-451-4792</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:erimz@mail.nih.gov">erimz@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


### Synopsis

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIBIB R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral, and clinical research needs. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. This FOA seeks to support programs that include innovative approaches to enhance biomedical engineering design education to ensure a future workforce that can meet the nation’s needs in biomedical research and healthcare technologies. Applications are encouraged from institutions that propose to establish new or to enhance existing team-based design courses or programs in undergraduate biomedical engineering departments or other degree-granting programs with biomedical engineering tracks/minors. This FOA targets the education of undergraduate biomedical engineering/bioengineering students in a team-based environment. While current best practices such as multidisciplinary/interdisciplinary education, introduction to the regulatory pathway and other issues related to the commercialization of medical devices, and clinical immersion remain encouraged components of a strong BME program, this FOA also challenges institutions to propose other novel, innovative, and/or ground-breaking activities that can form the basis of the next generation of biomedical engineering design education.

<table>
<thead>
<tr>
<th>Grant Number</th>
<th>Title</th>
<th>Funding Agency</th>
<th>PA</th>
<th>Deadline Date</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>073285</td>
<td>Research on the Health of Transgender and Gender Nonconforming Populations (R01 Clinical Trial Optional)</td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PA-18-729</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>063272</td>
<td>Small Grants for Secondary Analyses of Existing Data Sets and Stored Biospecimens (R03)</td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PA-17-299</td>
<td>07-May-2020</td>
<td>100,000 USD</td>
</tr>
</tbody>
</table>

**Contact Information**

**Research on the Health of Transgender and Gender Nonconforming Populations (R01 Clinical Trial Optional):**
- **Contact Name:** Della B. White, PhD
- **Contact Telephone:** 301-435-2712
- **Contact Email:** whitede@mail.nih.gov

**Small Grants for Secondary Analyses of Existing Data Sets and Stored Biospecimens (R03):**
- **Contact Name:** Regina Bures, PhD
National Institute of Child Health and Human Development (NICHD) invites applications that propose to conduct secondary analyses of publicly available NICHD-funded data sets or stored biospecimens. The goal of this program is to facilitate innovative yet cost-effective research utilizing data and biospecimens collected with NICHD resources. This program will use the NIH Small Research Grant (R03) award mechanism.

National Institute of Child Health and Human Development (NICHD) invites applications for research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices. Applications can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies, prospective randomized controlled trials, or any combinations thereof. It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring an optimal short- and long-term outcomes for all newborn infants and children. This FOA will use the NIH R03 Small Grant Program award mechanism.
### synopsis

National Institute of Child Health and Human Development (NICHD) invites applications that will identify molecular targets for pregnancy associated/induced disorders and will lead to the development of new safer and more effective medications for use in pregnancy. This FOA will use the NIH Research Project (R01) award mechanism.

#### contact information
- **Name:** Ekaterini Tsiou, MD
- **Telephone:** 301-496-6287
- **Email:** tsiloue@mail.nih.gov

#### program details
- **Deadline Dates:**
  - 07-May-2020
  - 05-Jun-2020
  - 07-Sep-2020
  - 05-Oct-2020
  - 07-Jan-2021

### synopsis

National Institute of Child Health and Human Development (NICHD) invites applications to repurpose already FDA approved drugs for new neonatal and obstetric indications, in order to overcome the difficulties associated with the traditional development of drugs appropriate for use in neonates and pregnant women and facilitate treatment of these vulnerable populations. This FOA will use the NIH Research Project (R01) award mechanism.

#### contact information
- **Name:** Marion Koso-Thomas, M.D, MPH
- **Telephone:** 301-435-6873
- **Email:** kosomari@mail.nih.gov

#### program details
- **Deadline Dates:**
  - 07-May-2020
  - 05-Jun-2020
  - 07-Sep-2020
  - 05-Oct-2020
  - 07-Jan-2021
transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices. Applications can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies, prospective randomized controlled trials, or any combinations thereof. It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Program Title</th>
<th>Agency</th>
<th>FOA Code</th>
<th>Application Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>074138</td>
<td>Identification and Management of Behavioral Symptoms and Mental Health Conditions in Individuals with Intellectual Disabilities (R01 - Clinical Trial Optional)</td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PAR-18-766</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>072576</td>
<td>Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R03 Clinical Trial Optional)</td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PA-18-687</td>
<td>07-May-2020</td>
<td>100,000 USD</td>
</tr>
</tbody>
</table>
### Synopsis
National Institute of Child Health and Human Development (NICHD) and National Institute of Mental Health (NIMH) invite applications for multidisciplinary, investigator-initiated basic translational and clinical research in developmental pharmacodynamics. This FOA seeks grant applications that propose studies to increase and establish data on developmental pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population. This FOA will use the NIH R03 Small Grant Program award mechanism.

#### Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R01 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>George P. Giacoia MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-5589</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:giacoiag@exchange.nih.gov">giacoiag@exchange.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

#### Innovative Therapies and Tools for Screenable Disorders in Newborns (R21 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Melissa Parisi, MD, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-435-6880</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:parisima@mail.nih.gov">parisima@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

#### Deadline Dates (ALL)
National Institute of Child Health and Human Development (NICHD) and National Institute of Mental Health (NIMH) invite applications for multidisciplinary, investigator-initiated basic translational and clinical research in developmental pharmacodynamics. This FOA seeks grant applications that propose studies to increase and establish data on developmental pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population. This FOA will use the NIH R03 Small Grant Program award mechanism.

#### Innovative Therapies and Tools for Screenable Disorders in Newborns (R21 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Melissa Parisi, MD, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-435-6880</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:parisima@mail.nih.gov">parisima@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

#### Deadline Dates (ALL)
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future.
future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

<table>
<thead>
<tr>
<th>FOA Number</th>
<th>FOA Title</th>
<th>Sponsor</th>
<th>PAR-Number</th>
<th>Due Date</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>072588</td>
<td>Innovative Therapies and Tools for Screenable Disorders in Newborns (R03 Clinical Trial Optional)</td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PAR-18-690</td>
<td>07-May-2020</td>
<td>100,000 USD</td>
</tr>
<tr>
<td>072577</td>
<td>Innovative Therapies and Tools for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)</td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PAR-18-689</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

Contact Name: Melissa Parisi, MD, PhD
Contact Telephone: 301-435-6880
Contact Email: parisima@mail.nih.gov
Sponsor Website: [Link to program URL](#)
Program URL: [Link to program URL](#)
Synopsis: National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH R03 Small Grant Program award mechanism.
screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>073287</th>
<th>Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional)</th>
<th>National Institute of Child Health and Human Development/NIH/DHHS</th>
<th>PA-18-728</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Della B. White, PhD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-435-2712</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:whitede@mail.nih.gov">whitede@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>060364</th>
<th>Biomarkers: Bridging Pediatric and Adult Therapeutics (R21)</th>
<th>National Institute of Child Health and Human Development/NIH/DHHS</th>
<th>PAR-17-169</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>George P. Giacoia, MD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-5589</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:gg65m@nih.gov">gg65m@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Child Health and Human Development (NICHD) invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to pediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported by this FOA will include those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have pediatric applications. Discovery of new biomarkers for use in new drug</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

84
### Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01)

**National Institute of Child Health and Human Development/NIH/DHHS**

| PAR-17-193 | 07-May-2020 | Not Specified |

**Synopsis**

National Institute of Child Health and Human Development (NICHD) invites applications to address different and complementary research needs for the development and acceptability of pediatric drug formulations in different age groups. Development and testing of novel pediatric drug delivery systems is also part of this initiative. This FOA will use the NIH Research Project (R01) award mechanism.

### Promoting NICHD Areas of Research for HIV/AIDS in Maternal and Child Health (R01)

**National Institute of Child Health and Human Development/NIH/DHHS**

| PA-17-262 | 07-May-2020 | Not Specified |

**Synopsis**

National Institute of Child Health and Human Development (NICHD) invites applications for HIV/AIDS research by addressing scientific areas of primary interest to NICHD, Maternal and Pediatric Infectious Disease Branch (MPIDB) and the Office of AIDS Research (OAR). This FOA will further explain our interests over the next three years. This FOA will use the NIH Research Project (R01) award mechanism.

### Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R01 - Clinical Trial Optional)

**National Institute of Child Health and Human Development/NIH/DHHS**

| PA-18-790 | 07-May-2020 | Not Specified |

**Synopsis**

Development or in preclinical studies is also part of this FOA. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.
Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 Clinical Trial Optional)

National Institute of Child Health and Human Development/NIH/DHHS

PA-18-838 07-May-2020 2,499,995 USD

Contact Name: Ravi Ravindranath, PhD
Contact Telephone: 301-435-6889
Contact Email: ravindrn@mail.nih.gov
Sponsor Website: Link to program URL
Program URL: Link to program URL

Deadlines:

Synopsis:
National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG,
HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>FOA Number</th>
<th>Title</th>
<th>Agency</th>
<th>PAR Number</th>
<th>Submission Date</th>
<th>Funding</th>
<th>Contact Person</th>
<th>Contact Phone</th>
<th>Email</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>061397</td>
<td>Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R21)</td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PAR-17-192</td>
<td>07-May-2020</td>
<td>275,000</td>
<td>George P. Giacoia, M.D.</td>
<td>301-496-5589</td>
<td><a href="mailto:giacoiag@exchange.nih.gov">giacoiag@exchange.nih.gov</a></td>
<td>Link to program URL</td>
<td>07-May-2020</td>
<td>National Institute of Child Health and Human Development (NICHD) invites applications to address different and complementary research needs for the development and acceptability of pediatric drug formulations in different age groups. This FOA also encourages the development of novel drug delivery systems in the pediatric population. Investigators are encouraged to explore approaches and concepts new to the area of pediatric formulation development and testing and use newly developed techniques superior to the ones currently used in the field. Applications submitted under this mechanism should be exploratory and novel. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.</td>
</tr>
<tr>
<td>061404</td>
<td>Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R03)</td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PAR-17-191</td>
<td>07-May-2020</td>
<td>100,000</td>
<td>George P. Giacoia, M.D.</td>
<td>301-496-5589</td>
<td><a href="mailto:giacoiag@exchange.nih.gov">giacoiag@exchange.nih.gov</a></td>
<td>Link to program URL</td>
<td>07-May-2020</td>
<td>National Institute of Child Health and Human Development (NICHD) invites applications to address different and complementary research needs for the development and acceptability of pediatric drug formulations in different age groups. This FOA also encourages the development of novel drug delivery systems in the pediatric population. Investigators are encouraged to explore approaches and concepts new to the area of pediatric formulation development and testing and...</td>
</tr>
</tbody>
</table>
use newly developed techniques superior to the ones currently used in the field. Applications submitted under this mechanism should be exploratory and novel. This FOA will use the NIH R03 Small Grant Program grant mechanism.

<table>
<thead>
<tr>
<th>Grant ID</th>
<th>Title</th>
<th>Agency</th>
<th>FOA Code</th>
<th>Submission Date</th>
<th>Award Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>074839</td>
<td>Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical Trial Optional)</td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PA-18-791</td>
<td>07-May-2020</td>
<td>100,000 USD</td>
</tr>
<tr>
<td>075841</td>
<td>Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R21 Clinical Trial Optional)</td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PA-18-839</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
</tbody>
</table>

Contact Name: Marion Koso-Thomas, M.D, MPH  
Contact Telephone: 301-435-6873  
Contact Email: kosomari@mail.nih.gov  
Sponsor Website:  
Program URL: Link to program URL  

Synopsis: National Institute of Child Health and Human Development (NICHD) invites applications for a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness. This FOA will use the NIH R03 Small Grant Program award mechanism.

Contact Name: Ravi Ravindranath, PhD  
Contact Telephone: 301-435-6889  
Contact Email: ravindrn@mail.nih.gov  
Sponsor Website:  
Program URL: Link to program URL  

Synopsis: National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to
gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

<table>
<thead>
<tr>
<th>085590</th>
<th>Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)</th>
<th>National Institute of Child Health and Human Development/NIH/DHHS</th>
<th>PAR-19-375 07-May-2020</th>
<th>200,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synopsis</td>
<td>The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The goal of the Gabriella Miller Kids First Pediatric Data Resource is to build a collection of curated genomic and phenotypic data from childhood cancer and birth defects cohorts and provide a central portal where data and analysis tools will be readily accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>079181</th>
<th>Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 - Clinical Trial Required)</th>
<th>National Institute of Child Health and Human Development/NIH/DHHS</th>
<th>PAR-19-133 25-Feb-2020</th>
<th>300,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Mahua Mukhopadhyay, PhD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-435-6886</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:mukhopam@mail.nih.gov">mukhopam@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Synopsis**
The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences for undergraduate students and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Regina Bures, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-9485</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:regina.bures@nih.gov">regina.bures@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**
The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>NICHD Referral Office</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td><a href="mailto:NICHDReferral@mail.nih.gov">NICHDReferral@mail.nih.gov</a></td>
</tr>
</tbody>
</table>

**Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)**

| National Institute of Child Health and Human Development/NIH/DHHS | PAR-20-064 | 07-May-2020 | 100,000 USD |

**NICHD Exploratory/Developmental Research Grant (R21 - Clinical Trial Optional)**

| National Institute of Child Health and Human Development/NIH/DHHS | PA-18-482 | 07-May-2020 | 275,000 USD |

90
<table>
<thead>
<tr>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Link to program URL</td>
<td>07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021</td>
<td>National Institute of Child Health and Human Development (NICHD) invites applications for exploratory and developmental research projects that fall within the NICHD mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
<td></td>
</tr>
<tr>
<td>070064 <strong>NICHD Small Grant Program (R03 Clinical Trial Optional)</strong></td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PA-18-481</td>
<td>07-May-2020</td>
</tr>
<tr>
<td>Contact Name</td>
<td>NICHD Referral Office</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:NICHDReferral@mail.nih.gov">NICHDReferral@mail.nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Child Health and Human Development (NICHD) invites applications for small research projects that can be carried out in a short period of time with limited resources. The R03 activity code supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This FOA will use the NIH R03 Small Grant Program award mechanism.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>070059 <strong>NICHD Research Project Grant (R01 - Clinical Trial Required)</strong></td>
<td>National Institute of Child Health and Human Development/NIH/DHHS</td>
<td>PA-18-480</td>
<td>07-May-2020</td>
</tr>
<tr>
<td>Contact Name</td>
<td>NICHD Referral Office</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:NICHDReferral@mail.nih.gov">NICHDReferral@mail.nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
National Institute of Child Health and Human Development (NICHD) invites applications for clinical trials that fall within the NICHD mission. This FOA will use the NIH Research Project (R01) award mechanism.

### Biological Testing Facility Access For Contraceptive Development (X01 Clinical Trial Not Allowed)

**Contact Name:** David H. Weinberg, PhD  
**Contact Telephone:** 301-526-0349  
**Contact Email:** david.weinberg@nih.gov

**Program URL**: [Link to program URL](#)

**Deadline Dates (ALL):** 01-May-2020

**Synopsis:** The NICHD has a state-of-the-art Biological Testing Facility for advancing male and/or female non-hormonal contraception development with the capabilities and capacity for preclinical and Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., fertility studies, pharmacology, toxicology, reproductive tract histopathology, sperm morphology). The purpose of this FOA is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program.

### Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Independent Clinical Trial Not Allowed)

**Contact Name:** Lynn Mertens King, PhD  
**Contact Telephone:** 301-594-5006  
**Contact Email:** Lynn.King@nih.gov

**Program URL**: [Link to program URL](#)


**Synopsis:** This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career enhancement (K18) awards in dental, oral and craniofacial (DOC) research with a focus on behavioral and social sciences, and on genetics, genomics, bioinformatics and computational biology research. The intent of this program is to provide mid-career and senior investigators with short-term training in the theories, tools, methods or approaches of another scientific area, in order to enhance their existing research program.

Two categories of candidates are targeted: (a) established DOC research investigators who seek training with investigators from another field, in order to enrich their existing DOC research program;
and (b) established investigators in other fields who seek training with DOC research investigators in order to facilitate the introduction of DOC research into an existing research program. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

**Clinical Research to Improve the Oral Health of Older Adults (R01 Clinical Trial Not Allowed)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Darien Weatherspoon, DDS, MPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-594-5394</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:darien.weatherspoon@mail.nih.gov">darien.weatherspoon@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td><a href="https://nih.gov">Link to program URL</a></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to address gaps in our knowledge related to the risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines “older adults” as those individuals age 65 years and older.</td>
</tr>
</tbody>
</table>

**Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01 Clinical Trial Not Allowed)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Kathryn Stein, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-827-4653</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:kathryn.stein@nih.gov">kathryn.stein@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td><a href="https://nih.gov">Link to program URL</a></td>
</tr>
<tr>
<td>Synopsis</td>
<td>This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS, and NICHD solicit applications that use animal models, in vitro systems, or ex vivo approaches to conduct mechanistic...</td>
</tr>
</tbody>
</table>
### NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

**Synopsis**

National Institute of Dental and Craniofacial Research (NIDCR) invites applications for UG3/UH3 phased cooperative agreement research applications to plan and implement clinical trials within the mission of NIDCR. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase will permit the Program Director/Principal Investigator to finalize the study team and will support activities to develop: the final clinical protocol; the Clinical Investigator’s Brochure (or equivalent), if needed; the data management system and other tools for data collection and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UG3 planning phase is not designed for pre-clinical studies with animals, the collection of preliminary data on the efficacy of the intervention (such as pilot testing), or the collection of observational data from humans to support the rationale for a clinical trial. Evaluation of the potential subject population to determine individuals’ eligibility for participation in the future UH3 trial is allowed in the UG3 phase but not required. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>J Dena Fischer, DDS, MSD, MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-594-4876</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:dena.fischer@nih.gov">dena.fischer@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

### Precision Imaging of Oral Lesions (R21-Clinical Trial Not Allowed)

**Synopsis**

National Institute of Dental and Craniofacial Research (NIDCR) invites applications for UG3/UH3 phased cooperative agreement research applications to plan and implement clinical trials within the mission of NIDCR. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase will permit the Program Director/Principal Investigator to finalize the study team and will support activities to develop: the final clinical protocol; the Clinical Investigator’s Brochure (or equivalent), if needed; the data management system and other tools for data collection and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UG3 planning phase is not designed for pre-clinical studies with animals, the collection of preliminary data on the efficacy of the intervention (such as pilot testing), or the collection of observational data from humans to support the rationale for a clinical trial. Evaluation of the potential subject population to determine individuals’ eligibility for participation in the future UH3 trial is allowed in the UG3 phase but not required. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Chiayeng Wang, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-827-4647</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:chiayeng.wang@nih.gov">chiayeng.wang@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>-------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>072634</th>
<th>Basic and Translational Oral Health Research Related to HIV/AIDS (R21 Clinical Trial Not Allowed)</th>
<th>National Institute of Dental and Craniofacial Research/NIH/DHHS</th>
<th>PA-18-695</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Gallya Gannot, DMD, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-451-5096</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:gallya.gannot@nih.gov">gallya.gannot@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Dental and Craniofacial Research (NIDCR) invites applications for innovative basic and translational research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in the oral cavity. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>083077</th>
<th>Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21 Clinical Trial Not Allowed)</th>
<th>National Institute of Dental and Craniofacial Research/NIH/DHHS</th>
<th>PAR-19-293</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Kathryn Stein, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-827-4653</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:kathryn.stein@nih.gov">kathryn.stein@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS, and NICHD solicit applications to develop novel and robust experimental systems that offer approaches complementary to human epidemiologic or in vivo studies to facilitate mechanistic investigation of gene-environment interplay in dental, oral, craniofacial, and other diseases and conditions.

<table>
<thead>
<tr>
<th>FOA Number</th>
<th>Title</th>
<th>Agency</th>
<th>PA/Grant</th>
<th>Due Date</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>076575</td>
<td><strong>Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R21 - Clinical Trial Not Allowed)</strong></td>
<td>National Institute of Dental and Craniofacial Research/NIH/DHHS</td>
<td>PA-18-874</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td>074728</td>
<td><strong>Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed)</strong></td>
<td>National Institute of Dental and Craniofacial Research/NIH/DHHS</td>
<td>PAR-18-787</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

**Synopsis**

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the NIH Research Project (R01) award mechanism.
<table>
<thead>
<tr>
<th>Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01 - Clinical Trial Not Allowed)</th>
<th>National Institute of Dental and Craniofacial Research/NIH/DHHS PAR-18-875 07-May-2020 Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Darien Weatherspoon, DDS, MPH</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-594-5394</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:darien.weatherspoon@mail.nih.gov">darien.weatherspoon@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence. This FOA will use the NIH Research Project (R01) award mechanism.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NIDCR Small Grant Program for New Investigators (R03)</th>
<th>National Institute of Dental and Craniofacial Research/NIH/DHHS PAR-19-370 07-May-2020 200,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>R. Dwayne Lunsford, PhD</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-827-4635</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:lunsfordr@nidcr.nih.gov">lunsfordr@nidcr.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Small Grant Program for New Investigators. The program supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator-initiated Research Project Grant (R01) or equivalent application. This FOA will utilize the NIH R03 Small Grant Program.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)</th>
<th>National Institute of Dental and Craniofacial Research/NIH/DHHS PAR-19-134 25-Feb-2020 300,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
</tr>
</tbody>
</table>
The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees in health professions and have received less than $6 million per year of NIH support (total costs) in 4 of the last 7 fiscal years. In this FOA, a college is a stand-alone entity and not a component of a university system.

**Synopsis**

National Institute of Dental and Craniofacial Research (NIDCR) invites research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include traditional clinical trials to develop and test behavior change interventions for preventing and treating dental, oral, or craniofacial conditions, as well as interventions that are used as tools to understand mechanisms of behavior change. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application,
following the instructions described in this FOA. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UH3 phase of the award will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stage 0 & I) through implementation and cost-effectiveness research (Stages IV/V). This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.

### Improving Oral Health and Reducing Disparities in Adolescents (R21 Clinical Trial Not Allowed)

**Contact Name:** Darien Weatherspoon, DDS, MPH  
**Contact Telephone:** 301-594-5394  
**Contact Email:** darien.weatherspoon@nih.gov  
**Sponsor Website:** Link to program URL

**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.

### Improving Oral Health and Reducing Disparities in Adolescents (R01 Clinical Trial Not Allowed)

**Contact Name:** Darien Weatherspoon, DDS, MPH  
**Contact Telephone:** 301-594-5394  
**Contact Email:** darien.weatherspoon@nih.gov  
**Sponsor Website:** Link to program URL

**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.
### NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Dena Fischer, DDS, MSD, MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-594-4876</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:dena.fischer@nih.gov">dena.fischer@nih.gov</a></td>
</tr>
</tbody>
</table>

**Synopsis**

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.

### NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Basic Experimental Studies with Humans Required)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Leslie A. Frieden, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-4263</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></td>
</tr>
</tbody>
</table>

**Synopsis**

The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with opportunity to transition from mentored research experiences in the NIH Intramural program to extramural institutions as new investigators with independent...
research funding. This Funding Opportunity Announcement (FOA) is designed specifically for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should apply to the companion ‘Clinical Trial Required’ FOA (PAR-18-360). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-19-152).

The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-18-359).
<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Darien Weatherspoon, DDS, MPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-594-5394</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:darien.weatherspoon@nih.gov">darien.weatherspoon@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

### Synopsis

The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or to develop needed statistical methodology for analyzing oral and craniofacial data using existing oral or craniofacial databases. The R03 grant mechanism supports research limited in time and amount for studies in categorical program areas.
The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trial Required’ NIDCR K01 (PAR-18-359). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NIDCR K01 PAR-19-160 Clinical Trial Not Allowed.
The purpose of the NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00) is to support outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical, clinical, behavioral and social sciences, over the transition from predoctoral to postdoctoral research training. This phased award program will facilitate completion of graduate PhD or dual degree clinician scientist programs (F99) and progression to mentored postdoctoral positions in dental, oral and craniofacial research (K00). It is anticipated that successful completion of this phased award program will enable achievement of an independent research faculty position and subsequent NIDCR career development and research project awards. This Funding Opportunity Announcement (FOA) does not allow prospective fellows to propose to lead an independent clinical trial, but does allow prospective fellows to propose research experience in a clinical trial led by a sponsor or co-sponsor.

### NIDCR Research Grants for Analyses of Existing Genomics Data (R01 Clinical Trial Not Allowed)

**National Institute of Dental and Craniofacial Research/NIH/DHHS**

| PAR-20-045 | 07-May-2020 | Not Specified |

**Contact Name** Lu Wang, Ph.D.

**Contact Telephone** 301-594-4846

**Contact Email** wanglu@nidcr.nih.gov

**Sponsor Website** [Link to program URL](#)

**Program URL** [Link to program URL](#)


**Synopsis**

The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML). In addition to analysis of existing data, experimental or in silico work is required to validate data analysis results, or to validate a newly developed analytic method. Work that tackles causal mechanisms of action for onset and progression of disease for identified candidate causal genetic variants is highly encouraged.

### NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)

**National Institute of Dental and Craniofacial Research/NIH/DHHS**

| PAR-20-046 | 07-May-2020 | 200,000 USD |

**Contact Name** Lu Wang, Ph.D.

**Contact Telephone** 301-594-4846

**Contact Email** wanglu@nidcr.nih.gov

**Sponsor Website** [Link to program URL](#)

**Program URL** [Link to program URL](#)


**Synopsis**

The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML). In addition to analysis of existing data, experimental or in silico work is required to validate data analysis results, or to validate a newly developed analytic method. Work that tackles causal mechanisms of action for onset and progression of disease for identified candidate causal genetic variants is highly encouraged.
### NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01-Clinical Trial Required)

**Contact Name**: Lynn Mertens King, PhD  
**Contact Telephone**: 301-594-5006  
**Contact Email**: lynn.king@nih.gov  
**Sponsor Website**: Link to program URL  
**Program URL**: Link to program URL  

**Synopsis**: The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML).

<table>
<thead>
<tr>
<th>Program Name</th>
<th>Sponsor</th>
<th>FOA Number</th>
<th>Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01-Clinical Trial Required)</td>
<td>National Institute of Dental and Craniofacial Research/NIH/DHHS</td>
<td>PAR-18-359</td>
<td>07-May-2020</td>
<td>625,000 USD</td>
</tr>
</tbody>
</table>

### NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Required)

**Contact Name**: Leslie A. Frieden, PhD  
**Contact Telephone**: 301-496-4263  
**Sponsor Website**: Link to program URL  
**Program URL**: Link to program URL  

**Synopsis**: National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Mentored Career Development Award. The award is designed to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior faculty who are from groups that have been shown to be nationally underrepresented in the basic and clinical biomedical, behavioral, and social sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K01 Research Scientist Development Award - Research & Training award mechanism.

<table>
<thead>
<tr>
<th>Program Name</th>
<th>Sponsor</th>
<th>FOA Number</th>
<th>Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Required)</td>
<td>National Institute of Dental and Craniofacial Research/NIH/DHHS</td>
<td>PAR-18-360</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>
National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program. This program provides highly qualified dentists in NIH Intramural postdoctoral fellowship positions with an opportunity to receive further mentored research experience in the NIH Intramural program, and then to provide them with independent funding to facilitate the transition of their research programs as new investigators at extramural institutions. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K22 Career Transition Award mechanism.

Contact Name: Leslie A. Frieden, Ph.D.
Contact Telephone: 301-496-4263
Contact Email: leslie.frieden@mail.nih.gov
Sponsor Website: Link to program URL
Program URL: Link to program URL
Synopsis: National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the Pathway to Independence Award (K99/R00). The primary purpose of the Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical specialty training at no more than 3 person-months effort (25% effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K99/R00 Career Transition Award/Research Transition Award mechanism.
<table>
<thead>
<tr>
<th>079225</th>
<th>NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)</th>
<th>National Institute of Dental and Craniofacial Research/NIH/DHHS</th>
<th>PAR-19-144</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Leslie A. Frieden, PhD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-4263</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-18-432). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19-141). The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase.

<table>
<thead>
<tr>
<th>079222</th>
<th>NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Independent Basic Experimental Studies with Humans Required)</th>
<th>National Institute of Dental and Craniofacial Research/NIH/DHHS</th>
<th>PAR-19-141</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Leslie A. Frieden, PhD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-4263</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ FOA (PAR-18-432). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-19-144).

### 081272 Clinical Research to Improve the Oral Health of Older Adults (R21 Clinical Trial Not Allowed)

**National Institute of Dental and Craniofacial Research/NIH/DHHS**

PAR-19-240 07-May-2020 275,000 USD

**Contact Name**
Darien Weatherspoon, DDS, MPH

**Contact Telephone**
301-594-5394

**Contact Email**
darien.weatherspoon@mail.nih.

**Sponsor Website**
[Link to program URL](#)

**Deadline Dates (ALL)**

**Synopsis**
The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to address risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines “older adults” as those individuals age 65 years and older.

### 072628 Basic and Translational Oral Health Research Related to HIV/AIDS (R01 Clinical Trial Not Allowed)

**National Institute of Dental and Craniofacial Research/NIH/DHHS**

PA-18-699 07-May-2020 Not Specified

**Contact Name**
Gallya Gannot, DMD, Ph.D.

**Contact Telephone**
301-451-5096

**Synopsis**
This FOA is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ FOA (PAR-18-432). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-19-144).
<table>
<thead>
<tr>
<th>Program Title</th>
<th>Sponsor</th>
<th>FOA ID</th>
<th>Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)</strong></td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</td>
<td>PAR-19-222</td>
<td>07-May-2020</td>
<td>375,000 USD</td>
</tr>
<tr>
<td><strong>Medical Simulators for Practicing Patient Care Providers Skill Acquisition, Outcomes Assessment and Technology Development (R01 Clinical Trial Not Allowed)</strong></td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</td>
<td>PA-19-065</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>
The purpose of the Funding Opportunity Announcement (FOA) is to promote the assessment and further development of simulation technologies intended to improve patient safety and healthcare outcomes provided by practicing patient care providers and experienced (not trainee) physicians. The FOA seeks applications directed toward three areas of research: 1) Skill Acquisition: to evaluate strategies and protocols for simulation-based methods for skill acquisition and maintenance by experienced clinicians; 2) Outcomes Assessment: to assess the relationship of simulation-based assessments of skills demonstrated by experienced clinicians with the quality of clinical care delivered by those clinicians, and to identify strategies to increase the quality of simulation-based assessments of skills; and 3) Technology Development: to develop “virtual coaches” by incorporating intelligent technologies into existing simulators to provide adaptive, cognitive assistance to coach experienced practitioners in retaining, retraining and improving performance levels in the context of the user environment (and physiological system as appropriate).
junior faculty (usually with a Ph.D. degree) in biomedical, behavioral, or clinical sciences who are pursuing careers in research areas supported by the NIDDK. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial that is itself comprised of a clinical trial intervention(s). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training award mechanism.

**NIDDK Multi-Center Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)**

- National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
- PAR-18-415
- 07-May-2020
- Not Specified

**Contact Name**: Marva Moxey-Mims, M.D
- **Contact Telephone**: 301-594-7717
- **Contact Email**: mimsm@mail.nih.gov
- **Sponsor Website**: Link to program URL
- **Deadline Dates (ALL)**: 07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021

**Synopsis**: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for investigator-initiated, multi-center clinical trials involving three or more clinical centers. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-18-423). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application. This program use the NIH U01 grant mechanism.

**NIDDK Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)**

- National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
- PAR-18-414
- 07-May-2020
- Not Specified

**Contact Name**: Tracy Rankin, Ph.D., M.P.H.
- **Contact Telephone**: 301-594-4748
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for investigator-initiated, multi-center clinical trials involving three or more clinical centers. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-18-423). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application. This program uses the NIH U01 grant mechanism.

<table>
<thead>
<tr>
<th>Program Code</th>
<th>Program Title</th>
<th>Sponsor</th>
<th>Type</th>
<th>PAR Number</th>
<th>Application Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>069920</td>
<td>NIDDK Mentored Research Scientist Development Award (K01 - Clinical Trial Required)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</td>
<td>Grant</td>
<td>PAR-18-418</td>
<td>07-May-2020</td>
<td>575,000 USD</td>
</tr>
</tbody>
</table>

Synopsis:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for Mentored Research Scientist Development Awards (K01). The awards provide support and protected time for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. The NIDDK invites K01 applications from experienced postdoctoral (two years minimum) and/or recently appointed junior faculty (usually with a Ph.D. degree) in biomedical, behavioral, or clinical sciences who are pursuing careers in research areas supported by the NIDDK. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. The ancillary study

Contact Name: Lisa M. Spain, Ph.D.
Contact Telephone: 301-451-9871
Contact Email: SpainL@niddk.nih.gov
Program URL: Link to program URL
must also meet the NIH clinical trial definition. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training award mechanism.

<table>
<thead>
<tr>
<th>FOA ID</th>
<th>FOA Title</th>
<th>Agency</th>
<th>PA</th>
<th>Deadline Date</th>
<th>Funding</th>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>069548</td>
<td>Pilot and Feasibility Therapeutic Clinical Trials in Diabetes, and Endocrine and Metabolic Diseases (R21 Clinical Trial Required)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</td>
<td>PA-18-405</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
<td>Yan Li</td>
<td>301-435-3721</td>
<td><a href="mailto:liy7@mail.nih.gov">liy7@mail.nih.gov</a></td>
<td>Link to program URL</td>
<td>07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites pilot and feasibility therapeutic trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diabetes or selected endocrine and genetic metabolic diseases within the mission of NIDDK. The program will support short-term clinical trials in humans to acquire preliminary data and/or refine power calculations that would lead to a larger, more definitive study impacting clinical care or health outcomes. This FOA is not appropriate for mechanistic clinical trials. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.</td>
<td></td>
</tr>
<tr>
<td>080578</td>
<td>RFA-DK-19-002 -- Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</td>
<td>RFA-DK-19-002</td>
<td>03-May-2020 [Optional][LOI/Pre-App]</td>
<td>3,750,000 USD</td>
<td>Mary E. Evans, Ph.D.</td>
<td>301-594-4578</td>
<td><a href="mailto:evansmary@niddk.nih.gov">evansmary@niddk.nih.gov</a></td>
<td>Link to program URL</td>
<td>03-May-2020 [Optional][LOI/Pre-App], 02-Jun-2020</td>
<td>This Funding Opportunity Announcement (FOA) invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and</td>
<td></td>
</tr>
</tbody>
</table>
The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity. NORCs support three primary research-related activities: Research Core services, a Pilot and Feasibility (P and F) program, and an Enrichment program. All activities pursued by Nutrition Obesity Research Centers are designed to enhance the efficiency, productivity, effectiveness and multidisciplinary nature of research in nutrition and obesity. The NIDDK Nutrition Obesity Research Centers program consists of 12 Centers, each located at outstanding research institutions with documented programs of excellence in nutrition and/or obesity research.

<table>
<thead>
<tr>
<th>ID</th>
<th>Program Name</th>
<th>Sponsor</th>
<th>PAR-Number</th>
<th>Submission Dates</th>
<th>Budget (USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>073342</td>
<td><strong>New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)</strong></td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</td>
<td>PAS-18-730</td>
<td>07-May-2020</td>
<td>600,000</td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney diseases. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.
### Synopsis
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications in nonmalignant hematology research. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build and promote research activities in nonmalignant hematology. Innovative research project applications that will steer the field in new directions are invited. Each project will propose proof of principle research that is tightly focused into one specific aim and is directed at validating novel concepts and approaches that promise to open up new pathways for discovery. Research applications submitted under this FOA should be more limited in scope (a single central aim) and duration (1-3 years) than typical R01 grant applications. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>Grant Number</th>
<th>Title</th>
<th>Agency</th>
<th>PA Number</th>
<th>Name of Principal Investigator</th>
<th>Application Due Date</th>
<th>Budget</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>073411</td>
<td>Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</td>
<td>PA-18-741</td>
<td>Aynur Unalp-Arida, MD, MSc, PhD</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
<td></td>
</tr>
</tbody>
</table>
Research that explores innovative hypotheses through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentation of data. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

<table>
<thead>
<tr>
<th>Program URL</th>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>073445</td>
<td>Ziya Kirkali, M.D.</td>
<td>301-594-7717</td>
<td><a href="mailto:ziya.kirkali@nih.gov">ziya.kirkali@nih.gov</a></td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</td>
<td>07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of prevention, diagnosis or treatment of urologic disorders. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.</td>
</tr>
</tbody>
</table>
**Synopsis**

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children. Exploratory epidemiological research with a goal of informing translational/clinical research will also be supported within this program. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.

<table>
<thead>
<tr>
<th>FOA Number</th>
<th>Funding Opportunity Title</th>
<th>Lead Institute</th>
<th>PA Number</th>
<th>Due Date</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>065495</td>
<td>Limited Competition: Lasker Clinical Research Scholars Transition Award (R00)</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</td>
<td>PAR-17-450</td>
<td>07-May-2020</td>
<td>2,495,000 USD</td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Institute of Environmental Health Sciences (NIEHS) invite applications for support of research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility. This FOA will use the NIH R00 Research Transition Award mechanism.

<table>
<thead>
<tr>
<th>FOA Number</th>
<th>Funding Opportunity Title</th>
<th>Lead Institute</th>
<th>PA Number</th>
<th>Due Date</th>
<th>Amount</th>
</tr>
</thead>
</table>
**Deadline Dates (ALL)**


National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity related policy and/or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. This FOA will utilize the NIH R01 Research Project Grant award mechanism.

<table>
<thead>
<tr>
<th>076238</th>
<th><strong>Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Not Allowed)</strong></th>
<th>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</th>
<th>PA-18-856</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Mary Evans, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-594-4578</td>
<td>Contact Email</td>
<td><a href="mailto:evansmary@niddk.nih.gov">evansmary@niddk.nih.gov</a></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:evansmary@niddk.nih.gov">evansmary@niddk.nih.gov</a></td>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021, 05-Feb-2021, 07-May-2021, 05-Jun-2021, 07-Sep-2021</td>
<td>Synopsis</td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet...</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

<table>
<thead>
<tr>
<th>FOA Code</th>
<th>Title</th>
<th>Agency</th>
<th>Program Code</th>
<th>Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>076246</td>
<td><strong>Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)</strong></td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</td>
<td>PAR-18-857</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td>076910</td>
<td><strong>Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21 Clinical Trial Optional)</strong></td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</td>
<td>PA-18-903</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
</tbody>
</table>

Contact Name: Mary Evans, Ph.D.
Contact Telephone: 301-594-4578
Contact Email: evansmary@niddk.nih.gov
Sponsor Website: [Link to program URL](#)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for research concepts for clinical pilot and feasibility research studies; and translational research studies in digestive diseases and nutrition. Specifically, this FOA is inviting two types of studies: Clinical Pilot and Feasibility study proposals; and Clinical Translational Science proposals that will promote exploratory and novel science through the use of human subjects biospecimens. The following studies will not be supported by this FOA: those that have obesity as a component of the study proposal (please refer to the Office of Extramural Research Grants and Funding to search for multiple obesity related Funding Opportunity Announcements at https://grants.nih.gov/grants/oer.htm ); and translational studies that utilize animal models. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)

National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS

PAR-19-365 07-May-2020 150,000 USD

Contact Name Lisa M. Spain, Ph.D.
Contact Telephone 301-451-9871
Contact Email SpainL@niddk.nih.gov
Sponsor Website Link to program URL
Program URL


Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to provide NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or
The purpose of this Funding Opportunity Announcement is to invite U54 cooperative agreement applications for Cooperative Centers of Excellence in Hematology (CCEH). The NIDDK Hematology Centers Program is designed to increase access to critical research resources and collaboration in the national multidisciplinary research effort to combat nonmalignant hematologic diseases and to study normal hematopoiesis. In addition, it aims to improve cost-effectiveness of preparing critical reagents, maintaining state-of-the-art resources, and running multi-step molecular biologic assays. Each CCEH will support a minimum of three Biomedical Research Cores, an Administrative Core, and an Enrichment Program. The CCEH are expected to work collaboratively with the NIDDK Hematology Central Coordinating Center -- together comprising the NIDDK Hematology Centers Program. By providing state-of-the-art equipment, resources, and expertise to the greater nonmalignant hematology research community, the program will serve as a national hub for nonmalignant hematology research, supporting career development of scientists just beginning their careers in the field and attracting established investigators from other domains. Funded Centers will cooperate with the NIDDK to facilitate research collaborations and interactions within and among Centers and with the wider research community.
# Bioinformatics Interdisciplinary Postdoctoral Fellowship in Diabetes, Endocrinology and Metabolic Diseases (F32)

This funding opportunity is to enable promising postdoctoral fellows to obtain interdisciplinary training from outstanding faculty sponsors in bioinformatics and scientific research relevant to the mission of NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD). This training will require mentorship in both bioinformatics and metabolic disease disciplines. In order to advance bioinformatics science and encourage its application to these diseases and disorders, NIDDK invites applications from individuals with novel individual development plans (IDP). The fellowship training plan should focus on interdisciplinary approaches and mentorship among data or computer science and medicine in topics related to diabetes, endocrinology and metabolic diseases. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Arthur L. Castle, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-594-7719</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:castlea@niddk.nih.gov">castlea@niddk.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>This Funding Opportunity Announcement (FOA) is to enable promising postdoctoral fellows to obtain interdisciplinary training from outstanding faculty sponsors in bioinformatics and scientific research relevant to the mission of NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases.</td>
</tr>
</tbody>
</table>
Diseases (DDEMD). This training will require mentorship in both bioinformatics and metabolic disease disciplines. In order to advance bioinformatics science and encourage its application to these diseases and disorders, NIDDK invites applications from individuals with novel individual development plans (IDP). The fellowship training plan should focus on interdisciplinary approaches and mentorship among data or computer science and medicine in topics related to diabetes, endocrinology and metabolic diseases. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

**Investigator-Initiated Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)**

- **Contact Name**: Tracy Rankin, Ph.D., M.P.H.
- **Contact Telephone**: 301-594-4748
- **Contact Email**: rankint@mail.nih.gov
- **Sponsor Website**: Link to program URL
- **Program URL**: Link to program URL
- **Deadline Dates (ALL)**: 07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021

**Synopsis**

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for investigator-initiated clinical trials within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to be conducted at no more than two clinical research centers. NIDDK is committed to improving the health of people with diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic and hematologic diseases. Applications for clinical trials submitted under this FOA should be hypothesis driven, have clearly described aims and objectives, and have a high likelihood that the trial findings will improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. This FOA will use the NIH Research Project (R01) award mechanism.

**RFA-DK-19-017 -- The Physiology of the Weight Reduced State Clinical Trial Consortium (UG3/UH3 Clinical Trial Required)**

- **Contact Name**: Maren R Laughlin, Ph.D.
- **Contact Telephone**: 301-594-8802

**Synopsis**

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for investigator-initiated clinical trials within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to be conducted at no more than two clinical research centers. NIDDK is committed to improving the health of people with diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic and hematologic diseases. Applications for clinical trials submitted under this FOA should be hypothesis driven, have clearly described aims and objectives, and have a high likelihood that the trial findings will improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. This FOA will use the NIH Research Project (R01) award mechanism.
Following intentional weight loss, physiological processes including altered appetite and decreased energy expenditure create a tendency toward regain of lost weight. This Funding Opportunity Announcement (FOA) invites UG3/UH3 cooperative agreement applications from multidisciplinary teams that propose to conduct collaborative mechanistic clinical trials focused on elucidation of the physiological mechanisms underlying individual variability in maintenance of reduced weight over time. This FOA will not support studies with a goal to evaluate the efficacy of interventions for weight loss or maintenance of reduced weight. Participants must be studied before and after a successful behavioral/lifestyle weight loss intervention to determine the extent, durability, and mechanisms for physiologic adaptations to weight loss, including metabolic and biobehavioral mechanisms. It is expected that tissue biospecimens will be collected that can be used to identify potential metabolic pathways that are altered after weight loss and may render it more difficult to maintain the reduced weight. This Funding Opportunity Announcement (FOA) will use the bi-phasic, milestone-driven UG3/UH3 cooperative agreement mechanism in parallel with a companion FOA, RFA DK-19-018, Physiology of the Weight Reduced State Data Coordinating Center (U24 Clinical Trial Not Allowed). Awards made under this FOA will initially support a planning/preparation phase (UG3) for approximately one year with possible transition to a study (UH3) phase of up to four additional years once planning milestones are met. Applications submitted in response to this FOA must propose activities for both phases and are expected to include plans for project management and performance milestones for each phase.
This Funding Opportunity Announcement (FOA) invites U24 cooperative agreement applications for a Data Coordination Center to participate in a clinical trial focused on elucidation of the physiological mechanisms underlying individual variability in maintenance of reduced weight over time. A companion FOA (RFA DK-19-017, The Physiology of the Weight Reduced State Clinical Trial Consortium (UG3/UH3 Clinical Trial Required) invites Clinical Centers (CC) to recruit and study participants before and after a behavioral/lifestyle weight loss intervention to determine the extent, durability and mechanisms for physiologic adaptations to weight loss, including metabolic and biobehavioral mechanisms. It is expected that tissue biospecimens will be collected that can be used to identify potential metabolic pathways that are altered after weight loss and may render it more difficult to maintain the reduced weight.

<table>
<thead>
<tr>
<th>087569</th>
<th><strong>Limited Competition: NIDDK Program Projects (P01 Clinical Trial Optional)</strong></th>
<th>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</th>
<th>PAR-20-075</th>
<th>18-Mar-2020</th>
<th>6,250,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Contact Name</strong></td>
<td>Bonnie Burgess-Beusse, Ph.D.</td>
<td><strong>Contact Telephone</strong></td>
<td>301-594-4726</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:Bonnie.Burgess-Beusse@nih.gov">Bonnie.Burgess-Beusse@nih.gov</a></td>
<td><strong>Sponsor Website</strong></td>
<td>Link to program URL</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Synopsis</strong></td>
<td>This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Research Program Project Grant (P01) renewal (Type 2) applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at <a href="https://www.niddk.nih.gov/about-niddk/research-areas">https://www.niddk.nih.gov/about-niddk/research-areas</a>.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>071705</th>
<th><strong>Pilot and Feasibility Studies of HIV and Animal Models for HIV Infection within the Mission of NIDDK (R21 Clinical Trial Optional)</strong></th>
<th>National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS</th>
<th>PA-18-615</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Contact Name</strong></td>
<td>Peter J. Perrin, Ph.D.</td>
<td><strong>Contact Telephone</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td><strong>Deadline Dates (ALL)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Synopsis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

125
| **Synopsis** | This Funding Opportunity Announcement (FOA) invites applications for innovative basic and translational research projects examining HIV infection, persistence, and comorbidities as they relate to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that are consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) in NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. |
| **Program URL** | Link to program URL |
| **Contact Name** | Peter J. Perrin, Ph.D. |
| **Contact Telephone** | 301-451-3759 |
| **Contact Email** | Peter.Perrin@nih.gov |

| **High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)** | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAS-18-698 | 07-May-2020 | Not Specified |
| **Contact Name** | Peter J. Perrin, Ph.D. |
| **Contact Telephone** | 301-451-3759 |
| **Contact Email** | Peter.Perrin@nih.gov |
| **Sponsor Website** | Link to program URL |
| **Program URL** | Link to program URL |
| **Synopsis** | This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities are described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. |

| **Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Independent Basic Experimental Studies with Humans Required)** | National Institute of Environmental Health Sciences/NIH/DHHS | PAR-19-225 | 07-May-2020 | 375,000 USD |
| **Contact Name** | Carol Shreffler, PhD |
The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. Note: This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion ‘Independent Clinical Trial Required’ PAR 18-261.
This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.

<table>
<thead>
<tr>
<th>RFA-ES-20-006</th>
<th>18-Apr-2020</th>
<th>3,400,000 USD</th>
</tr>
</thead>
</table>

This Funding Opportunity Announcement (FOA) invites grant applications for Environmental Health Sciences Core Centers (EHSCC). As intellectual hubs for environmental health science research, the EHSCC is expected to be the thought leaders for the field and advance the goals of the NIEHS Strategic Plan (http://www.niehs.nih.gov/about/strategicplan/). The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators conducting environmental health sciences research. An EHSCC enables researchers to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively. The overall goal of an EHSCC is to identify and capitalize on emerging issues that advance improving the understanding of the relationships among environmental exposures, human biology, and disease. The EHSCC supports community engagement and translational research as key approaches to improving public health.
<table>
<thead>
<tr>
<th>Grant Number</th>
<th>Grant Description</th>
<th>Institute</th>
<th>PAR-Number</th>
<th>Start Date</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>085464</td>
<td>Maximizing Investigators' Research Award (R35 - Clinical Trial Optional)</td>
<td>National Institute of General Medical Sciences/NIH/DHHS</td>
<td>PAR-19-367</td>
<td>18-May-2020</td>
<td>3,750,000 USD</td>
</tr>
</tbody>
</table>

**Contact Name:** Zhongzhen Nie, Ph.D.  
**Contact Telephone:**  
**Contact Email:** MIRA2019RESEARCH@NIGMS.NIH.GOV  
**Sponsor Website:**  
**Program URL:** Link to program URL  
**Deadline Dates (ALL):** 18-May-2020, 19-Jan-2021, 17-May-2021, 18-Jan-2022, 17-May-2022  

**Synopsis:** National Institute of General Medical Sciences (NIGMS) invites applications for the Maximizing Investigators' Research Award (MIRA). The award is a grant to provide support for the program of research in an investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is the collection of projects in the investigator's lab that are relevant to the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this mechanism will: Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively; Increase flexibility for investigators to follow important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies; More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs; Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research; Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment. This FOA will utilize the NIH R35 Outstanding Investigator Award.

<table>
<thead>
<tr>
<th>Grant Number</th>
<th>Grant Description</th>
<th>Institute</th>
<th>PAR-Number</th>
<th>Start Date</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>067381</td>
<td>National Institute of General Medical Sciences Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant (T32)</td>
<td>National Institute of General Medical Sciences/NIH/DHHS</td>
<td>PAR-17-341</td>
<td>25-May-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

**Contact Name:** Dr. Alison Gammie  
**Contact Telephone:** 301-594-3900  
**Contact Email:** alison.gammie@nih.gov  
**Sponsor Website:**  
**Program URL:**  

129
National Institute of General Medical Sciences (NIGMS) invites applications for the NIGMS-sponsored Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant (T32) program. The program is intended to develop a diverse pool of well-trained scientists available to address the Nation's biomedical research agenda. Specifically, this funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This FOA will use the NIH T32 Institutional National Research Service Award (NRSA) award mechanism.

The goal of the Medical Scientist Training Program (MSTP) is to develop a diverse pool of highly trained physician-scientist leaders available to meet the Nation's biomedical research needs. Specifically, this funding opportunity announcement (FOA) provides support to eligible domestic institutions to develop and implement effective, evidence-based approaches to integrated dual-degree training leading to the award of both clinical degrees, e.g., M.D., D.O., D.V.M., D.D.S., and research doctorate degrees (Ph.D. or equivalent). With the dual qualification of rigorous scientific research and clinical practice, graduates will be equipped with the skills to develop research programs that accelerate the translation of research advances to the understanding, detection, treatment and prevention of human disease, and to lead the advancement of biomedical research. Areas of particular importance to NIGMS are the iterative optimization of MSTP training efficacy.
and efficiency, fostering the persistence of MSTP alumni in research careers, and enhancing the diversity of the physician-scientist workforce. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

<table>
<thead>
<tr>
<th>072936</th>
<th>Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 - Clinical Trial Not Allowed)</th>
<th>National Institute of General Medical Sciences/NIH/DHHS</th>
<th>PAR-18-714</th>
<th>25-Feb-2020</th>
<th>300,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Alexandra M. Ainsztein, PhD.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-594-0943</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Alexandra.Ainsztein@nih.gov">Alexandra.Ainsztein@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of General Medical Sciences (NIGMS) invites applications for the Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions. The purpose of the award is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees, and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This FOA will use the NIH R15 Academic Research Enhancement Award (AREA) mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>088588</th>
<th>IDeA Networks of Biomedical Research Excellence (INBRE) (P20 Clinical Trial Optional)</th>
<th>National Institute of General Medical Sciences/NIH/DHHS</th>
<th>PAR-20-102</th>
<th>20-May-2020</th>
<th>13,750,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Krishan K. Arora, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:arorak@nigms.nih.gov">arorak@nigms.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The National Institute of General Medical Sciences (NIGMS) invites applications for Institutional Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) awards from investigators at biomedical research institutions within Institutional Development Award (IDeA)-eligible states that award doctoral degrees in health-related sciences or at independent biomedical research institutes with ongoing biomedical research programs funded by the NIH or other federal agencies. The purpose of the INBRE program is to augment and strengthen the biomedical research capacity of IDeA-eligible states. The INBRE program represents a collaborative effort to sponsor research between research intensive institutions and primarily undergraduate institutions (PUIs), community colleges, and Tribally Controlled Colleges and Universities (TCCUs). Only one award will be made per IDeA-eligible state. The primary goals of the INBRE program are to: 1) build on the established multi-disciplinary research network to strengthen the biomedical research expertise and infrastructure of the lead and partner institutions; 2) build and increase the research base and capacity by providing support to faculty, postdoctoral fellows, and graduate students at the participating institutions; 3) provide research opportunities for students from PUIs, community colleges, and TCCUs, and serve as a "pipeline" for these students to continue in biomedical research careers within IDeA states; and 4) enhance science and technology knowledge of the state's workforce.

<table>
<thead>
<tr>
<th>Sponsor Website</th>
<th>Link to program URL</th>
</tr>
</thead>
</table>

### Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34)

The goal of the Undergraduate Research Training Initiative for Student Enhancement (U-RISE) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D.)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Anissa J. Brown, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:anissa.brown@nih.gov">anissa.brown@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>21-May-2020 , 21-May-2021</td>
</tr>
</tbody>
</table>

The INBRE program represents a collaborative effort to sponsor research between research intensive institutions and primarily undergraduate institutions (PUIs), community colleges, and Tribally Controlled Colleges and Universities (TCCUs). Only one award will be made per IDeA-eligible state. The primary goals of the INBRE program are to: 1) build on the established multi-disciplinary research network to strengthen the biomedical research expertise and infrastructure of the lead and partner institutions; 2) build and increase the research base and capacity by providing support to faculty, postdoctoral fellows, and graduate students at the participating institutions; 3) provide research opportunities for students from PUIs, community colleges, and TCCUs, and serve as a "pipeline" for these students to continue in biomedical research careers within IDeA states; and 4) enhance science and technology knowledge of the state's workforce.
This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields. This program is limited to applications from training programs at baccalaureate degree-granting research-active institutions (i.e., those with an average of NIH Research Project Grant funding less than $7.5 million total costs (direct and F&A/indirect) per year over the last 3 fiscal years)). This Funding Opportunity Announcement (FOA) does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

<table>
<thead>
<tr>
<th>079035</th>
<th>Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32)</th>
<th>National Institute of General Medical Sciences/NIH/DHHS</th>
<th>PAR-19-102</th>
<th>21-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Luis A. Cubano, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-594-3900</td>
<td>Contact Email</td>
<td><a href="mailto:luis.cubano@nih.gov">luis.cubano@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td>Deadline Dates (ALL)</td>
<td>21-May-2020 , 21-May-2021</td>
</tr>
<tr>
<td>Synopsis</td>
<td>The goal of the Graduate Research Training Initiative for Student Enhancement (G-RISE) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-active institutions (i.e., those with an average of NIH Research Project Grant funding less than $7.5 million total costs per year over the last 3 fiscal years). This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>063949</td>
<td><strong>Biomedical Technology Research Resource (P41)</strong></td>
<td>National Institute of General Medical Sciences/NIH/DHHS</td>
<td>PAR-17-316</td>
<td>07-May-2020</td>
<td>4,000,000 USD</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Douglas M. Sheeley, Sc.D.</td>
<td>301-451-6446</td>
<td><a href="mailto:sheeleyd@mail.nih.gov">sheeleyd@mail.nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td>07-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>National Institute of General Medical Sciences (NIGMS) invites for national Biomedical Technology Research Resources (BTRR). These Resources conduct research and development of new or improved technologies driven by the needs of basic, translational, and clinical researchers. The Resources are charged to make their technologies available to the research community in a sustainable manner, to provide user training, and to disseminate the Resource’s technologies and experimental results. Resources should be at the leading edge of their field with respect to both technology development and engagement of the relevant research community. New applicants are strongly encouraged to submit a pre-application in response to PAR-17-315 (SPIN Program # 63948) The pre-application process provides feedback on whether the proposed technology development is appropriate for the NIGMS BTRR program, and the potential competitiveness of a full application. This FOA will utilize the NIH P41 Biotechnology Resource Grants award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>080561</th>
<th><strong>Maximizing Access to Research Careers (T34)</strong></th>
<th>National Institute of General Medical Sciences/NIH/DHHS</th>
<th>PAR-19-219</th>
<th>21-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Sailaja Koduri, Ph.D.</td>
<td>301-594-3900</td>
<td><a href="mailto:sailaja.koduri@nih.gov">sailaja.koduri@nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td>21-May-2020 , 21-May-2021</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Synopsis**

The goal of the Maximizing Access to Research Careers (MARC) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D. or M.D./Ph.D.). This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields. This program is limited to applications from training programs at baccalaureate degree-granting research-intensive institutions (i.e., those with an average of NIH Research Project Grant funding greater than or equal to $7.5 million total costs per year over the last 3 fiscal years). This Funding Opportunity Announcement (FOA) does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

**Limited Competition: Centers of Biomedical Research Excellence (COBRE) Phase 3 - Transitional Centers (P30 Clinical Trial Optional)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Hongwei Gao, M.D., Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td><a href="mailto:hongwei.gao@nih.gov">hongwei.gao@nih.gov</a></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>National Institute of General Medical Sciences/NIH/DHHS</td>
<td>PAR-20-115, 28-May-2020, 3,750,000 USD</td>
</tr>
</tbody>
</table>

**Biomedical Technology Research Resource (P41)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Haluk Resat, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institute of General Medical Sciences/NIH/DHHS</td>
<td>PAR-20-104, 26-May-2020, 4,250,000 USD</td>
</tr>
</tbody>
</table>
**Synopsis**

This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Technology Development and Dissemination (BTDD) Centers. The BTDD program supports the development of technologies once their feasibility has been established and the dissemination of these technologies to the wider biomedical research community. The program encourages investigators to propose projects that address any of the biomedical research areas within the mission of NIGMS. The Centers are required to make their technologies available to the research community in a sustainable manner, to provide user training, and to disseminate the Center’s technologies and results. Centers should be at the leading edge of their field with respect to both technology development and engagement of the relevant research community. Potential applicants are strongly encouraged to contact NIGMS staff at least 10 weeks prior to the application due date to ascertain whether the proposed project is appropriate for an NIGMS BTDD Center.

<table>
<thead>
<tr>
<th><strong>088591</strong></th>
<th><strong>Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional)</strong></th>
<th>National Institute of General Medical Sciences/NIH/DHHS</th>
<th>PAR-20-103</th>
<th>27-May-2020</th>
<th>7,500,000 USD</th>
</tr>
</thead>
</table>

Contact Name: Peter Preusch, Ph.D.
Contact Telephone: 301-594-8494
Contact Email: RM1mailbox@nigms.nih.gov
Sponsor Website: Link to program URL
Program URL: Link to program URL

This funding opportunity announcement (FOA) is designed to support highly integrated research teams of three to six PDs/PIs to address ambitious and challenging research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable with a collection of individual efforts or projects. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields. Applications that are mainly focused on the creation,
expansion, and/or maintenance of community resources, creation of new technologies, or infrastructure development are not appropriate for this FOA.

<table>
<thead>
<tr>
<th>070409</th>
<th><strong>Advancing Basic Neurobiology Toward Translation Through Assay Development (R01 Clinical Trial Not Allowed)</strong></th>
<th>National Institute of Mental Health/NIH/DHHS</th>
<th>PAR-18-505</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Contact Name</td>
<td>Jamie Driscoll</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-443-5288</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:jdrisco1@mail.nih.gov">jdrisco1@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to develop novel, robust assays to reveal changes in neuronal and/or glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function into phenotypic assays, with the intent to probe mechanisms or perturbations in an unbiased and efficient manner. These novel assays would provide opportunities to measure neurobiological endpoints to accelerate basic discovery and support target identification and therapeutic development efforts. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>065054</th>
<th><strong>Discovery of in vivo Chemical Probes for Novel Brain Targets (R01)</strong></th>
<th>National Institute of Mental Health/NIH/DHHS</th>
<th>PAR-17-336</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Contact Name</td>
<td>Enrique L. Michelotti, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-443 5415</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 05-Jun-2020, 07-Sep-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NEI, NIAAA, NIDA, NIAA...</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
and/or NIDCD and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>Funding Opportunity Announcement (FOA)</th>
<th>National Institute of Mental Health/NIH/DHHS</th>
<th>PAR-18-554</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)</td>
<td>National Institute of Mental Health/NIH/DHHS</td>
<td>PAR-18-554</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Bettina D. Buhring, Ph.D.</td>
<td>301-443-1576</td>
<td><a href="mailto:bettina.buhring@mail.nih.gov">bettina.buhring@mail.nih.gov</a></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-443-1576</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:bettina.buhring@mail.nih.gov">bettina.buhring@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Synopsis

National Institute of Mental Health's (NIMH) invites applications for projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.
<table>
<thead>
<tr>
<th>Program Number</th>
<th>Program Title</th>
<th>Sponsor</th>
<th>Award Type</th>
<th>Deadline Dates (ALL)</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>065058</td>
<td>Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21)</td>
<td>NIH</td>
<td>PAR-17-335</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Enrique L. Michelotti, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-443 5415</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 07-Sep-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Synopsis**
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate research in: 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIA, and/or NIDCD; and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be in the discovery of cell-based chemical probes. This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

<table>
<thead>
<tr>
<th>Program Number</th>
<th>Program Title</th>
<th>Sponsor</th>
<th>Award Type</th>
<th>Deadline Dates (ALL)</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>070683</td>
<td>Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01)</td>
<td>NIH</td>
<td>PAR-18-555</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Bettina D. Buhring, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-443-1576</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:bettina.buhring@mail.nih.gov">bettina.buhring@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 07-Sep-2020, 07-Jan-2021</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Synopsis**
National Institute of Mental Health’s (NIMH) invites applications for projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social...
Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>076836</th>
<th>Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)</th>
<th>National Institute of Mental Health/NIH/DHHS</th>
<th>PAR-18-894</th>
<th>07-Apr-2020</th>
<th>Not Specified</th>
</tr>
</thead>
</table>
| Contact Name | Christopher Sarampote, Ph.D.  
Contact Telephone | 301-443-1959  
Contact Email | csarampo@mail.nih.gov  
Sponsor Website | Link to program URL  
Program URL | National Institute of Mental Health (NIMH) invites applications for dissertation awards in all research areas within the strategic priorities of the NIMH to individuals from groups underrepresented in biomedical, behavioral, clinical and social sciences research. This award supports the completion of the doctoral research project. This FOA will utilize the NIH R36 Dissertation Award award mechanism.  

<table>
<thead>
<tr>
<th>072028</th>
<th>Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults (R34 Clinical Trial Optional)</th>
<th>National Institute of Mental Health/NIH/DHHS</th>
<th>PA-18-653</th>
<th>07-May-2020</th>
<th>450,000 USD</th>
</tr>
</thead>
</table>
| Contact Name | Susannah Allison, PhD  
Contact Telephone | 240-627-3861  
Contact Email | | | |
| Contact Email | allisonsu@mail.nih.gov |
| Sponsor Website | Link to program URL |
| Program URL | Link to program URL |
| Deadline Dates (ALL) | 07-May-2020, 07-Sep-2020, 07-Jan-2021 |
| Synopsis | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for developmentally tailored research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Research is encouraged to incorporate recent advances in adolescent and young adult developmental research to optimize outcomes in HIV prevention and care research for this heterogeneous population. This FOA will use the NIH R34 Planning Grant award mechanism. |

| Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults (R21 Clinical Trial Not Allowed) |
| National Institute of Mental Health/NIH/DHHS | PA-18-652 | 07-May-2020 | 275,000 USD |

| Contact Name | Susannah Allison, PhD |
| Contact Telephone | 240-627-3861 |
| Contact Email | allisonsu@mail.nih.gov |
| Sponsor Website | Link to program URL |
| Program URL | Link to program URL |
| Deadline Dates (ALL) | 07-May-2020, 07-Sep-2020, 07-Jan-2021 |
| Synopsis | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for developmentally tailored research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Exploratory research is encouraged to incorporate recent advances in adolescent and young adult developmental research to better understand HIV prevention and care of this heterogeneous population. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism. |

| Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults (R01 Clinical Trial Optional) |
| National Institute of Mental Health/NIH/DHHS | PA-18-651 | 07-May-2020 | Not Specified |

| Contact Name | Susannah Allison, PhD |
| Contact Telephone | 240-627-3861 |
### Synopsis

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for developmentally tailored research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Research is encouraged to incorporate recent advances in adolescent and young adult developmental research to optimize outcomes in HIV prevention and care research for this heterogeneous population. This FOA will use the NIH Research Project (R01) award mechanism.

### Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Anjené Addington</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-6653</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:anjene.addington@nih.gov">anjene.addington@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020 , 07-Sep-2020 , 07-Jan-2021</td>
</tr>
</tbody>
</table>

This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.
<table>
<thead>
<tr>
<th>FOA ID</th>
<th>Description</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>PAR</th>
<th>Deadline Dates</th>
<th>Award Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>077196</td>
<td>New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 (Collab) Clinical Trial Not Allowed)</td>
<td>Alexander Arguello, PhD</td>
<td>National Institute of Mental Health/NIH/DHHS</td>
<td>PA-18-907</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>060090</td>
<td>Advancing our Understanding of the Brain Epitranscriptomics (R21)</td>
<td>Enrique Michelotti, Ph.D.</td>
<td>National Institute of Mental Health/NIH/DHHS</td>
<td>PAR-17-152</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
</tbody>
</table>
### Synopsis
National Institute of Mental Health (NIMH) invites applications for research into the functions of modified RNAs in the brain and/or the associated modification proteins that act on RNA (readers, writers, and erasers) and play a role in basic neurobiological and behavioral processes implicated in mental and substance use disorders. This FOA will use the NIH Research Project (R01) award mechanism.

### New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 Clinical Trial Not Allowed)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Alexander Arguello, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-827-3547</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:alexander.arguello@nih.gov">alexander.arguello@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

National Institute of Mental Health (NIMH) invites applications for the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex etiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, taking into account the added complexities and nuances of brain diseases, and to ultimately inform novel treatment development based on human biology. This FOA will use the NIH Research Project (R01) award mechanism.

### RFA-MH-18-707 -- Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Sarah Morris, Ph.D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-9233</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:sarah.morris@nih.gov">sarah.morris@nih.gov</a></td>
</tr>
</tbody>
</table>

National Institute of Mental Health invites applications for the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex etiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, taking into account the added complexities and nuances of brain diseases, and to ultimately inform novel treatment development based on human biology. This FOA will use the NIH Research Project (R01) award mechanism.
National Institute of Mental Health (NIMH) invites applications to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit. This FOA will use the NIH R01 Research Project Grant award mechanism.

National Institute of Mental Health (NIMH) invites applications to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit. This FOA will use the NIH R01 Research Project Grant award mechanism.
adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy are novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.

<table>
<thead>
<tr>
<th>RFA-MH-18-704--Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required)</th>
<th>National Institute of Mental Health/NIH/DHHS</th>
<th>RFA-MH-18-704</th>
<th>16-May-2020 [Optional][LOI/Pre-App]</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Ann Wagner, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-443-3633</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:awagner@mail.nih.gov">awagner@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>[Link to program URL]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Mental Health (NIMH) invites applications to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy is novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of the intervention's impact on a target (a process or mechanism associated with risk for, causation, or maintenance of a clinical condition), that is, its target engagement. Contingent on meeting "go/no-go" milestones in the R61 phase, up to 3 years of additional support (R33 phase) may be provided for studies to replicate target engagement and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this R61/R33 FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award mechanism.

<table>
<thead>
<tr>
<th>Program ID</th>
<th>Program Name</th>
<th>Sponsor</th>
<th>PAR Number</th>
<th>Deadline</th>
<th>Sponsor URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>060089</td>
<td>Advancing our Understanding of the Brain Epitranscriptomics (R01)</td>
<td>National Institute of Mental Health/NIH/DHHS</td>
<td>PAR-17-153</td>
<td>07-May-2020</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>068979</td>
<td><strong>RFA-MH-18-703 -- Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33 - Clinical Trial Required)</strong></td>
<td>National Institute of Mental Health/NIH/DHHS</td>
<td>16-May-2020</td>
<td>[Optional][LOI/Pre-App]</td>
<td>Not Specified</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>National Institute of Mental Health (NIMH) invites applications to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single phased clinical trial awards. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>068977</th>
<th><strong>RFA-MH-18-702 -- Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 - Clinical Trial Required)</strong></th>
<th>National Institute of Mental Health/NIH/DHHS</th>
<th>16-May-2020</th>
<th>[Optional][LOI/Pre-App]</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Margaret Grabb, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>301-443-3563</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:mgrabb@mail.nih.gov">mgrabb@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
National Institute of Mental Health (NIMH) invites applications to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high risk applications. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award mechanism.

070073
First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS PAR-18-427 07-May-2020 Not Specified

Contact Name Lois Winsky, Ph.D.
Contact Telephone 301-443-5288
Contact Email lwinsky@mail.nih.gov
Sponsor Website
Program URL Link to program URL

National Institute of Mental Health (NIMH) invites applications for early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders.
Phase II/PoC studies must evaluate the drug's impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.

<table>
<thead>
<tr>
<th>079331</th>
<th>Drug Discovery For Nervous System Disorders [R21 Clinical Trials Not Allowed]</th>
<th>National Institute of Mental Health/NIH/DHHS</th>
<th>PAR-19-146</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
</table>

Contact Name: Enrique Michelotti, PhD  
Contact Telephone: 301-443-5415  
Contact Email: michelottiel@mail.nih.gov  
Sponsor Website: Link to program URL  
Program URL:  
Synopsis: This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders. This FOA is designed to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics, and 4) Initial drug metabolism and pharmacokinetics (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high payoff projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-19-147).
<table>
<thead>
<tr>
<th>Program Number</th>
<th>Program Title</th>
<th>Sponsor</th>
<th>PA Number</th>
<th>Deadline Dates (ALL)</th>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>059448</td>
<td><strong>HIV Infection Of The Central Nervous System (R01)</strong></td>
<td>NIH</td>
<td>PA-17-100</td>
<td>07-May-2020</td>
<td>Jeymohan Joseph, Ph.D.</td>
<td>240-627-3869</td>
<td><a href="mailto:jjeymoha@mail.nih.gov">jjeymoha@mail.nih.gov</a></td>
<td></td>
<td></td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications focused on defining and understanding the pathogenic mechanisms involved in Human Immunodeficiency Virus (HIV)-1 induced CNS dysfunction, but within the context of viral suppression and Antiretroviral therapy (ART). The FOA further supports research to identify therapeutic targets against which treatments may be developed to prevent the neurobehavioral and neurological co-morbidities in HIV-1 infected individuals. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. This program will use the NIH Research Project (R01) award mechanism.</td>
</tr>
<tr>
<td>059047</td>
<td><strong>Eradication of HIV-1 from Central Nervous system Reservoirs (R01)</strong></td>
<td>NIH</td>
<td>PA-17-084</td>
<td>07-May-2020</td>
<td>Jeymohan Joseph, Ph.D.</td>
<td>240-627-3869</td>
<td><a href="mailto:jjeymoha@mail.nih.gov">jjeymoha@mail.nih.gov</a></td>
<td></td>
<td></td>
<td>National Institutes of Health (NIH) participating Institutes and Centers invite applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system (CNS) in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. This program will use the NIH Research Project (R01) award mechanism.</td>
</tr>
<tr>
<td>FOA Number</td>
<td>Description</td>
<td>Agency</td>
<td>PAR</td>
<td>Deadline Dates</td>
<td>Contact Name</td>
<td>Contact Telephone</td>
<td>Contact Email</td>
<td>Sponsor Website</td>
<td>Program URL</td>
<td>Funded Amount</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>--------</td>
<td>-----</td>
<td>---------------</td>
<td>--------------</td>
<td>-------------------</td>
<td>---------------</td>
<td>----------------</td>
<td>-------------</td>
<td>---------------</td>
</tr>
<tr>
<td>079325</td>
<td>Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)</td>
<td>National Institute of Mental Health/NIH/DHHS</td>
<td>PAR-19-147</td>
<td>07-May-2020</td>
<td>Enrique Michelotti, PhD</td>
<td>301-443-5415</td>
<td><a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></td>
<td>Link to program URL</td>
<td>07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021, 05-Feb-2021, 07-May-2021, 05-Jun-2021, 07-Sep-2021, 05-Oct-2021, 07-Jan-2022</td>
<td>This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.</td>
</tr>
<tr>
<td>072648</td>
<td>Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 Clinical Trial Optional)</td>
<td>National Institute of Mental Health/NIH/DHHS</td>
<td>PAR-18-701</td>
<td>18-May-2020</td>
<td>Joel Sherrill, Ph.D.</td>
<td>301-443-2477</td>
<td><a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a></td>
<td>Link to program URL</td>
<td>18-May-2020</td>
<td>4,000,000 USD</td>
</tr>
</tbody>
</table>

National Institute of Mental Health (NIMH) invites applications for centers to support transdisciplinary teams of clinical and mental health services researchers, behavioral scientists, social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) to engage in high-impact studies that will significantly advance clinical practice and...
generate knowledge that will fuel transformation of mental health care in the United States. Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers will support the rapid development, testing, and refinement of novel and integrative approaches for (1) optimizing the effectiveness of therapeutic or preventive interventions for mental disorders within well-defined target populations; (2) organizing and delivering optimized mental health services within real world treatment settings; and (3) continuously improving the quality, impact, and durability of optimized interventions and service delivery within diverse care systems. The ALACRITY Centers program is intended to support research that demonstrates an extraordinary level of synergy across disciplines and has a high potential for increasing the public health impact of existing and emerging mental health interventions and service delivery strategies. The Centers are intended for transdisciplinary projects that could not be achieved using standard research project grant mechanisms. The ALACRITY Centers program is also expected to provide opportunities for graduate students, postdoctoral researchers, and new investigators to participate in transdisciplinary, T2 translational mental health research. This FOA will use the NIH P50 Specialized Center award mechanism.

<table>
<thead>
<tr>
<th>088297</th>
<th>Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)</th>
<th>National Institute of Mental Health/NIH/DHHS</th>
<th>PAR-20-093</th>
<th>27-May-2020</th>
<th>10,000,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Susan Koester, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-443-3563</td>
<td>Contact Email</td>
<td><a href="mailto:koesters@mail.nih.gov">koesters@mail.nih.gov</a></td>
</tr>
</tbody>
</table>
childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research that demonstrates an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms.

<table>
<thead>
<tr>
<th>088290</th>
<th>NIMH Mentoring Networks for Mental Health Research Education (R25 Clinical Trial Not Allowed)</th>
<th>National Institute of Mental Health/NIH/DHHS</th>
<th>PAR-20-080</th>
<th>26-May-2020</th>
<th>1,000,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Nick Gaiano, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-827-3420</td>
<td>Contact Email</td>
<td><a href="mailto:nick.gaiano@nih.gov">nick.gaiano@nih.gov</a></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Mentoring Activities and in particular, mentoring networks. Networks may be national or regional. All proposed networks should provide significant new opportunities, and should comprise efforts substantially beyond any ongoing mentoring, networking, or research education within academic programs, institutions, or pre-existing networks; or educational collaborations among institutions. Participants in proposed mentoring networks are limited to graduate/medical students, medical residents, postdoctoral scholars, and/or early-career faculty. Proposed networks are expected to enhance the participants’ professional development and to foster their career trajectory towards independent mental health research. Proposed programs are thus expected to contribute to the development of a skilled cadre of investigators in requisite scientific research areas to advance the objectives of the NIMH Strategic Plan.</td>
<td>088301</td>
<td>NIMH Research Education Programs for Psychiatry Residents (R25- Independent Clinical Trial Not Allowed)</td>
<td>National Institute of Mental Health/NIH/DHHS</td>
<td>PAR-20-094</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Mark Chavez, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Specifically, this FOA will support research-oriented experiences and activities designed to develop, maintain, and expand the scientific abilities of psychiatry residents in areas relevant to the mission of NIMH.

088348  
**NIMH Short Courses for Mental Health Related Research (R25 -Independent Clinical Trial Not Allowed)**  
National Institute of Mental Health/NIH/DHHS  
PAR-20-096  
26-May-2020  
1,000,000 USD

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Nick Gaiano, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-827-3420</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:nick.gaiano@nih.gov">nick.gaiano@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development. Proposed short courses are expected to facilitate the development of a sophisticated cadre of investigators with the requisite scientific research skills to advance the mission of the NIMH. Each short course is expected to include both didactics and hands-on research experiences. Participants are limited to graduate/medical students, medical residents, postdoctoral scholars, and/or early-career faculty.
<table>
<thead>
<tr>
<th>RFA-MH-18-700 -- Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 - Clinical Trial Required)</th>
<th>National Institute of Mental Health/NIH/DHHS</th>
<th>RFA-MH-18-700</th>
<th>16-May-2020 [Optional][LOI/Pre-App]</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Joel Sherrill, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-443-2477</td>
<td>Contact Email</td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Program URL</td>
<td>Link to program URL</td>
<td>16-May-2020 [Optional][LOI/Pre-App], 15-Jun-2020, 15-Sep-2020 [Optional][LOI/Pre-App], 15-Oct-2020</td>
<td>Deadline Dates (ALL)</td>
</tr>
<tr>
<td>National Institute of Mental Health (NIMH) invites applications to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principal Investigator (PD/PI) and the program provides a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. This FOA will use the NIH R01 Research Project Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Synopsis

National Institute of Mental Health (NIMH) invites applications to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA will use the NIH R01 Research Project Grant award mechanism.

<table>
<thead>
<tr>
<th>Program URL</th>
<th>Link to program URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synopsis</td>
<td>National Institute of Mental Health (NIMH) invites applications for exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Program URL</th>
<th>Link to program URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synopsis</td>
<td>National Institute of Mental Health (NIMH) invites applications to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA will use the NIH R01 Research Project Grant award mechanism.</td>
</tr>
</tbody>
</table>
strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

RFA-MH-18-706 -- Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions [R34- Clinical Trial Required]

National Institute of Mental Health/NIH/DHHS


Contact Name Joel Sherrill, Ph.D.
Contact Telephone 301-443-2477
Contact Email jsherril@mail.nih.gov
Sponsor Website Link to program URL
Program URL

Deadline Dates (ALL)
16-May-2020 [Optional][LOI/Pre-App], 15-Jun-2020 , 15-Sep-2020 [Optional][LOI/Pre-App], 15-Oct-2020

Synopsis
National Institute of Mental Health (NIMH) invites applications for pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Applications should provide resources for evaluating the feasibility, tolerability, acceptability and safety of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale intervention trial (e.g., comparative effectiveness study, practical trial) or large-scale services study. In this pilot phase of effectiveness research, NIMH places highest priority on approaches that can be justified in terms of their potential to substantially impact practice and public health and approaches that are empirically grounded. Adaptations or augmentations of efficacious interventions should only be undertaken if there is an empirical rationale for the adaptation target and for the corresponding mechanism by which the adapted intervention or augmentation is expected to substantially enhance outcomes. This FOA is intended to support pilot effectiveness trials that are designed to explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects. This FOA will use the NIH R34 Planning Grant award mechanism.
<table>
<thead>
<tr>
<th>070232</th>
<th>RFA-NS-18-018 -- BRAIN Initiative: Biology and Biophysics of Neural Stimulation (R01 Clinical Trial Optional)</th>
<th>National Institute of Neurological Disorders and Stroke/NIH/DHHS</th>
<th>RFA-NS-18-018</th>
<th>05-May-2020 [Optional][LOI/Pre-App]</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Contact Name: Nick Langhals, PhD</td>
<td>Contact Telephone: 301-496-1447</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email: <a href="mailto:BRAIN-FOAs@nih.gov">BRAIN-FOAs@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website: Link to program URL</td>
<td>Program URL: 05-May-2020 [Optional][LOI/Pre-App], 04-Jun-2020, 06-Sep-2020 [Optional][LOI/Pre-App], 06-Oct-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation. Development of new technologies and therapies, as well as of disease models are outside the scope of this FOA. However, activities related to combining multiple recording modalities are allowed. As part of this program, investigators will be required to participate in a consortium to develop standards and model systems for the evaluation of current and next generation neuromodulation technologies. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>065641</th>
<th>CREATE Bio Optimization Track for Biologics (U01)</th>
<th>National Institute of Neurological Disorders and Stroke/NIH/DHHS</th>
<th>PAR-17-456</th>
<th>07-May-2020</th>
<th>2,500,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Contact Name: Chris Boshoff, Ph.D.</td>
<td>Contact Telephone: 301-496-1779</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email: <a href="mailto:chris.boshoff@nih.gov">chris.boshoff@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website: Link to program URL</td>
<td>Program URL: 07-May-2020, 20-Jul-2020, 07-Sep-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA). This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

<table>
<thead>
<tr>
<th>NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-No Independent Clinical Trials)</th>
<th>National Institute of Neurological Disorders and Stroke/NIH/DHHS</th>
<th>PAR-18-469</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Michelle Jones-London, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-451-7966</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:jonesmiche@ninds.nih.gov">jonesmiche@ninds.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Synopsis

National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity. The NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity is designed to enhance the participation of highly trained early career investigators from underrepresented groups in neuroscience research. This opportunity provides postdoctoral fellows from underrepresented groups with strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position. Individuals are eligible for support under this award if they have doctoral research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research training at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K22 Career Transition Award mechanism.
<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Charles Cywin, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-1779</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:charles.cywin@nih.gov">charles.cywin@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
</tbody>
</table>

**Synopsis**

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program. This FOA will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast Track I award mechanism.
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.
National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the Faculty Development Award to Promote Diversity in Neuroscience Research. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH K01 Research Scientist Development Award - Research & Training mechanism.

Promoting Research in Basic Neuroscience (R01 Clinical Trial Not Allowed)

National Institute of Neurological Disorders and Stroke/NIH/DHHS

PAS-18-483

07-May-2020

Not Specified

Robert Riddle, PhD
301-496-5745
rr260c@nih.gov

Link to program URL


National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research addressing fundamental questions in basic neuroscience. Proposed projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the development, the structure and/or the function of the normal nervous system. While fundamental basic research often generates insights relevant to disorders of the nervous system, this FOA is not intended to stimulate research that is explicitly disease-related. This FOA will use the NIH Research Project (R01) award mechanism.
### NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-Clinical Trial Required)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Michelle Jones-London, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-451-7966</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:jonesmiche@ninds.nih.gov">jonesmiche@ninds.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

Synopsis:
National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity. This opportunity provides postdoctoral fellows from underrepresented groups with strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position. Individuals are eligible for support under this award if they have doctoral research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research training at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial that also meets the definition of a clinical trial, as part of their research and career development. NINDS will only accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a clinical trial and that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS Scientific/Research contact prior to submitting an application with human subjects to determine the appropriate funding opportunity. This FOA will utilize the NIH K22 Career Transition Award mechanism.

### CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U44 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Chris Boshoff, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-1779</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:chris.boshoff@nih.gov">chris.boshoff@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
</tbody>
</table>

Synopsis:
CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U44 Clinical Trial Optional)
### Synopsis

National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). This program will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast-track only.

<table>
<thead>
<tr>
<th>070137</th>
<th><strong>NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)</strong></th>
<th>National Institute of Neurological Disorders and Stroke/NIH/DHHS</th>
<th>PAR-18-486</th>
<th>07-May-2020</th>
<th>975,000 USD</th>
</tr>
</thead>
</table>

**Contact Name**

Michelle Jones-London, Ph.D.

**Contact Telephone**

301-451-7966

**Contact Email**

jonesmiche@ninds.nih.gov

**Sponsor Website**

[Link to program URL](#)

**Program URL**

[Link to program URL](#)

**Deadline Dates (ALL)**


National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the Faculty Development Award to Promote Diversity in Neuroscience Research. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is
designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. NINDS will only accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a clinical trial and that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. This Funding Opportunity Announcement (FOA) will utilize the NIH K01 Research Scientist Development Award - Research & Training mechanism.

CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U01 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Hao Wang, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-1779</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:CREATEinquiries@mail.nih.gov">CREATEinquiries@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 20-Jul-2020, 07-Sep-2020</td>
</tr>
</tbody>
</table>

Synopsis

National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase 1 clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). This program will use the NIH U01 Research Project – Cooperative Agreements award mechanism.

NINDS Exploratory Neuroscience Research Grant (R21- Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Timothy LaVaute, PHD</th>
</tr>
</thead>
</table>

National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development of therapeutics for the treatment of neurological disorders identified within the NINDS mission. Applications are encouraged in areas of basic or translational research focused on novel therapeutic approaches, including disease-modifying treatments, novel targets, and biomarkers for neurological disorders. This program will use the NIH R21 Research Project – Cooperative Agreements award mechanism.
### Synthetic's Fire

**Synopsis**

National Institute of Neurological Disorders and Stroke (NINDS) invites applications for exploratory and innovative research projects, which fall within the mission of the NINDS. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

**RFA-NS-18-021 -- BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Required)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Nick Langhals, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-1447</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:nick.langhals@nih.gov">nick.langhals@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td><a href="#">Link to program URL</a></td>
</tr>
<tr>
<td>Program URL</td>
<td><a href="#">Link to program URL</a></td>
</tr>
</tbody>
</table>

**Synopsis**

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for translational and clinical studies for recording and/or stimulating devices to treat nervous system disorders and better understand the human brain. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and a subsequent small clinical trial (e.g., Early Feasibility Study). The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the...
The clinical trial is expected to provide information that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement mechanism.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Nick Langhals, PhD</td>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-1447</td>
<td>Program URL</td>
<td>23-May-2020 [Optional][LOI/Pre-App], 22-Jun-2020 , 21-Sep-2020 [Optional][LOI/Pre-App], 21-Oct-2020</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:nick.langhals@nih.gov">nick.langhals@nih.gov</a></td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications from small business concerns (SBCs) to pursue translational non-clinical studies and clinical studies for recording and/or stimulating devices to treat nervous system disorders and thereby better understand the human brain. The program will utilize a cooperative agreement mechanism to support the non-clinical studies necessary for the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or to obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and the subsequent small clinical trial (e.g., Early Feasibility Study). Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement mechanism.</td>
<td></td>
</tr>
</tbody>
</table>
**Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Mary Ann Pelleymounter, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-1779</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:mary.pelleymounter@nih.gov">mary.pelleymounter@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

*Synopsis*

National Institute of Neurological Disorders and Stroke (NINDS) invites applications to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs. This FOA will utilize the R61/R33 Phased Innovation Award mechanism.

**Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus (R21 Clinical Trial Not Allowed)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Jill A. Morris, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-5745</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:jill.morris@nih.gov">jill.morris@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

*Synopsis*

National Institute of Neurological Disorders and Stroke (NINDS) invites applications to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs. This FOA will utilize the R61/R33 Phased Innovation Award mechanism.
Synopsis

National Institute of Neurological Disorders and Stroke (NINDS) invites applications that propose to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. The primary objective of this FOA is to remove barriers to hydrocephalus research that are due to scarcity of tools to investigate both the disease mechanisms and alternative therapies (non-shunt) in a rigorous manner. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

073885

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) Nationa
National Institute of Neur
National Institute of Neurological Disorders and Stroke (NINDS) invites applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational programs. This FOA will utilize the NIH R61/R33 Phased Innovation Award award mechanism.

073885

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Mary Ann Pelleymourter, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-1779</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:mary.pelleymourter@nih.gov">mary.pelleymourter@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>


National Institute of Neurological Disorders and Stroke (NINDS) invites applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational programs. This FOA will utilize the NIH R61/R33 Phased Innovation Award award mechanism.
<table>
<thead>
<tr>
<th>071756</th>
<th><strong>Disease Mechanisms of Prenatal and Pediatric Hydrocephalus (R01 Clinical Trial Not Allowed)</strong></th>
<th>National Institute of Neurological Disorders and Stroke/NIH/DHHS</th>
<th>PA-18-622</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Jill A. Morris, Ph.D.</td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:jill.morris@nih.gov">jill.morris@nih.gov</a></td>
<td><strong>Sponsor Website</strong></td>
<td>Link to program URL</td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>301-496-5745</td>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021, 05-Feb-2021, 07-May-2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>National Institute of Neurological Disorders and Stroke (NINDS) invites applications for hypothesis-driven research of prenatal and pediatric hydrocephalus. This FOA intends to support hydrocephalus research projects that examine the developmental etiology (intrinsic factors including genetics) and acquired etiology (extrinsic factors including hemorrhage and infection) of prenatal and/or pediatric hydrocephalus. Studies should focus on understanding the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>James Gnadt, Ph.D.</td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:BRAINResOppHu@ninds.nih.gov">BRAINResOppHu@ninds.nih.gov</a></td>
<td><strong>Sponsor Website</strong></td>
<td>Link to program URL</td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>301-496-9964</td>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>19-May-2020 [Optional][LOI/Pre-App], 19-Jun-2020, 19-Sep-2020 [Optional][LOI/Pre-App], 19-Oct-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to assemble diverse, integrated, multi-disciplinary teams that cross boundaries of interdisciplinary...</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
collaboration to overcome these fundamental barriers and to investigate high-impact questions in human neuroscience. Projects should maximize opportunities to conduct innovative in vivo neuroscience research made available by direct access to brain recording and stimulating from invasive surgical procedures. Projects should employ approaches guided by specified theoretical constructs and quantitative, mechanistic models where appropriate. Awardees will join a consortium work group, coordinated by the NIH, to identify consensus standards of practice, including neuroethical considerations, to collect and provide data for ancillary studies, and to aggregate and standardize data for dissemination among the wider scientific community. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

<table>
<thead>
<tr>
<th>072264</th>
<th>Clinical Validation of a Candidate Biomarker for Neurological Disease (U01 Clinical Trial Optional)</th>
<th>National Institute of Neurological Disorders and Stroke/NIH/DHHS</th>
<th>PAR-18-664</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Mary Ann Pelleymounter, PhD</td>
<td>Contact Telephone: 301-496-1779</td>
<td>Contact Email: <a href="mailto:mary.pelleymounter@nih.gov">mary.pelleymounter@nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL: <a href="#">Link to program URL</a></td>
<td>Deadline Dates (ALL): 07-May-2020, 20-Jul-2020, 07-Sep-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Neurological Disorders and Stroke (NINDS) invites applications for rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials and practice (Phase II clinical trials and beyond). This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>070605</th>
<th>Analytical Validation of a Candidate Biomarker for Neurological Disease (U01) (Clinical Trial Optional)</th>
<th>National Institute of Neurological Disorders and Stroke/NIH/DHHS</th>
<th>PAR-18-550</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Mary Ann Pelleymounter, PhD</td>
<td>Contact Telephone: 301-496-1779</td>
<td>Contact Email: <a href="mailto:mary.pelleymounter@nih.gov">mary.pelleymounter@nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL: <a href="#">Link to program URL</a></td>
<td>Deadline Dates (ALL): 07-May-2020, 20-Jul-2020, 07-Sep-2020</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

172
National Institute of Neurological Disorders and Stroke (NINDS) invites applications for Small Business Innovation Research (SBIR) from small business concerns (SBCs) to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials and practice (Phase II clinical trials and beyond). This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.
trials and practice (Phase II clinical trials and beyond). This FOA will utilize the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast Track mechanism.

<table>
<thead>
<tr>
<th><strong>FOA Number</strong></th>
<th><strong>Title</strong></th>
<th><strong>Sponsor</strong></th>
<th><strong>Program Code</strong></th>
<th><strong>Application Deadline</strong></th>
<th><strong>Contact Person</strong></th>
<th><strong>Contact Information</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>070598</td>
<td>Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)</td>
<td>National Institute of Neurological Disorders and Stroke/NIH/DHHS</td>
<td>PAR-18-549</td>
<td>07-May-2020</td>
<td>Mary Ann Pellemounter, PhD</td>
<td><a href="mailto:mary.pelleymounter@nih.gov">mary.pelleymounter@nih.gov</a></td>
</tr>
<tr>
<td>086471</td>
<td>NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)</td>
<td>National Institute of Neurological Disorders and Stroke/NIH/DHHS</td>
<td>PAR-20-021</td>
<td>07-May-2020</td>
<td>Stephen Korn, Ph.D.</td>
<td><a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a></td>
</tr>
</tbody>
</table>
The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 3 years of a candidate’s activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of “mentored training” within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch
The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent small clinical trial as part of their research and career development. Applicants not planning an independent small clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-049).

<table>
<thead>
<tr>
<th>NINDS Postdoctoral Mentored Career Development Award (K01 - No Independent Clinical Trial Allowed)</th>
<th>National Institute of Neurological Disorders and Stroke/NIH/DHHS</th>
<th>PAR-20-049</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Korn, PhD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="mailto:korns@mail.nih.gov">korns@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent small clinical trial as part of their research and career development. Applicants not planning an independent small clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-049).
project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent small clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing an independent small clinical trial as lead investigator, should apply to the companion FOA (PAR-20-050).

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>069923</td>
<td><strong>NINDS Exploratory Clinical Trials (U01 Clinical Trial Required)</strong></td>
<td>National Institute of Neurological Disorders and Stroke/NIH/DHHS</td>
<td>PAR-18-420</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td><strong>Synopsis</strong></td>
<td>National Institute of Neurological Disorders and Stroke (NINDS) invites applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (<a href="https://www.ninds.nih.gov/">https://www.ninds.nih.gov/</a>). This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 069928  | **NINDS Efficacy Clinical Trials (U01 Clinical Trial Required)** | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-18-422 | 07-May-2020 | Not Specified |
|         | **Synopsis** | National Institute of Neurological Disorders and Stroke (NINDS) invites applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). This FOA will use the NIH Research Project (R01) award mechanism. |
### HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Michael B. Wolfson</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-451-4778</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Michael.Wolfson@nih.gov">Michael.Wolfson@nih.gov</a></td>
</tr>
</tbody>
</table>

**Sponsor Website**

[Link to program URL](#)

**Program URL**

[Link to program URL](#)

**Deadline Dates (ALL)**

- 23-May-2020 [Optional][LOI/Pre-App], 22-Jun-2020, 21-Sep-2020 [Optional][LOI/Pre-App], 21-Oct-2020, 22-Jan-2021 [Optional][LOI/Pre-App], 21-Feb-2021

**Synopsis**

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical trial (e.g., Early Feasibility Study). The clinical trial is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress. This FOA will leverage Public-Private Partnership Programs (PPP) initiated under the NIH BRAIN Initiative, the Office of Strategic Coordination – The Common Fund’s Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program, and the HEAL Initiative. These programs include agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without the need for significant additional non-clinical data. For more
<table>
<thead>
<tr>
<th><strong>078982</strong></th>
<th><strong>HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)</strong></th>
<th>National Institute of Neurological Disorders and Stroke/NIH/DHHS</th>
<th><strong>RFA-NS-19-018</strong></th>
<th><strong>23-May-2020</strong></th>
<th><strong>Not Specified</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Nick Langhals, PhD</td>
<td><strong>Contact Telephone</strong></td>
<td>301-496-1447</td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:nick.langhals@nih.gov">nick.langhals@nih.gov</a></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td><a href="#">Link to program URL</a></td>
<td><strong>Program URL</strong></td>
<td><a href="#">Link to program URL</a></td>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>23-May-2020 [Optional][LOI/Pre-App], 22-Jun-2020 , 21-Sep-2020 [Optional][LOI/Pre-App], 21-Oct-2020 , 22-Jan-2021 [Optional][LOI/Pre-App], 21-Feb-2021</td>
</tr>
</tbody>
</table>

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants. The clinical trial should provide data to answer key questions about the function or final design of a device and is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress. This FOA will leverage Public-Private Partnership Programs (PPP) initiated under the NIH BRAIN Initiative, the Office of Strategic Coordination – The Common Fund’s Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program, and the HEAL Initiative. These programs include agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices’ existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without the need for significant additional non-clinical data. For more information see [https://braininitiative.nih.gov/resources/brain_ppp/index.htm](https://braininitiative.nih.gov/resources/brain_ppp/index.htm), [https://commonfund.nih.gov/sparc/newmarkets](https://commonfund.nih.gov/sparc/newmarkets), and [https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/public-private-partnership](https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/public-private-partnership). Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities.
### HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)

**Contact Name:** Stephanie Fertig, MBA  
**Contact Telephone:** 301-496-1779  
**Contact Email:** fertigs@ninds.nih.gov  
**Sponsor Website:** [Link to program URL](https://braininitiative.nih.gov/resources/brain_ppp/index.htm)  
**Deadline Dates (ALL):**  
- 23-May-2020 [Optional][LOI/Pre-App], 22-Jun-2020, 21-Sep-2020 [Optional][LOI/Pre-App], 21-Oct-2020, 22-Jan-2021 [Optional][LOI/Pre-App], 21-Feb-2021  

**Synopsis:**  
The purpose of this Funding Opportunity Announcement (FOA) is to encourage small business concerns (SBCs) to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical trial (e.g., Early Feasibility Study). The clinical trial is expected to provide information about the device function or final design that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress. This FOA will leverage Public-Private Partnership Programs (PPP) initiated under the NIH BRAIN Initiative, the Office of Strategic Coordination – The Common Fund’s Stimulating Peripheral Activity to Relieve Conditions (SPARC) Program, and the NIH HEAL Initiative. These programs include agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without the need for significant additional non-clinical data. For more information see [https://braininitiative.nih.gov/resources/brain_ppp/index.htm](https://braininitiative.nih.gov/resources/brain_ppp/index.htm), [https://commonfund.nih.gov/sparc/newmarkets](https://commonfund.nih.gov/sparc/newmarkets), and [https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/public-private-partnership](https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/public-private-partnership). Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities.

### Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

**Contact Name:** Stephanie Fertig, MBA  
**Contact Telephone:** 301-496-1779  
**Contact Email:** fertigs@ninds.nih.gov  
**Sponsor Website:** [Link to program URL](https://braininitiative.nih.gov/resources/brain_ppp/index.htm)  
**Deadline Dates (ALL):**  
- 07-May-2020  

**Synopsis:**  
Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or any of the companion opportunities.
**Synopsis**

National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, and pharmacodynamic markers that will be utilized to facilitate the development of neurotherapeutics. Ideally, models, model systems and pharmacodynamic markers proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery. This FOA will utilize the NIH R61/R33 Phased Innovation Award mechanism.

| Deadline Dates (ALL) | National Institute of Neurological Disorders and Stroke/NIH/DHHS PAR-19-171 07-May-2020 Not Specified |
|----------------------|---------------------------------------------------------------|-------------------------------------------------|

**Synopsis**

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is
particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.

**065643 CREATE Bio Optimization Track for Biologics (SBIR-U44)**

<table>
<thead>
<tr>
<th>National Institute of Neurological Disorders and Stroke/NIH/DHHS</th>
<th>PAR-17-457</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Chris Boshoff, Ph.D.</td>
<td>301-496-1779</td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:chris.boshoff@nih.gov">chris.boshoff@nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 20-Jul-2020, 07-Sep-2020</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

National Institute of Neurological Disorders and Stroke (NINDS) invites SBIR applications for the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, convincing in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. This program will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreements - Phase II, and Fast-Track award mechanism.

**068924 RFA-NS-18-012 -- Translational Neural Devices (U44 Clinical Trial Required) (Defunct)**

<table>
<thead>
<tr>
<th>National Institute of Neurological Disorders and Stroke/NIH/DHHS</th>
<th>RFA-NS-18-012</th>
<th>23-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Nick Langhals, PhD</td>
<td>301-496-1447</td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:nick.langhals@nih.gov">nick.langhals@nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

National Institute of Neurological Disorders and Stroke (NINDS) invites applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food
and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design. This FOA will use the NIHU44 Small Business Innovation Research (SBIR) Cooperative Agreements - Fast-Track award mechanism.

<table>
<thead>
<tr>
<th>Program Number</th>
<th>Program Name</th>
<th>Sponsor</th>
<th>PAR</th>
<th>Deadline Dates</th>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>080855</td>
<td>Institutional Translational Research Training Program (T32)</td>
<td>NINDS</td>
<td>PAR-19-228</td>
<td>27-May-2020</td>
<td>Letitia Weigand, Ph.D.</td>
<td>301-496-4188</td>
<td><a href="mailto:letitia.weigand@nih.gov">letitia.weigand@nih.gov</a></td>
<td>NINDS Program Project Grant (P01 Clinical Trial Optional)</td>
<td>National Institute of Neurological Disorders and Stroke/NIH/DHHS</td>
<td>PAR-18-421</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Letitia Weigand, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-4188</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:letitia.weigand@nih.gov">letitia.weigand@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>NINDS Program Project Grant (P01 Clinical Trial Optional)</td>
<td>National Institute of Neurological Disorders and Stroke/NIH/DHHS</td>
<td>PAR-18-421</td>
<td>07-May-2020</td>
<td>Not Specified</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates</td>
<td>27-May-2020, 26-May-2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The purpose of the Institutional Translational Research Training Program is to equip trainees with the knowledge and skills needed to advance basic research toward clinical application. These programs will support, students and/or postdocs conducting basic, disease-relevant research in an environment that includes 1) basic scientists and clinicians who are actively engaged in collaborative research projects, 2) neuroscience researchers with expertise in translational processes who are conducting research designed to move basic discoveries toward clinical application and 3) relationships with industry and government regulatory agencies. Programs will have a cohesive educational approach to translational training in areas relevant to the NINDS and NIA missions, and in which students and postdocs learn the processes involved in translational research in the context of their individual projects. Programs supported by this FOA must include activities that ensure a thorough understanding of experimental design, strong statistical and analytical skills, and skills for communicating science with a wide variety of audiences. These programs are intended to be 2 years in duration and support training of one or more of the following groups: advanced predoctoral students, postdoctoral fellows and fellowship-stage clinicians. Upon completion of the program, trainees will be prepared to address basic research problems with an understanding of the requirements for translating discoveries into viable therapies. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.
<table>
<thead>
<tr>
<th>Contact Email</th>
<th><a href="mailto:do47h@nih.gov">do47h@nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute of Neurological Disorders and Stroke (NINDS) invites applications that propose to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants. This FOA will utilize the NIH P01 Research Program Projects award mechanism.

080424 **NINDS Institutional Research Training Program (T32)**

| Contact Name | Letitia Weigand, Ph.D. |
| Contact Telephone | 301-496-4188 |
| Contact Email | letitia.weigand@nih.gov |
| Sponsor Website | Link to program URL |
| Program URL | Link to program URL |
| Deadline Dates (ALL) | 27-May-2020, 26-May-2021 |

**Synopsis**

The purpose of this FOA is to provide support for institutional research training programs in areas relevant to the NINDS mission. These institutional research training programs should produce well-trained neuroscientists who leave the program with the research skills and scientific knowledge to make a significant contribution to neuroscience research. Programs should be designed to enhance the breadth and depth of training in NINDS mission areas by incorporating didactic, research and career development components in the context of a defined scientific theme. Programs may support basic, clinical and/or translational research. Critical components of programs supported by this FOA include mechanisms to ensure a thorough understanding of experimental design, strong statistics and analytical skills, and skills for communicating science, both orally and in writing, to a wide variety of audiences. Regardless of theme, programs should provide opportunities and activities that will foster the development of quantitative literacy and the application of quantitative approaches to the trainees' research. NINDS institutional training programs are intended to be 1-2 years in duration and support training of one or more of the following groups: dissertation stage predoctoral students in their 3rd and/or 4th year of graduate school, postdoctoral fellows and fellowship-stage clinicians. (NINDS does not support first or second year graduate students under this PAR). This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to
lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-

<table>
<thead>
<tr>
<th>FOA ID</th>
<th>Title</th>
<th>Sponsor</th>
<th>FOA Date</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>088962</td>
<td><strong>RFA-NS-20-016 -- Biological Measures for Prognosing and Monitoring of Persistent Concussive Symptoms in Early and Middle Adolescents: Center Without Walls (PCS-EMA C WOW)</strong> <em>(US4 Clinical Trial Not Allowed)</em></td>
<td>National Institute of Neurological Disorders and Stroke/NIH/DHHS</td>
<td>27-May-2020</td>
<td>10,000,000 USD</td>
</tr>
<tr>
<td>083919</td>
<td><strong>Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)</strong></td>
<td>National Institute of Neurological Disorders and Stroke/NIH/DHHS</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

**Synopsis**

This Funding Opportunity Announcement (FOA) is to promote the development and initial clinical validation of objective biological measures to be used for prognosing, and monitoring recovery of adolescents who either clinically present with or are at risk for developing prolonged/persistent concussive symptoms following exposure to repetitive head impacts and/or concussion. Resultant biological measures should be incorporated into risk stratification algorithms to inform clinical care and patient stratification for future clinical trials. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data to further advance research in the area of persistent concussive symptoms in early and middle adolescent (EMA; ages 11-17 years old) populations.

**Contact Details**

<table>
<thead>
<tr>
<th>FOA ID</th>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>088962</td>
<td>Patrick SF Bellgowan, Ph.D.</td>
<td>301-496-1447</td>
<td><a href="mailto:psfb@mail.nih.gov">psfb@mail.nih.gov</a></td>
<td>Link to program URL</td>
<td>27-May-2020 [Optional][LOI/Pre-App], 26-Jun-2020</td>
<td>27-May-2020 [Optional][LOI/Pre-App], 26-Jun-2020</td>
</tr>
</tbody>
</table>
The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

<table>
<thead>
<tr>
<th>076050</th>
<th>Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)</th>
<th>National Institute of Nursing Research/NIH/DHHS</th>
<th>PA-18-850</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Mary C. Roary, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-594-2154</td>
<td>Contact Email</td>
<td><a href="mailto:mary.roary@nih.gov">mary.roary@nih.gov</a></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>FOA Number</th>
<th>Title</th>
<th>Agency</th>
<th>PA</th>
<th>Deadline</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>066276</td>
<td>Symptom Cluster Characterization in Chronic Conditions (R21)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-17-461</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td>069482</td>
<td>Family-Centered Self-Management of Chronic Conditions (R01 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-383</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>066708</td>
<td>New Onset Depressive Symptoms in Acute Illness (R21 Clinical Trial Not Allowed)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-17-487</td>
<td>16-May-2020</td>
<td>275,000 USD</td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. This FOA will use the NIH Research Project (R01) award mechanism.

**Symptom Cluster Characterization in Chronic Conditions (R21)**

- **Contact Name**: Michelle R.J. Hamlet, PhD
- **Contact Telephone**: 301-496-9623
- **Contact Email**: Michelle.hamlet@nih.gov
- **Program URL**: Link to program URL
- **Deadline Dates (ALL)**: 07-May-2020, 07-Sep-2020, 07-Jan-2021

**Family-Centered Self-Management of Chronic Conditions (R01 Clinical Trial Optional)**

- **Contact Name**: Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI
- **Contact Telephone**: 301-594-5970
- **Contact Email**: hussk@mail.nih.gov
- **Program URL**: Link to program URL
- **Deadline Dates (ALL)**: 07-May-2020, 07-Sep-2020, 07-Jan-2021

**New Onset Depressive Symptoms in Acute Illness (R21 Clinical Trial Not Allowed)**

- **Contact Name**: Martha Matocha, PhD
- **Contact Telephone**: 301-594-2775
National Institute of Nursing Research (NINR) and National Institute of Mental Health (NIMH) invite applications for research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

### Synopsis
National Institute of Nursing Research (NINR) invites applications for preclinical and clinical research and secondary data analysis on symptom cluster characterization that has potential to inform treatment and interventions that improve functional outcomes and quality of life in patients with chronic conditions. This FOA will use the NIH Research Project (R01) award mechanism.

### Contact Information
- **Contact Name**: Michelle R.J. Hamlet, PhD
- **Contact Telephone**: 301-496-9623
- **Contact Email**: Michelle.hamlet@nih.gov
- **Sponsor Website**
- **Program URL**

### Deadline Dates (ALL)

Synopsis
National Institute of Nursing Research (NINR) and National Institute of Mental Health (NIMH) invite applications for research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness. This FOA will use the NIH Research Project (R01) award mechanism.

065717  Symptom Cluster Characterization in Chronic Conditions (R21) National Institute of Nursing Research/NIH/DHHS PA-17-461 07-May-2020 275,000 USD

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Michelle R.J. Hamlet, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-9623</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Michelle.hamlet@nih.gov">Michelle.hamlet@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

Synopsis
National Institute of Nursing Research (NINR) invites applications for preclinical and clinical research and secondary data analysis on symptom cluster characterization that has potential to inform treatment and interventions that improve functional outcomes and quality of life in patients with chronic conditions. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

070260  End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional) National Institute of Nursing Research/NIH/DHHS PA-18-498 07-May-2020 Not Specified

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Lynn S. Adams, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-594-8911</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:adamsls@nih.gov">adamsls@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

Synopsis
National Institute of Nursing Research (NINR) invites applications for research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel
strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>FOA ID</th>
<th>FOA Title</th>
<th>Funding Institute</th>
<th>Project Code</th>
<th>Date</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>070341</td>
<td>Community Partnerships to Advance Research (CPAR) (R21 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-381</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td>067106</td>
<td>Addressing Chronic Wound Trajectories Through Social Genomics Research (R01 - Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-17-492</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute of Nursing Research (NINR) invites applications for researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

National Institute of Nursing Research (NINR) invites applications for clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. The field of social genomics focuses on how the social environment influences gene expression, and how this gene expression may in turn impact health outcomes. Chronic wounds (e.g., diabetic ulcers, venous or arterial ulcers) are multidimensional and, as such, there is benefit to a holistic approach that goes beyond a focus on the wound (i.e., repairing the skin and underlying tissue) to include an approach that focuses on the person with the wound. A better understanding of social environmental factors (positive and negative) and associated molecular mechanisms is needed to advance therapeutic strategies aimed at reducing chronic wound risk in
### Promoting Caregiver Health Using Self-Management (R01 Clinical Trial Optional)

**Synopsis**

Promoting Caregiver Health Using Self-Management (R01 Clinical Trial Optional)

National Institute of Nursing Research/NIH/DHHS

PA-18-150

07-May-2020

Not Specified

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-594-5970</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
</tbody>
</table>

National Institute of Nursing Research (NINR) invites applications for research in promoting caregiver health using self-management. Caregiving is an important science area since the number of people living longer with chronic conditions is growing. Informal caregivers (lay caregivers) are defined as unpaid individuals (spouses, partners, family members, friends, or neighbors) involved in assisting others with activities of daily living and/or medical tasks. Formal caregivers are paid, delivering care in one’s home or care settings (daycare, residential care facility). This concept focuses on informal caregivers. This FOA will use the NIH Research Project (R01) award mechanism.

### mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R21 Clinical Trial Optional)

**Synopsis**

mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R21 Clinical Trial Optional)

National Institute of Nursing Research/NIH/DHHS

PA-18-389

07-May-2020

275,000 USD

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Augie Diana, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-402-6423</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:dianaa@mail.nih.gov">dianaa@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

National Institute of Nursing Research (NINR) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient–provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that...
consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

<table>
<thead>
<tr>
<th>067127</th>
<th><strong>Implementing the Most Successful Interventions to Improve HIV/AIDS Outcomes in U.S. Communities (R21-Clinical Trial Optional)</strong></th>
<th>National Institute of Nursing Research/NIH/DHHS</th>
<th>PAR-17-490 07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Rebecca Henry, PhD, RN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-594-5976</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:rebecca.henry@nih.gov">rebecca.henry@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Nursing Research (NINR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal, is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>068669</th>
<th><strong>Chronic Condition Self-Management in Children and Adolescents (R01 Clinical Trial Optional)</strong></th>
<th>National Institute of Nursing Research/NIH/DHHS</th>
<th>PA-18-151 07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Dr. Rebecca Roof</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-594-5971</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Rebecca.Roof@nih.gov">Rebecca.Roof@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
National Institute of Nursing Research (NINR) invites applications for research to improve self-management and quality of life in children and adolescents with chronic conditions. Managing a chronic condition is an unremitting responsibility for children and their families. Children with a chronic condition and their families have a long-term responsibility for self-management. This FOA encourages research that takes into consideration various factors that influence self-management such as individual differences, biological and psychological factors, family/caregivers and sociocultural context, family-community dynamics, healthcare system factors, technological advances, and the role of the environment. This program will use the NIH Research Project (R01) award mechanism.

**Healthy Habits: Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R01 Clinical Trial Optional)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Mary C. Roary, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-594-2154</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:mary.roary@nih.gov">mary.roary@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
</tr>
</tbody>
</table>

The sponsors invite applications that employ innovative research to identify mechanisms of influence and/or promote positive sustainable health behavior(s) in children and youth (birth to age 21). Positive health behaviors may include: developing healthy sleep patterns, developing effective self-regulation strategies, adaptive decision-making in risk situations, practicing proper dental hygiene, eating a balanced and nutritious diet, engaging in age-appropriate physical activity and/or participating in healthy relationships. Applications to promote positive health behavior(s) should target social and cultural factors, including, but not limited to: schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include: effective, sustainable processes for influencing young people to make healthy behavior choices; identification of the appropriate stage of influence for learning sustainable lifelong health behaviors; the role of technology and new media in promoting healthy behavior; identification of factors that support healthy behavior development in vulnerable populations, identification of barriers to healthy behaviors; and, identification of mechanisms and mediators that are common to the development of a range of habitual health behaviors. Given the many factors involved in developing sustainable health behaviors, applications from multidisciplinary teams are strongly encouraged. The ultimate goal of this FOA is to promote research that identifies and enhances processes that promote sustainable positive behavior or changes social and cultural norms that influence health and future health behaviors. This FOA will use the NIH Research Project (R01) award mechanism.
<table>
<thead>
<tr>
<th>Project Title</th>
<th>Agency</th>
<th>Award Number</th>
<th>Application Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self-Management for Health in Chronic Conditions (R21 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-384</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</td>
<td>Contact Telephone</td>
<td>301-594-5970</td>
<td>Contact Email</td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td>Deadline Dates (ALL)</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-499</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Lynn S. Adams, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-594-8911</td>
<td>Contact Email</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute of Nursing Research (NINR) invites applications for research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-348</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Lois A. Tully, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-594-5968</td>
<td></td>
</tr>
</tbody>
</table>
Contact Email | tullyla@mail.nih.gov
---|---
Sponsor Website | Link to program URL
Program URL | 

National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invites applications for clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers. This FOA will use the NIH Research Project (R01) award mechanism.

069491  

mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R01 Clinical Trial Optional)  

National Institute of Nursing Research/NIH/DHHS  
PAA-18-386  
07-May-2020  
Not Specified

Contact Name | Augie Diana, Ph.D.
---|---
Contact Telephone | 301-402-6423
Contact Email | dianaa@mail.nih.gov
Sponsor Website | Link to program URL
Program URL | 

National Institute of Nursing Research (NINR) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient–provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions...
utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>FOA ID</th>
<th>FOA Title</th>
<th>Sponsor</th>
<th>PA Number</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>070340</td>
<td>Community Partnerships to Advance Research (CPAR) (R01 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-377</td>
<td>07-May-2020</td>
<td>National Institute of Nursing Research (NINR) invites applications for researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes. This FOA will use the NIH Research Project (R01) award mechanism.</td>
</tr>
<tr>
<td>070051</td>
<td>Obesity and Asthma: Awareness and Self-Management (R01 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-379</td>
<td>07-May-2020</td>
<td>National Institute of Nursing Research (NINR) invites applications for research that examines the relationship between asthma, obesity and self-management. It seeks to build the science of obesity, asthma, and self-management awareness. This FOA will use the NIH Research Project (R01) award mechanism.</td>
</tr>
<tr>
<td>067124</td>
<td>Implementing the Most Successful Interventions to Improve HIV/AIDS Outcomes in U.S. Communities (R01- Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PAR-17-491</td>
<td>07-May-2020</td>
<td>National Institute of Nursing Research (NINR) invites applications for research that examines the relationship between asthma, obesity and self-management. It seeks to build the science of obesity, asthma, and self-management awareness. This FOA will use the NIH Research Project (R01) award mechanism.</td>
</tr>
</tbody>
</table>
Addressing Chronic Wound Trajectories Through Social Genomics Research (R21 - Clinical Trial Optional)

National Institute of Nursing Research (NINR) invites applications for clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. The field of social genomics focuses on how the social environment influences gene expression, and how this gene expression may in turn impact health outcomes. Chronic wounds (e.g., diabetic ulcers, venous or arterial ulcers) are multidimensional and, as such, there is benefit to a holistic approach that goes beyond a focus on the wound (i.e., repairing the skin and underlying tissue) to include an approach that focuses on the person with the wound. A better understanding of social environmental factors (positive and negative) and associated molecular mechanisms is needed to advance therapeutic strategies aimed at reducing chronic wound risk in addition to improving healing outcomes and quality of life. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

National Institute of Nursing Research/NIH/DHHS
PA-17-493 07-May-2020 275,000 USD

Contact Name: Lois Tully, PhD
Contact Telephone: 301-594-5968
Contact Email: tullyla@mail.nih.gov
Sponsor Website: Link to program URL
Program URL: Link to program URL

National Institute of Nursing Research (NINR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression. This FOA will use the NIH Research Project (R01) award mechanism.

Synopsis:
National Institute of Nursing Research (NINR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression. This FOA will use the NIH Research Project (R01) award mechanism.

Contact Name: Rebecca Henry, PhD
Contact Telephone: 301-594-5968
Contact Email: rebecca.henry@nih.gov
Sponsor Website: Link to program URL
Program URL: Link to program URL

Synopsis:
National Institute of Nursing Research (NINR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression. This FOA will use the NIH Research Project (R01) award mechanism.
<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
<th>Logo</th>
<th>Agency</th>
<th>PA</th>
<th>Deadline Date</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>070320</td>
<td><strong>Self-Management for Health in Chronic Conditions (R01 Clinical Trial Optional)</strong></td>
<td></td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-376</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td>Contact Name: Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone: 301-594-5970</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email: <a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website: <a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis: National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>070317</td>
<td><strong>Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21 Clinical Trial Optional)</strong></td>
<td></td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-347</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name: Lois A. Tully, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone: 301-594-5968</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email: <a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website: <a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis: National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invites applications for clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOA ID</td>
<td>FOA Title</td>
<td>Agency</td>
<td>FOA Number</td>
<td>Application Due Date</td>
<td>Budget</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>------------</td>
<td>----------------------</td>
<td>--------</td>
<td></td>
</tr>
<tr>
<td>069458</td>
<td>Healthy Habits: Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R21 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-354</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
<td></td>
</tr>
<tr>
<td>069486</td>
<td>Family-Centered Self-Management of Chronic Conditions (R21 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-380</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
<td></td>
</tr>
</tbody>
</table>

**Contact Name:** Mary C. Roary, Ph.D.  
**Contact Telephone:** 301-594-2154  
**Contact Email:** mary.roary@nih.gov  
**Sponsor Website:**  
**Program URL:** Link to program URL  

**Synopsis:** The sponsors invite applications that employ innovative research to identify mechanisms of influence and/or promote positive sustainable health behavior(s) in children and youth (birth to age 21). Positive health behaviors may include: developing healthy sleep patterns, developing effective self-regulation strategies, adaptive decision-making in risk situations, practicing proper dental hygiene, eating a balanced and nutritious diet, engaging in age-appropriate physical activity and/or participating in healthy relationships. Applications to promote positive health behavior(s) should target social and cultural factors, including, but not limited to: schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include: effective, sustainable processes for influencing young people to make healthy behavior choices; identification of the appropriate stage of influence for learning sustainable lifelong health behaviors; the role of technology and new media in promoting healthy behavior; identification of factors that support healthy behavior development in vulnerable populations, identification of barriers to healthy behaviors; and, identification of mechanisms and mediators that are common to the development of a range of habitual health behaviors. Given the many factors involved in developing sustainable health behaviors, applications from multidisciplinary teams are strongly encouraged. The ultimate goal of this FOA is to promote research that identifies and enhances processes that promote sustainable positive behavior or changes social and cultural norms that influence health and future health behaviors. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

**Contact Name:** Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI  
**Contact Telephone:** 301-594-5970  
**Contact Email:** hussk@mail.nih.gov  
**Sponsor Website:**  
**Program URL:** Link to program URL
### Synopsis
National Institute of Nursing Research (NINR) invites applications for research to build the science of family-centered self-management (FCSM) in chronic conditions. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

<table>
<thead>
<tr>
<th>FOA ID</th>
<th>Title</th>
<th>Sponsor</th>
<th>PAR-19-320</th>
<th>Deadline Dates (ALL)</th>
<th>Amount</th>
</tr>
</thead>
</table>

Contact Name: Karen A. Kehl, PhD, RN, FPCN
Contact Telephone: 301-594-8010
Contact Email: karen.kehl@mail.nih.gov
Sponsor Website: [Link to program URL](#)
Program URL: [Link to program URL](#)

The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.
illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.

<table>
<thead>
<tr>
<th>FOA Number</th>
<th>Title</th>
<th>Sponsor</th>
<th>PAR</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>085700</td>
<td>Omics-guided Biobehavioral Interventions for Improved Health Outcomes: A Step Forward in Translation (R01 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PAR-19-377 07-May-2020</td>
<td>Not Specified</td>
<td>The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that harnesses the wealth of advances in the fields of genomics and other omics (e.g., metabolomics, microbiomics, proteomics, transcriptomics, epigenomics, etc.) to incorporate these advances into translatable, personalized biobehavioral interventions for improved health outcomes.</td>
</tr>
<tr>
<td>079184</td>
<td>Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PAR-19-135 25-Feb-2020</td>
<td>300,000 USD</td>
<td>The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and health professional institutions otherwise unlikely to participate extensively in NIH-funded research to conduct research that addresses key national priorities.</td>
</tr>
</tbody>
</table>
research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions (e.g., the university or college with a unique Employee Identification Number [EIN]) must award NIH-relevant baccalaureate or advanced degrees in health professions and have received no more than $6 million per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by the institution as a whole (meaning all schools and colleges within an institution). In other words, the funding for all the institution’s health professional schools, graduate schools, and colleges and all the institution’s non-health professional schools and colleges that are part of the institution are considered together and summed as total NIH funding when determining institutional eligibility. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.

<table>
<thead>
<tr>
<th>079344</th>
<th>End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)</th>
<th>National Institute of Nursing Research/NIH/DHHS</th>
<th>PAR-19-153</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Lynn S. Adams, Ph.D.</td>
<td><strong>Contact Telephone</strong></td>
<td>301-594-8911</td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:lynn.adams@nih.gov">lynn.adams@nih.gov</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>078362</th>
<th>End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21 Clinical Trial Optional)</th>
<th>National Institute of Nursing Research/NIH/DHHS</th>
<th>PAR-19-044</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Karen A. Kehl, Ph.D.</td>
<td><strong>Contact Telephone</strong></td>
<td>301-594-8010</td>
<td><strong>Sponsor Website</strong></td>
<td><a href="#">Link to program URL</a></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:kehlka@nih.gov">kehlka@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>----------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Lois A. Tully, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-594-5968</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual’s chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Augie Diana, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-402-6423</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:dianaa@mail.nih.gov">dianaa@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
</tr>
</tbody>
</table>
### Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional)

- **Contact Name:** Martha Matocha, PhD
- **Contact Telephone:** 301-594-2775
- **Contact Email:** matocham@mail.nih.gov
- **Sponsor Website:** Link to program URL
- **Synopsis:** The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.

| 077789 | Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional) | National Institute of Nursing Research/NIH/DHHS | PA-18-946 | 07-May-2020 | 275,000 USD |

### End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)

- **Contact Name:** Karen A. Kehl, Ph.D.
- **Contact Telephone:** 301-594-8010
- **Contact Email:** kehlka@nih.gov
- **Sponsor Website:** Link to program URL
- **Synopsis:** The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.

<p>| 078345 | End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional) | National Institute of Nursing Research/NIH/DHHS | PAR-19-045 | 07-May-2020 | Not Specified |</p>
<table>
<thead>
<tr>
<th>Funding Opportunity Announcement</th>
<th>National Institute of Nursing Research/NIH/DHHS</th>
<th>PA-18-945</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>Martha Matocha, PhD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-594-2775</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:matocham@mail.nih.gov">matocham@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Funding Opportunity Announcement</th>
<th>National Institute of Nursing Research/NIH/DHHS</th>
<th>PA-19-024</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Addressing Caregiver Symptoms through Technological Tools (R21 Clinical Trial Optional)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>Augie Diana, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-402-6423</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:dianaa@mail.nih.gov">dianaa@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Funding Opportunity Announcement</th>
<th>National Institute of Nursing Research/NIH/DHHS</th>
<th>PA-19-074</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Telomeres in Wellness and Disease: A Biobehavioral Approach (R01 Clinical Trial Optional)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>Lois A. Tully, PhD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-594-5968</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Number</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>PA#</td>
<td>Submission Date</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>-----</td>
<td>--------------------</td>
</tr>
<tr>
<td>079185</td>
<td><strong>End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)</strong></td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PAR-19-136</td>
<td>07-May-2020</td>
</tr>
<tr>
<td></td>
<td><strong>Synopsis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>078414</td>
<td><strong>Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional)</strong></td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PAR-19-058</td>
<td>07-May-2020</td>
</tr>
<tr>
<td></td>
<td><strong>Synopsis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| Contact Email | Lynn S. Adams, Ph.D. |
| Contact Telephone | 301-594-8911 |
| Contact Email | <a href="mailto:adamsls@nih.gov">adamsls@nih.gov</a> |</p>
<table>
<thead>
<tr>
<th>Sponsor Website</th>
<th>Link to program URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities.</td>
</tr>
<tr>
<td>078411 Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Lynn S. Adams, Ph.D.</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-594-8911</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:adamsls@nih.gov">adamsls@nih.gov</a></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities.</td>
</tr>
<tr>
<td>077787 Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Lois A. Tully, PhD</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-594-5968</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a></td>
</tr>
</tbody>
</table>
### Synopsis

The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual’s chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness.

<table>
<thead>
<tr>
<th>FOA ID</th>
<th>Title</th>
<th>Agency</th>
<th>PA Number</th>
<th>Application Deadline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>078636</td>
<td>Telomeres in Wellness and Disease: A Biobehavioral Approach (R21 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-19-073</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>068622</td>
<td>Mechanisms, Models, Measurement, &amp; Management in Pain Research (R21 Clinical Trial Optional)</td>
<td>National Institute of Nursing Research/NIH/DHHS</td>
<td>PA-18-159</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
</tbody>
</table>

The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are
needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.
### Synopsis
National Institute on Aging (NIA) invites revision applications to ongoing NIA-supported program project (P01) awards and resubmissions of unfunded program project applications (including unfunded revision requests). The applications should address scientific areas relevant to the NIA mission. Revision applications should include expansion of (an) existing, or proposal of (a) new project or projects within a program project. Revision applications may not request support beyond the end date of the parent P01 award. This FOA will use the Program Project P01 award mechanism.

### Limitied Competition: NIA Genome Center for Alzheimer's Disease (GCAD) (U54 Clinical Trial Not Allowed)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Marilyn Miller, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-9350</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's disease (AD) and AD-related dementias (ADRD), in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.

### Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Chhanda Dutta, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-4161</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:duttac@mail.nih.gov">duttac@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
</tbody>
</table>

This FOA invites applications to small-scale clinical studies and secondary analyses of clinical trials to evaluate the potential protective effects of metformin in aging and age-related conditions. The FOA supports preclinical and clinical studies to assess the therapeutic potential of metformin in reducing age-related diseases, with a focus on identifying potential therapeutic avenues for age-related conditions.
### Synopsis

National Institute on Aging (NIA) and National Cancer Institute (NCI) invite applications for research projects including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformin’s human physiologic and cellular effects that would be useful in identifying novel molecular targets. This FOA will use the NIH Research Project (R01) award mechanism.

070904 **Underactive Bladder and Detrusor Activity in Aging (R01 Clinical Trial Optional)**  
National Institute on Aging/NIH/DHHS  
PA-18-570  
07-May-2020  
Not Specified

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Marcel E. Salive, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-6761</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:saliveme@mail.nih.gov">saliveme@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

### Synopsis

National Institute on Aging (NIA) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH Research Project (R01) award mechanism.

070905 **Underactive Bladder and Detrusor Activity in Aging (R21 Clinical Trial Optional)**  
National Institute on Aging/NIH/DHHS  
PA-18-572  
07-May-2020  
275,000 USD

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Marcel E. Salive, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-6761</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:saliveme@mail.nih.gov">saliveme@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>
**Synopsis**

National Institute on Aging (NIA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basicclinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

**Examining Diversity, Recruitment and Retention in Aging Research (R24 Clinical Trial Not Allowed)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Cerise Elliott, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-9350</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:elliottce@mail.nih.gov">elliottce@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>25-May-2020, 25-Sep-2020, 25-Jan-2021</td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute on Aging (NIA) invites applications for collaborative teams to target gaps in methods and outcomes regarding research participant recruitment and retention. The team approach encouraged by this initiative will be used to generate a research resource to advance processes for high yield recruitment, formulate breakthrough ideas, concepts and approaches to research participant recruitment and retention, strengthen outreach and community engagement practices, and devise improved communication strategies. Teams will demonstrate the success of these improvements by engaging a large diverse population. The primary outcome will be the development of a population of diverse community members ready to engage in NIA funded clinical research studies. This FOA will use the NIH R24 Resource-Related Research Projects award mechanism.

**Underactive Bladder and Detrusor Activity in Aging (R03 Clinical Trial Optional)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Marcel E. Salive, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-6761</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:saliveme@mail.nih.gov">saliveme@mail.nih.gov</a></td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute on Aging (NIA) invites applications for collaborative teams to target gaps in methods and outcomes regarding research participant recruitment and retention. The team approach encouraged by this initiative will be used to generate a research resource to advance processes for high yield recruitment, formulate breakthrough ideas, concepts and approaches to research participant recruitment and retention, strengthen outreach and community engagement practices, and devise improved communication strategies. Teams will demonstrate the success of these improvements by engaging a large diverse population. The primary outcome will be the development of a population of diverse community members ready to engage in NIA funded clinical research studies. This FOA will use the NIH R24 Resource-Related Research Projects award mechanism.
National Institute on Aging (NIA) invites pilot/feasibility projects that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Pilot/feasibility research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH R03 Small Grant Program award mechanism.

<table>
<thead>
<tr>
<th>Sponsor Website</th>
<th>Link to program URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**
National Institute on Aging (NIA) invites applications employing secondary analysis of existing data sets or stored biospecimens, to address clinically related issues on aging changes influencing health across the lifespan, and/or on diseases and disabilities in older persons. Use of cohorts that are linked to electronic health record systems and/or Centers for Medicare and Medicaid Services (CMS) administrative data are especially welcome. This FOA will support activities addressing specific hypotheses in clinical aging research and/or to inform the design and implementation of future epidemiologic or human intervention studies, or current geriatric practice in maintenance of health, management of disease, and prevention of disability. Existing data sets may also be used to develop and test new statistical analytical approaches. Costs for archiving of data to be made publicly available and those associated with data harmonization or assay refinement/validation may be included in the budget, as long as these activities are pertinent to the proposed secondary analyses. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.

<table>
<thead>
<tr>
<th>059151</th>
<th>Exploratory Analyses of Existing Cohorts, Data Sets, and Stored Biospecimens to Address Clinical Aging Research Questions (R21)</th>
<th>National Institute on Aging/NIH/DHHS</th>
<th>PA-17-089</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Chhanda Dutta, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-496-4161</td>
<td>Contact Email</td>
<td><a href="mailto:duttac@mail.nih.gov">duttac@mail.nih.gov</a></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>062697</th>
<th>NIA Academic Leadership Career Award (K07)</th>
<th>National Institute on Aging/NIH/DHHS</th>
<th>PAR-17-287</th>
<th>07-May-2020</th>
<th>625,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Robin A. Barr, D. Phil.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-402-7715</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:BarrR@mail.nih.gov">BarrR@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 12-Jun-2020, 07-Sep-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute on Aging (NIA) invites applications for the NIA Research Leadership Career Award (K07). The award is intended to provide support for more senior investigators who have the expertise and leadership skills to enhance the aging and geriatric research capacity within their academic institution. This FOA will use the NIH K07 Academic/Teacher Award (ATA) mechanism.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Chhanda Dutta, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-4161</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:duttac@mail.nih.gov">duttac@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute on Aging (NIA) invites applications employing secondary analysis of existing data sets or stored biospecimens, to address clinically related issues on aging changes influencing health across the lifespan, and/or on diseases and disabilities in older persons. Use of cohorts that are linked to electronic health record systems and/or Centers for Medicare and Medicaid Services (CMS) administrative data are especially welcome. This FOA will support activities addressing specific hypotheses in clinical aging research and/or to inform the design and implementation of future epidemiologic or human intervention studies, or current geriatric practice in maintenance of health, management of disease, and prevention of disability. Existing data sets may also be used to develop and test new statistical analytical approaches. Costs for archiving of data to be made publicly available and those associated with data harmonization or assay refinement/validation may be included in the budget, as long as these activities are pertinent to the proposed secondary analyses. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>083966</th>
<th>NIA Program Project Applications (P01 Clinical Trial Optional)</th>
<th>National Institute on Aging/NIH/DHHS</th>
<th>PAR-19-314</th>
<th>25-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>059149</td>
<td>Secondary Analyses of Existing Cohorts, Data Sets and Stored Biospecimens to Address Clinical Aging Research Questions (R01)</td>
<td>National Institute on Aging/NIH/DHHS</td>
<td>PA-17-088</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>
Contact Name: Robin A. Barr, D.Phil
Contact Telephone: 301-496-9322
Contact Email: BarrR@mail.nih.gov
Sponsor Website: 
Program URL: Link to program URL

Synopsis:
The National Institute on Aging (NIA) invites the submission of investigator-initiated program project (P01) applications addressing scientific areas relevant to the NIA mission. Each application submitted to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective and an administrative core to lead the project. Revision applications should include expansion of an existing, or proposal of a new, project or projects within a program project. Revision applications may not request support beyond the end date of the parent P01 award.

075498 Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

Contact Name: Lorenzo M. Refolo, Ph.D.
Contact Telephone: 301-594-7576
Contact Email: refolol@nia.nih.gov
Sponsor Website: 
Program URL: Link to program URL

Synopsis:
National Institute on Aging's (NIA) invites applications for pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Agency</th>
<th>Program #</th>
<th>Deadline</th>
<th>Contact Info</th>
<th>Synopsis</th>
</tr>
</thead>
</table>
| 085643 | Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) | National Institute on Aging/NIH/DHHS | PAR-19-374 | 25-Apr-2020 [Optional][LOI/Pre-App] | Not Specified | Contact Name: Sanoj Suneja, PhD  
Contact Telephone: 301-402-7710  
Contact Email: sunejas@mail.nih.gov  
Sponsor Website:  
Program URL: Link to program URL  
Synopsis: National Institute on Aging (NIA) invites applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions. This FOA will use the NIH U19 Research Program – Cooperative Agreements award mechanism. |
| 08649 | Aging Research Dissertation Awards to Increase Diversity (R36 Clinical Trial Not Allowed) | National Institute on Aging/NIH/DHHS | PAR-19-394 | 07-May-2020 | Not Specified | Contact Name: Shahrooz Vahedi, Ph.D.  
Contact Telephone: 301-496-9322  
Contact Email: shahrooz.vahedi@nih.gov  
Sponsor Website:  
Program URL: Link to program URL  
Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to provide dissertation awards in all areas of research within NIA’s strategic priorities to increase the diversity of the scientific research workforce engaged in research on aging and aging-related health conditions. |
<p>| 057968 | Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01) | National Institute on Aging/NIH/DHHS | PAR-17-033 | 07-May-2020 | 3,750,000 USD |</p>
<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Suzana Petanceska, Ph.D.</th>
<th>Contact Telephone</th>
<th>301-496-9350</th>
<th>Contact Email</th>
<th><a href="mailto:petanceskas@mail.nih.gov">petanceskas@mail.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute on Aging (NIA) invites applications that apply a cross-disciplinary, team science approach to gain comprehensive, mechanistic understanding of the impact of sex differences on the trajectories of brain aging and phenotypes of AD risk and on the responsiveness to pharmacologic and non-pharmacologic interventions. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 057967 Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer's Disease (R01) | National Institute on Aging/NIH/DHHS | PAR-17-032 | 07-May-2020 | 2,500,000 USD |

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Suzana Petanceska, Ph.D.</th>
<th>Contact Telephone</th>
<th>301-496-9350</th>
<th>Contact Email</th>
<th><a href="mailto:petanceskas@mail.nih.gov">petanceskas@mail.nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute on Aging (NIA) invites applications that integrate the use of computational approaches to identify individual drugs currently used for other conditions with potential to be efficacious in AD or AD-related dementias (as single drugs or as drug combinations) with proof-of-concept efficacy studies in cell-based models, animal models and/or humans. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 086966 RFA-AG-21-007 -- Leadership Award for Alzheimer's Disease and Related Dementias Research (R35 Clinical Trial Not Allowed) | National Institute on Aging/NIH/DHHS | RFA-AG-21-007 [Optional][LOI/Pre-App] | 19-May-2020 | 3,000,000 USD |

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Cerise Elliott, Ph.D.</th>
<th>Contact Telephone</th>
<th>301-496-9350</th>
<th>Contact Email</th>
<th><a href="mailto:elliottce@nih.gov">elliottce@nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td>Deadline Dates (ALL)</td>
<td>[Optional][LOI/Pre-App]</td>
</tr>
<tr>
<td>Synopsis</td>
<td></td>
<td>National Institute on Aging (NIA) invites applications that integrate the use of computational approaches to identify individual drugs currently used for other conditions with potential to be efficacious in AD or AD-related dementias (as single drugs or as drug combinations) with proof-of-concept efficacy studies in cell-based models, animal models and/or humans. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>---------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>19-May-2020 [Optional][LOI/Pre-App], 19-Jun-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>NIA invites applications for the Leadership Award for Alzheimer's Disease and Related Dementias Research (R35). Applicants will be supported to develop and implement innovative multidisciplinary research and mentoring programs through an interchange of ideas that enable individuals and their institutions to strengthen existing programs and the development of new research programs that are specific to the goals/milestones of the NIH Alzheimer's Disease and Alzheimer's Disease Related Dementias Summits.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RFA-AG-21-001 -- NIA Research Centers Collaborative Network (RCCN) (U24 Clinical Trial Optional)</th>
<th>National Institute on Aging/NIH/DHHS</th>
<th>RFA-AG-21-001</th>
<th>15-Apr-2020 [Optional][LOI/Pre-App]</th>
<th>3,375,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Basil Eldadah, M.D., Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-6761</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:eldadahb@nia.nih.gov">eldadahb@nia.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>15-Apr-2020 [Optional][LOI/Pre-App], 15-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of this FOA is to support a network to enhance collaborations across NIA's 6 centers programs. These collaborations are intended to leverage NIA's substantial investments by fostering and sustaining the development of novel interdisciplinary efforts in aging research. This opportunity will provide resources to build additional infrastructure and establish specific collaborative activities that could include, but are not limited to, information and data exchange, meetings and conferences, pilot studies, research opportunities for early investigators, visiting scholar programs, dissemination, and other collaborative efforts. The successful awardee will involve all 6 centers programs.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)</th>
<th>National Institute on Aging/NIH/DHHS</th>
<th>PAR-18-189</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Basil A. Eldadah, MD, PhD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-6761</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:eldadahb@nia.nih.gov">eldadahb@nia.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020 , 05-Jun-2020 , 07-Sep-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOA Number</td>
<td>Program Title</td>
<td>Institute</td>
<td>Application Type</td>
<td>Sponsor Website</td>
</tr>
<tr>
<td>------------</td>
<td>---------------</td>
<td>-----------</td>
<td>------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>069782</td>
<td>Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)</td>
<td>National Institute on Aging/NIH/DHHS</td>
<td>PAR-18-190</td>
<td>07-May-2020</td>
</tr>
<tr>
<td>087731</td>
<td>RFA-AG-21-002 -- Mechanisms of Rejuvenation and Age-Acceleration in Heterochronic Blood Exchange (R01 Clinical Trial Not Allowed)</td>
<td>National Institute on Aging/NIH/DHHS</td>
<td>RFA-AG-21-002</td>
<td>17-May-2020</td>
</tr>
</tbody>
</table>
**Deadline Dates (ALL)**

17-May-2020 [Optional][LOI/Pre-App], 17-Jun-2020

**Synopsis**

This FOA will support research on aspects of rejuvenation and accelerated aging observed specifically in heterochronic blood exchange (HBE) experiments. The objectives are to identify the multiple factors involved, the multiple cell types involved, and the mechanisms underlying rejuvenation or accelerated aging that is observed in the transfer of phenotypes between young and old laboratory animals. It is also anticipated that molecular signatures of rejuvenation or accelerated aging will be obtained from research supported under this FOA.

<table>
<thead>
<tr>
<th>RFA-AG-21-010 -- Glial Plasticity in the Aging Brain (R01 Clinical Trial Not Allowed)</th>
<th>National Institute on Aging/NIH/DHHS</th>
<th>RFA-AG-21-010</th>
<th>17-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Amanda M. DiBattista, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-9350</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:amanda.dibattista@nih.gov">amanda.dibattista@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td>Link to program URL</td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>17-May-2020 [Optional][LOI/Pre-App], 17-Jun-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>Recent reports highlight the enormous spatial and temporal diversity of glia, even within the same glial cell type. This within-glial-cell-type heterogeneity evolves during aging, suggesting that subtypes of glia with distinct physiological roles could emerge to influence brain aging processes. The goal of this Funding Opportunity Announcement is to support research addressing critical knowledge gaps in our understanding of how these glial subpopulations could contribute to vulnerability and resilience to brain aging.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent Clinical Trial Not Allowed)</th>
<th>National Institute on Aging/NIH/DHHS</th>
<th>PAR-20-095</th>
<th>25-May-2020</th>
<th>900,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Basil Eldadah, MD, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-6761</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:basil.eldadah@nih.gov">basil.eldadah@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td>Link to program URL</td>
<td></td>
</tr>
<tr>
<td>088437</td>
<td><strong>Harmonization of Alzheimer’s Disease and Related Dementias (AD/ADRD) Genetic, Epidemiologic, and Clinical Data to Enhance Therapeutic Target Discovery (U24 Clinical Trial Not Allowed)</strong></td>
<td>National Institute on Aging/NIH/DHHS</td>
<td>PAR-20-099</td>
<td>25-May-2020</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Name</strong></td>
<td>Marilyn Miller, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>301-496-9350</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>The National Institute on Aging (NIA) invites applications specific to infrastructure that will support, under a single cooperative agreement (U24), phenotypic data harmonization on subjects with Alzheimer’s Disease Sequencing Project (ADSP) genetic and genomic data. These data will become a long-lived “legacy” data set that will be perpetually curated. The FOA will fund a single vanguard network of researchers with expertise in genetics, epidemiology, and clinical specialties who will work with the ADSP and with study cohort leads on data harmonization efforts to optimize the ability to identify well-targeted therapeutic approaches for Alzheimer’s disease and related dementias (AD/ADRD).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>088523</td>
<td><strong>RFA-AG-21-012 -- Resource Networks for Protein Polymorphisms in Alzheimer’s Disease and its Related Dementias (AD/ADRD) (U24 Clinical Trial Not Allowed)</strong></td>
<td>National Institute on Aging/NIH/DHHS</td>
<td>RFA-AG-21-012</td>
<td>17-May-2020</td>
</tr>
<tr>
<td><strong>Contact Name</strong></td>
<td>Austin Yang, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>301-496-9350</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:austin.yang@nih.gov">austin.yang@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>17-May-2020 [Optional][LOI/Pre-App], 17-Jun-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This Funding Opportunity Announcement (FOA) invites U24 Cooperative Agreement applications aiming to establish several mis-folded protein polymorphisms resource networks in the area of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The central goal of these resource networks is to standardize and distribute seed, oligomers, and fibrils to other investigators in order to clarify and improve the reproducibility of experiments in AD/ADRD. For the past several years, many studies have developed assays and reagents to understand the biophysical properties of various tau and Aβ structural variants such as oligomers, protofibrils, and fibrils. As a result, many imaging, chemical, and immunological tools have been developed to detect different types of Aβ and tau polymorphs. Establishing standards, understanding the pathological roles of these protein polymorphs, and using newly developed analytic tools to address the direct correlation between patient-to-patient variations in Aβ and tau polymorphs are the long-term goals of the resource networks supported by this FOA.

### Synopsis

This FOA invites applications for a National Alzheimer's Coordinating Center (NACC) whose purpose is to serve NIA and the Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) field as 1) a national data resource, collecting data from the Alzheimer's Disease Research Centers (ADRCs), affiliated data, and sample repositories; 2) a facilitator of current and future AD/ADRD research; and 3) the central hub for organizing and enabling communication within and outside the ADRC program, including annual meetings and steering committees.

### Contact Information

**Contact Name:** Nina Silverberg  
**Contact Telephone:** 301-496-9350  
**Contact Email:** silverbergn@nih.gov  
**Sponsor Website:** Link to program URL  
**Program URL:**  
**Deadline Dates (ALL):** 17-May-2020 [Optional][LOI/Pre-App], 17-Jun-2020

### Contact Information

**Contact Name:** Robin A. Barr, D. Phil.  
**Contact Telephone:** 301-402-7715  
**Contact Email:** BarrR@mail.nih.gov  
**Sponsor Website:** Link to program URL  
**Program URL:**  
**Deadline Dates (ALL):** 07-May-2020 , 25-May-2020 , 07-Sep-2020
**Synopsis**
National Institute on Aging (NIA) invites applications for research education activities in the mission areas of the NIH. The over-arching goal of this NIA R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce in aging. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences and Curriculum or Methods Development. This FOA will utilize the NIH R25 Education Projects award mechanism.

<table>
<thead>
<tr>
<th>070491</th>
<th>Institutional Training Programs to Advance Translational Research on Alzheimer's Disease and AD Related Dementias (T32)</th>
<th>National Institute on Aging/NIH/DHHS</th>
<th>PAR-18-524</th>
<th>25-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Robin Barr, D.Phil.</td>
<td>Contact Telephone</td>
<td>301-496-9322</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:robin.barr@nih.gov">robin.barr@nih.gov</a></td>
<td>Contact Email</td>
<td><a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Synopsis**
National Institute on Aging (NIA) invites applications for institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e. basic biology, translational and clinical research, data science). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational and clinical research for AD and AD-related dementias. This FOA does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor. This FOA will use the NIH T32 Institutional National Research Service Award (NRSA) mechanism.

<table>
<thead>
<tr>
<th>088853</th>
<th>National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (U24 Clinical Trial Not Allowed)</th>
<th>National Institute on Aging/NIH/DHHS</th>
<th>PAR-20-110</th>
<th>25-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Marilyn M. Miller. Ph.D.</td>
<td>Contact Telephone</td>
<td>301-496-9350</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></td>
<td>Contact Email</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This Funding Opportunity Announcement (FOA) invites applications specific to infrastructure that will support the storage, analysis, and sharing of primary and secondary data for the genetics and genomics of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).

National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications that propose to conduct the secondary analysis of existing data sets with the goal of enhancing our understanding of patterns of alcohol consumption, the epidemiology and etiology, including genetics, of alcohol-related problems. Research grants for the Secondary Analyses of Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest. This FOA will use the NIH R03 Small Grant Program award mechanism.

National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications that propose to conduct the secondary analysis of existing data sets with the goal of enhancing our understanding of patterns of alcohol consumption, the epidemiology and etiology, including genetics, of alcohol-related problems. Research grants for the Secondary Analyses of Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest. This FOA will use the NIH R03 Small Grant Program award mechanism.
Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>063269</th>
<th>Alcohol-Induced Effects on Tissue Injury and Repair (R21)</th>
<th>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</th>
<th>PA-17-296</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Bill Dunty, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-443-7351</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 16-Jun-2020, 07-Sep-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Excessive alcohol consumption has the potential to adversely affect multiple organ systems including the liver, brain, heart, pancreas, lung, kidney, endocrine and immune systems, as well as bone and skeletal muscle. In addition, there is accumulating evidence that long term alcohol consumption is associated with reduced host capacity for recovery and repair following trauma. The mechanisms for these alcohol-induced effects on tissue injury and repair are currently not fully understood. NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. This FOA also encourages the study of alcohol’s effect on stem cells, embryonic development, and regeneration. Also encourages are studies on molecular and cellular actions of moderate alcohol consumption. A better understanding of these underlying mechanisms may provide new avenues for developing more effective and novel approaches for prognosis, diagnosis, intervention, and treatment of alcohol-induced organ damage. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>069680</th>
<th>Epidemiology and Prevention in Alcohol Research (R01 - Clinical Trial Optional)</th>
<th>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</th>
<th>PA-18-390</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Marcia Scott, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-402-6328</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:mscott@mail.nih.gov">mscott@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

225
<table>
<thead>
<tr>
<th>Program URL</th>
<th>Link to program URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders. This program will use the NIH Research Project (R01) award mechanism.

| 069708 Epidemiology and Prevention in Alcohol Research (R21 - Clinical Trial Optional) | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS PA-18-391 | 07-May-2020 | 275,000 USD |
| Contact Name | Marcia Scott, Ph.D. |
| Contact Telephone | 301-402-6328 |
| Contact Email | mscott@mail.nih.gov |
| Sponsor Website |  |
| Program URL | Link to program URL |
| Deadline Dates (ALL) | 07-May-2020 |

**Synopsis**

National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

| 070392 Effects of In Utero Alcohol Exposure on Adult Health and Disease (R21 Clinical Trial Optional) | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS PA-18-508 | 07-May-2020 | 275,000 USD |
| Contact Name | Bill Dunty, Ph.D. |
| Contact Telephone | 301-443-7351 |
| Contact Email | duntyw@mail.nih.gov |
| Sponsor Website |  |
| Program URL | Link to program URL |

**Synopsis**

National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for novel research on how prenatal alcohol exposure may contribute to the etiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease (DOHaD) concept which suggests that fetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to: 1) leverage existing prospective birth cohorts to define the role of maternal alcohol
consumption in the DOHaD process; 2) investigate the biological, cellular, and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life; and 3) identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring. Studies supported by this FOA will provide fundamental insights into a possible fetal-basis to adult disease that is influenced by maternal alcohol use. This FOA will use the NIH R21 Research Project Grant award mechanism.

<table>
<thead>
<tr>
<th>069709</th>
<th>Epidemiology and Prevention in Alcohol Research (R03 Clinical Trial Optional)</th>
<th>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</th>
<th>PA-18-413</th>
<th>07-May-2020</th>
<th>100,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Marcia Scott, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-402-6328</td>
<td>Contact Email</td>
<td><a href="mailto:mscott@mail.nih.gov">mscott@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders. This program will use the NIH R03 Small Grant Program award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>070391</th>
<th>Effects of In Utero Alcohol Exposure on Adult Health and Disease (R01 Clinical Trial Optional)</th>
<th>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</th>
<th>PA-18-507</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Bill Dunty, Ph.D.</td>
<td>Contact Telephone</td>
<td>301-443-7351</td>
<td>Contact Email</td>
<td><a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for novel research on how prenatal alcohol exposure may contribute to the etiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease (DOHaD) concept which suggests that fetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to: 1) leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process; 2) investigate the biological, cellular, and molecular mechanisms by which prenatal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
alcohol exposure may impact disease outcomes later in life; and 3) identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring. Studies supported by this FOA will provide fundamental insights into a possible fetal-basis to adult disease that is influenced by maternal alcohol use. This FOA will use the NIH Research Project (R01) award mechanism.

**068482 Increasing the Use of Medications for the Treatment of Alcohol Use Disorders (R01 Clinical Trial Optional)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Lori Ducharme, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-451-8507</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Lori.Ducharme@nih.gov">Lori.Ducharme@nih.gov</a></td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for health services research designed to increase the public health impact of Food and Drug Administration (FDA)-approved pharmacotherapies for the treatment of alcohol use disorder. Significant progress is needed in developing generalizable, scalable, cost-effective strategies to move these evidence-based interventions into the mainstream of alcohol use disorder treatment, in both general medical and specialty care settings. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to conduct hypothesis-driven research to identify effective methods for increasing the utilization of currently-available medications, by addressing their acceptability (to prescribers and patients), perceived effectiveness, affordability, and feasibility of use within existing care delivery systems. This FOA will use the NIH Research Project (R01) award mechanism.

**069234 Leveraging Electronic Health Records for Alcohol Services Research (R21/R33 Clinical Trial Optional)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Lori Ducharme, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-451-8507</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Lori.Ducharme@nih.gov">Lori.Ducharme@nih.gov</a></td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for health services research designed to increase the public health impact of Food and Drug Administration (FDA)-approved pharmacotherapies for the treatment of alcohol use disorder. Significant progress is needed in developing generalizable, scalable, cost-effective strategies to move these evidence-based interventions into the mainstream of alcohol use disorder treatment, in both general medical and specialty care settings. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to conduct hypothesis-driven research to identify effective methods for increasing the utilization of currently-available medications, by addressing their acceptability (to prescribers and patients), perceived effectiveness, affordability, and feasibility of use within existing care delivery systems. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>068482</td>
<td>Increasing the Use of Medications for the Treatment of Alcohol Use Disorders (R01 Clinical Trial Optional)</td>
<td>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</td>
<td>PAR-18-196</td>
<td>07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>069234</td>
<td>Leveraging Electronic Health Records for Alcohol Services Research (R21/R33 Clinical Trial Optional)</td>
<td>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</td>
<td>PAR-18-203</td>
<td>07-May-2020</td>
<td>1,025,000 USD</td>
</tr>
</tbody>
</table>
### Genetics of Alcohol Sensitivity and Tolerance (R01 Clinical Trial Not Allowed)

**National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS**

PA-18-660 07-May-2020 Not Specified

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Hemin R. Chin, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-1282</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:chinh@mail.nih.gov">chinh@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for novel genetic mechanisms underlying the development of tolerance and the progression to alcohol use disorder. Alcohol use disorders is complex, multifactorial, and influenced both by genetic and environmental factors. The purpose of this FOA is to stimulate and support efforts on identifying genetic, genomic and epigenetic factors contributing to the development of sensitivity and tolerance to alcohol. This FOA will use the NIH Research Project (R01) award mechanism.</td>
</tr>
</tbody>
</table>

### Alcohol Research Resource Awards (R24)

**National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS**

PAR-17-170 07-May-2020 Not Specified

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Gary J Murray, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-9940</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:gary.murray@nih.gov">gary.murray@nih.gov</a></td>
</tr>
</tbody>
</table>
### Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (R01 Clinical Trial Optional)

**National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS**  
*PA-18-619*  
07-May-2020  
Not Specified

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Brett T. Hagman</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-0638</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:brett.hagman@nih.gov">brett.hagman@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**  
National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications that seek to examine processes of recovery and relapse in the treatment of Alcohol Use Disorders. Applications high in innovation and significance are highly encouraged that address the following potential topics: 1) defining recovery; 2) Examining new and innovative methods to examine precipitants of relapse; 3) Understanding mechanisms of mutual help and recovery; 4) Evaluating recovery systems of care; and 5) Examining processes of extended treatment for AUD. This FOA will use the NIH Research Project (R01) award mechanism.

### Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Not Allowed)

**National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS**  
*PAR-18-659*  
07-May-2020  
Not Specified

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Elizabeth M Powell, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>Elizabeth M Powell, PhD</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:elizabeth.powell3@nih.gov">elizabeth.powell3@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**  
National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to support investigator-initiated research projects that will maintain and expand the availability of resources to serve biomedical research within NIAAA’s priority areas as described in the strategic plan. This FOA will use the National Institutes of Health (NIH) R24 Resource-Related Research Projects award mechanism.
Synopsis

National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications on sensitivity and tolerance mechanisms underlying the development of alcohol use disorders. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol dependence. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. This FOA will use the NIH R21/R33 Phased Innovation Award mechanism.

083915  Mechanisms of Tolerance (R21/R33 - Clinical Trial Required)  National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  PAR-19-311  07-May-2020  1,775,000 USD

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Elizabeth M Powell, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-0786</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:elizabeth.powell3@nih.gov">elizabeth.powell3@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial required, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. Applicants interested in animal studies on the mechanisms of tolerance may consider FOA (PAR-18-659) or in the genetic basis of tolerance may consider FOA (PA-18-660).</td>
</tr>
</tbody>
</table>

059893  Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R21)  National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  PA-17-132  07-May-2020  275,000 USD

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Gregory Bloss, M.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-3865</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Gregory.Bloss@nih.gov">Gregory.Bloss@nih.gov</a></td>
</tr>
</tbody>
</table>

Contact Name
Contact Telephone
Contact Email
National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, marijuana, and other substances. The purpose of the FOA is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This FOA is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported by this FOA include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, marijuana-, and other substance-related behaviors and outcomes; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, marijuana-, and other substance-related behaviors and outcomes. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.
marijuana-, and other substance-related behaviors and outcomes. This FOA will use the NIH R01 Research Project Grant award mechanism.

### 060834 Mechanisms of Alcohol-associated Cancers (R01)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Bill Dunty, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-7351</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020, 05-Jun-2020, 07-Sep-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Cancer Institute (NCI) invite applications for research investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption. This FOA will use the NIH Research Project (R01) award mechanism.</td>
</tr>
</tbody>
</table>

### 059895 Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R03)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Gregory Bloss, M.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-3865</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Gregory.Bloss@nih.gov">Gregory.Bloss@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, marijuana, and other substances. The purpose of the FOA is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This FOA is intended to</td>
</tr>
</tbody>
</table>
support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported by this FOA include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, marijuana-, and other substance-related behaviors and outcomes; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, marijuana-, and other substance-related behaviors and outcomes. This FOA will use the NIH Small Research Grant (R03) award mechanism.

<table>
<thead>
<tr>
<th>Program URL</th>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Link to program URL</td>
<td>Rosalind Breslow, Ph.D., M.P.H., R.D.</td>
<td>301-594-6231</td>
<td><a href="mailto:rbreslow@mail.nih.gov">rbreslow@mail.nih.gov</a></td>
<td>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</td>
<td>07-May-2020</td>
<td>National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications that propose to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this program announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
</tr>
<tr>
<td>Link to program URL</td>
<td>Rosalind Breslow, Ph.D., M.P.H., R.D.</td>
<td>301-594-6231</td>
<td><a href="mailto:rbreslow@mail.nih.gov">rbreslow@mail.nih.gov</a></td>
<td>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</td>
<td>07-May-2020</td>
<td>National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications that propose to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this program announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
</tr>
</tbody>
</table>
An announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease. This program will use the NIH R03 Small Grant Program award mechanism.

**076324** Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R21 - Clinical Trial Optional)  
National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  
PA-18-862 07-May-2020 275,000 USD  
Contact Name: Robert Freeman, Ph.D.  
Contact Telephone: 301-443-8820  
Contact Email: rfreeman@mail.nih.gov  
Sponsor Website:  
Program URL: Link to program URL  
Synopsis: National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.

**060837** Mechanisms of Alcohol-associated Cancers (R21)  
National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  
PA-17-219 07-May-2020 275,000 USD  
Contact Name: Bill Dunty, Ph.D.  
Contact Telephone: 301-443-7351  
Contact Email: duntyw@mail.nih.gov  
Sponsor Website:  
Program URL: Link to program URL  
Synopsis: National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Cancer Institute (NCI) invite applications for research investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the
molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

<table>
<thead>
<tr>
<th>FOA ID</th>
<th>FOA Title</th>
<th>Sponsor</th>
<th>PA Number</th>
<th>Application Due Date</th>
<th>Award Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>076327</td>
<td>Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional)</td>
<td>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</td>
<td>PA-18-861</td>
<td>07-May-2020</td>
<td>100,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name: Robert Freeman, Ph.D.</td>
<td>Contact Telephone: 301-443-8820</td>
<td>Contact Email: <a href="mailto:rfreeman@mail.nih.gov">rfreeman@mail.nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website: Link to program URL</td>
<td>Program URL: Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL): 07-May-2020, 16-Jun-2020, 07-Sep-2020, 16-Oct-2020, 07-Jan-2021, 16-Feb-2021, 07-May-2021, 16-Jun-2021, 07-Sep-2021</td>
<td>Synopsis: National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R03 Small Grant Program award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 076319   | Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R01 - Clinical Trial Optional) | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS | PA-18-863 | 07-May-2020          | Not Specified |
|          | Contact Name: Robert Freeman, Ph.D.                                       | Contact Telephone: 301-443-8820                                        | Contact Email: rfreeman@mail.nih.gov |
|          | Sponsor Website: Link to program URL                                      | Program URL: Link to program URL                                       |           |
|          | Deadline Dates (ALL): 07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021, 05-Feb-2021, 07-May-2021, 05-Jun-2021, 07-Sep-2021 | Synopsis: National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to |
contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>080374</th>
<th><strong>Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)</strong></th>
<th>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</th>
<th>PAR-19-207</th>
<th>07-May-2020</th>
<th>1,000,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Lori Ducharme, PhD</td>
<td>Contact Telephone</td>
<td>301-451-8507</td>
<td>Contact Email</td>
<td><a href="mailto:ducharmel@mail.nih.gov">ducharmel@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this IC Name R25 program is to support educational activities that complement and/or foster a better understanding of biomedical, behavioral and clinical research and its implications. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Outreach. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIAAA/NIDA R25 program is to support educational activities that foster a better understanding of biomedical, behavioral, and clinical research on alcohol and other substance use disorders and their implications. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Outreach. Specifically, this FOA will support projects designed to engage practicing health care professionals in education about current and emerging knowledge derived from scientific research on the neurobiology, epidemiology, prevention, and/or treatment of alcohol and other substance use disorders and related health conditions.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>060718</th>
<th><strong>Nutrition and Alcohol-Related Health Outcomes (R01)</strong></th>
<th>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</th>
<th>PA-17-211</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Rosalind Breslow, Ph.D., M.P.H., R.D.</td>
<td>Contact Telephone</td>
<td>301-594-6231</td>
<td>Contact Email</td>
<td><a href="mailto:rbreslow@mail.nih.gov">rbreslow@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>07-May-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

237
### Synopsis

National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications that propose to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this program announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease. This program will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>Project ID</th>
<th>Title</th>
<th>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</th>
<th>PA</th>
<th>Deadline Dates (ALL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>063268</td>
<td>Alcohol-Induced Effects on Tissue Injury and Repair (R01)</td>
<td></td>
<td></td>
<td>07-May-2020, 05-Jun-2020, 07-Sep-2020</td>
</tr>
</tbody>
</table>

**Contact**
- **Name**: Bill Dunty, Ph.D.
- **Telephone**: 301-443-7351
- **Email**: duntyw@mail.nih.gov

### Synopsis

National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Excessive alcohol consumption has the potential to adversely affect multiple organ systems including the liver, brain, heart, pancreas, lung, kidney, endocrine and immune systems, as well as bone and skeletal muscle. In addition, there is accumulating evidence that long term alcohol consumption is associated with reduced host capacity for recovery and repair following trauma. The mechanisms for these alcohol-induced effects on tissue injury and repair are currently not fully understood. NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. This FOA also encourages the study of alcohol’s effect on stem cells, embryonic development, and regeneration. Also encourages are studies on molecular and cellular actions of moderate alcohol consumption. A better understanding of these underlying mechanisms may provide new avenues for developing more effective and novel approaches for prognosis, diagnosis, intervention, and treatment of alcohol-induced organ damage. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>Project ID</th>
<th>Title</th>
<th>National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS</th>
<th>PAR</th>
<th>Deadline Dates (ALL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>080217</td>
<td>Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)</td>
<td></td>
<td>PAR-19-197</td>
<td>17-Mar-2020</td>
</tr>
</tbody>
</table>

**Contact**
- **Name**: L Lynn Morin
- **Telephone**: 301-402-0176
- **Email**: Lynn.Morin@nih.gov

Sponsor Website
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

**Synopsis**

National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists. This award is designed to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K01 Research Scientist Development Award - Research & Training award mechanism.

**Contact**

Alberto L. Rivera-Rentas, Ph.D.
301-496-1804
riverara@nidcd.nih.gov
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Synopsis</td>
<td>National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for the NIDCD Research Career Enhancement Award for Established Investigators (K18) program to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K18 Career Enhancement Award mechanism.</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Alberto L. Rivera-Rentas, Ph.D.</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-1804</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td><a href="#">Link to program URL</a></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists. This award is designed to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD’s mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will use the NIH K01 Research Scientist Development Award - Research &amp; Training award mechanism.</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Trinh T. Ly, M.D.</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-5061</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for the NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required) program. This FOA supports research projects that involve clinical trials in communication disorders and are focused on developing, evaluating, or refining the efficacy and safety of interventions for communication disorders across the lifespan. This program is designed for investigators who are interested in conducting clinical trials that address key questions in the field of communication disorders. The FOA will support studies that involve the use of new or existing interventions in the treatment of communication disorders, or the evaluation of existing interventions in new populations or settings. The FOA will use the NIH R01 Research Project Grant - Research &amp; Training award mechanism.</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Trinh T. Ly, M.D.</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-5061</td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for the NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required) program. This FOA supports research projects that involve clinical trials in communication disorders and are focused on developing, evaluating, or refining the efficacy and safety of interventions for communication disorders across the lifespan. This program is designed for investigators who are interested in conducting clinical trials that address key questions in the field of communication disorders. The FOA will support studies that involve the use of new or existing interventions in the treatment of communication disorders, or the evaluation of existing interventions in new populations or settings. The FOA will use the NIH R01 Research Project Grant - Research &amp; Training award mechanism.</td>
</tr>
<tr>
<td>Contact Name</td>
<td>Trinh T. Ly, M.D.</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-5061</td>
</tr>
</tbody>
</table>
### Synopsis
National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>FOA ID</th>
<th>FOA Title</th>
<th>Agency</th>
<th>PAR Number</th>
<th>Deadline</th>
<th>Contact Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>070868</td>
<td>NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)</td>
<td>National Institute on Deafness &amp; Other Communication Disorders/NIH/DHHS</td>
<td>PAR-18-564</td>
<td>07-May-2020</td>
<td>Alberto L. Rivera-Rentas, Ph.D.</td>
</tr>
<tr>
<td>072862</td>
<td>NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) (Clinical Trials Not Allowed)</td>
<td>National Institute on Deafness &amp; Other Communication Disorders/NIH/DHHS</td>
<td>PAR-18-700</td>
<td>08-Apr-2020</td>
<td>Alberto L. Rivera-Rentas, Ph.D.</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-496-1804</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>08-Apr-2020 , 07-May-2020 , 08-Aug-2020 , 07-Sep-2020 , 08-Dec-2020 , 07-Jan-2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Synopsis**

National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Research Dissertation Fellowship for Au.D. Audiologists. The intent of the program is to support a comprehensive, rigorous biomedical research training, and dissertation research leading to a research doctorate (i.e., Ph.D.) in the biomedical, behavioral, or clinical sciences. This FOA will use the NIH F32 Postdoctoral Individual National Research Service Award mechanism.

| 079239 NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required) | National Institute on Deafness & Other Communication Disorders/NIH/DHHS | PAR-19-142 | 07-May-2020 | 315,000 USD |

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Alberto L. Rivera-Rentas, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-1804</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:riverara@mail.nih.gov">riverara@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**

The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Independent Clinical Trial Required' (PAR-18-435). Applicants not planning an independent clinical trial, or proposing to gain research in a clinical trial led by another investigator must apply to the companion 'Independent Clinical Trial Not Allowed' (PAR-18-436) FOA.
### NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Alberto L. Rivera-Rentas, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-1804</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:riverara@mail.nih.gov">riverara@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**

The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate FOA: PAR-18-562 ‘Independent Clinical Trial Required.’ Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to companion FOA PAR-18-564 ‘Independent Clinical Trial Not Allowed’ FOA.

### Advancing Research in Augmentative and Alternative Communication (AAC) (R21 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Lana Shekim, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-5061</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:shekiml@nidcd.nih.gov">shekiml@nidcd.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Program URL**

[Link to program URL](#)
### Advancing Research in Augmentative and Alternative Communication (AAC) (R01 Clinical Trial Optional)

**Contact Name:** Lana Shekim, Ph.D.  
**Contact Telephone:** 301-496-5061  
**Contact Email:** shekiml@nidcd.nih.gov  
**Sponsor Website:** [Link to program URL](https://www.nih.gov)  
**Synopsis:** This funding opportunity announcement (FOA) seeks Research Project Grants (R01) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R01s only and encourages a range of research inclusive of basic, clinical, and translational.

### Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03 Clinical Trial Optional)

**Contact Name:** Cora Lee Wetherington, Ph.D.  
**Contact Telephone:** 301-435-1319  
**Contact Email:** cwetheri@mail.nih.gov  
**Sponsor Website:** [Link to program URL](https://www.nih.gov)  
**Synopsis:** This funding opportunity announcement (FOA) seeks Research Project Grants (R03) applications on Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R03s only and encourages a range of research inclusive of basic, clinical, and translational.
National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH R03 Small Grant Program award mechanism.

### Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 - Clinical Trial Optional)

<table>
<thead>
<tr>
<th>National Institute on Drug Abuse/NIH/DHHS</th>
<th>PAR-18-509</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
</table>
| Contact Name: Rao Rapaka, PhD  
Contact Telephone: 301-435-1304  
Contact Email: rrapaka@nida.nih.gov  
Sponsor Website:  
Program URL: Link to program URL  
Deadline Dates (ALL): 07-May-2020  |  |  |  |

Synopsis: National Institute on Drug Abuse (NIDA) invites applications for research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

### Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R03 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>National Institute on Drug Abuse/NIH/DHHS</th>
<th>PA-18-080</th>
<th>07-May-2020</th>
<th>100,000 USD</th>
</tr>
</thead>
</table>
| Contact Name: Shelley Su, Ph.D.  
Contact Telephone: 301-402-3869  
Contact Email: shelley.su@nih.gov  
Sponsor Website:  
Program URL: Link to program URL  
Deadline Dates (ALL): 07-May-2020  |  |  |  |

Synopsis: National Institute on Drug Abuse (NIDA) and National Institute on Aging (NIA) invite applications for research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science,
clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations. This FOA will use the NIH R03 Small Grant Program award mechanism.

068413  **Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R01 Clinical Trial Optional)**

**National Institute on Drug Abuse/NIH/DHHS**

PA-18-061  07-May-2020  Not Specified

- **Contact Name**: Shelley Su, Ph.D.
- **Contact Telephone**: 301-402-3869
- **Contact Email**: shelley.su@nih.gov
- **Synopsis**: National Institute on Drug Abuse (NIDA) and National Institute on Aging (NIA) invite applications for research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations. This FOA will use the NIH Research Project (R01) award mechanism.

070444  **Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 Clinical Trial Optional)**

**National Institute on Drug Abuse/NIH/DHHS**

PAR-18-510  07-May-2020  Not Specified

- **Contact Name**: Rao Rapaka, PhD
- **Contact Telephone**: 301-435-1304
- **Contact Email**: rrapaka@nida.nih.gov
- **Synopsis**: National Institute on Drug Abuse (NIDA) and National Institute on Aging (NIA) invite applications for research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations. This FOA will use the NIH Research Project (R01) award mechanism.
### Synopsis

National Institute on Drug Abuse (NIDA) invites applications for research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment. This FOA will use the NIH Research Project (R01) award mechanism.

<table>
<thead>
<tr>
<th>FOA Number</th>
<th>FOA Title</th>
<th>Sponsor</th>
<th>PA/Grant Year</th>
<th>Application Due Date</th>
<th>Award Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>068414</td>
<td>Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R21 Clinical Trial Optional)</td>
<td>National Institute on Drug Abuse/NIH/DHHS</td>
<td>PA-18-079</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
</tbody>
</table>

- **Contact Name:** Shelley Su, Ph.D.
- **Contact Telephone:** 301-402-3869
- **Contact Email:** shelley.su@nih.gov
- **Program URL:** Link to program URL

<table>
<thead>
<tr>
<th>FOA Number</th>
<th>FOA Title</th>
<th>Sponsor</th>
<th>PAR/Grant Year</th>
<th>Application Due Date</th>
<th>Award Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>070450</td>
<td>Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional)</td>
<td>National Institute on Drug Abuse/NIH/DHHS</td>
<td>PAR-18-527</td>
<td>07-May-2020</td>
<td>100,000 USD</td>
</tr>
</tbody>
</table>

- **Contact Name:** Rao Rapaka, PhD
- **Contact Telephone:** 301-435-1304
- **Contact Email:** rrapaka@nida.nih.gov
- **Program URL:** Link to program URL

### Synopsis

National Institute on Drug Abuse (NIDA) and National Institute on Aging (NIA) invite applications for research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.
National Institute on Drug Abuse (NIDA) invites applications for research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment. This FOA will use the NIH R03 Small Grant Program award mechanism.

<table>
<thead>
<tr>
<th>083682</th>
<th>Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)</th>
<th>National Institute on Drug Abuse/NIH/DHHS</th>
<th>PAR-19-310</th>
<th>07-May-2020</th>
<th>75,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Holly Moore, Ph.D.</td>
<td><strong>Contact Telephone</strong></td>
<td>301-827-7376</td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:holly.moore@nih.gov">holly.moore@nih.gov</a></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>This Funding Opportunity from the National Institute on Drug Abuse (NIDA) will use a NIH Small Research Grant (R03) award mechanism to support studies that apply affective, cognitive and behavioral science approaches to research questions relevant to substance use disorders (SUD). With this R03 mechanism, NIDA aims to seed innovative affective, cognitive and behavioral hypotheses, models, and methods in preclinical and clinical SUD research. The B/START R03 is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time. Studies supported by B/START are expected to produce a coherent set of preliminary findings that would inform the design of a more complete study and serve as preliminary data supporting feasibility or scientific rationale in an R01, R21 or similar application.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>071884</th>
<th>NIDA Small Research Grant Program (R03 Clinical Trial Required)</th>
<th>National Institute on Drug Abuse/NIH/DHHS</th>
<th>PA-18-634</th>
<th>07-May-2020</th>
<th>100,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td>Guifang Lao, Ph.D.</td>
<td><strong>Contact Telephone</strong></td>
<td>301-827-5931</td>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:laog@nida.nih.gov">laog@nida.nih.gov</a></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td><strong>Program URL</strong></td>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>07-May-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>This Funding Opportunity from the National Institute on Drug Abuse (NIDA) will use a NIH Small Research Grant (R03) award mechanism to support studies that apply affective, cognitive and behavioral science approaches to research questions relevant to substance use disorders (SUD). With this R03 mechanism, NIDA aims to seed innovative affective, cognitive and behavioral hypotheses, models, and methods in preclinical and clinical SUD research. The B/START R03 is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time. Studies supported by B/START are expected to produce a coherent set of preliminary findings that would inform the design of a more complete study and serve as preliminary data supporting feasibility or scientific rationale in an R01, R21 or similar application.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>060134</td>
<td><strong>Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21)</strong></td>
<td>National Institute on Drug Abuse/NIH/DHHS</td>
<td>PA-17-157</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>National Institute on Drug Abuse (NIDA) invites applications for basic functional genetic and genomic research in two areas: 1) functional validation to determine which candidate genes/variants/epigenetic/non-coding RNA features have an authentic role in SUDs, and 2) detailed elucidation of the molecular pathways and processes modulated by candidate genes/variants, particularly for those genes with an unanticipated role in SUDs. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Name</strong></td>
<td>John Satterlee, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>301-435-1020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:satterleej@nida.nih.gov">satterleej@nida.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>07-May-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>071788</th>
<th><strong>Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional)</strong></th>
<th>National Institute on Drug Abuse/NIH/DHHS</th>
<th>PAS-18-625</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synopsis</strong></td>
<td>National Institute on Drug Abuse (NIDA) invites applications for innovative research to characterize the consequences of psychosocial stress on affective/cognitive functioning and/or pain processing as it relates to opioid use disorder (OUD). This FOA encourages research that elucidates mechanisms of action and determinants of vulnerability and/or resilience by</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Name</strong></td>
<td>Vani Pariyadath, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>301-443-3209</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:vani.pariyadath@nih.gov">vani.pariyadath@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>07-May-2020, 16-Jun-2020, 07-Sep-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
which psychosocial stress influence OUD trajectories. Research using basic or clinical approaches is appropriate. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

<table>
<thead>
<tr>
<th>071556</th>
<th><strong>Women &amp; Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01 Clinical Trial Optional)</strong></th>
<th>National Institute on Drug Abuse/NIH/DHHS</th>
<th>PA-18-603 07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synopsis</strong></td>
<td>National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH Research Project (R01) award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Name</strong></td>
<td>Cora Lee Wetherington, Ph.D.</td>
<td>301-435-1319</td>
<td><a href="mailto:cwetheri@mail.nih.gov">cwetheri@mail.nih.gov</a></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>071560</th>
<th><strong>Women &amp; Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21 Clinical Trial Optional)</strong></th>
<th>National Institute on Drug Abuse/NIH/DHHS</th>
<th>PA-18-602 07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synopsis</strong></td>
<td>National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Name</strong></td>
<td>Cora Lee Wetherington, Ph.D.</td>
<td>301-435-1319</td>
<td><a href="mailto:cwetheri@mail.nih.gov">cwetheri@mail.nih.gov</a></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>077319</th>
<th><strong>AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)</strong></th>
<th>National Institute on Drug Abuse/NIH/DHHS</th>
<th>PA-18-916 07-May-2020</th>
<th>200,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synopsis</strong></td>
<td>National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Deadline Dates (ALL)</td>
<td>Synopsis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Link to program URL</td>
<td>07-May-2020 , 07-Sep-2020 , 07-Jan-2021 , 07-May-2021 , 07-Sep-2021</td>
<td>National Institute on Drug Abuse (NIDA) provides support to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug misuse and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating drug misuse and/or use disorder and HIV/AIDS across all areas of research supported by NIDA. This program will use the NIH Small Research Grant (R03) award mechanism.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Link to program URL</td>
<td>07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021</td>
<td>National Institute on Drug Abuse (NIDA) invites applications for formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. For the purposes of this FOA, &quot;intervention&quot; may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected. This FOA will use the NIH R34 Planning Grant award mechanism.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Link to program URL</td>
<td>07-May-2020</td>
<td>National Institute on Drug Abuse (NIDA) provides support to facilitate the entry of newly independent investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug misuse and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating drug misuse and/or use disorder and HIV/AIDS across all areas of research supported by NIDA. This program will use the NIH Small Research Grant (R03) award mechanism.</td>
</tr>
</tbody>
</table>
### International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Steven Gust, Ph.D., Director</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-6480</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:ipdirector@nida.nih.gov">ipdirector@nida.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. This FOA will use the NIH Research Project (R01) award mechanism.

### Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Steven Grant, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-4877</td>
</tr>
</tbody>
</table>

**Synopsis**
National Institute on Drug Abuse (NIDA) solicits collaborative research applications on drug abuse and addiction that: Take advantage of unusual opportunities that exist outside the United States to access talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery; Describe how the research will significantly advance U.S. health sciences; Demonstrate specific relevance to the NIDA mission and objectives. To determine whether your research plan is relevant to the NIDA mission and objectives, review the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). Where feasible, applications should address NIDA’s international scientific priority areas (https://www.drugabuse.gov/international/research-priorities); and Include an investigator from a U.S. institution and a non-U.S. citizen partner living and working in another country. This FOA will use the NIH Research Project (R01) award mechanism.
National Institute on Drug Abuse (NIDA) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources. This program will use the NIH Small Research Grant (R03) award mechanism.

**Synopsis**

National Institute on Drug Abuse (NIDA) invites applications for basic functional genetic and genomic research in two areas: 1) functional validation to determine which candidate genes/variants/epigenetic/non-coding RNA features have an authentic role in SUDs, and 2) detailed elucidation of the molecular pathways and processes modulated by candidate genes/variants, particularly for those genes with an unanticipated role in SUDs. This FOA will use the NIH Research Project (R01) award mechanism.

**Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)**

National Institute on Drug Abuse/NIH/DHHS

**PA-18-774 07-May-2020 450,000 USD**

Contact Name | Sarah Q. Duffy, Ph.D.
Contact Telephone | 301-451-4998
Contact Email | duffys@nida.nih.gov
Sponsor Website | Link to program URL
Program URL | Link to program URL
Deadline Dates (ALL) | 07-May-2020
Synopsis | National Institute on Drug Abuse (NIDA) invites applications for basic functional genetic and genomic research in two areas: 1) functional validation to determine which candidate genes/variants/epigenetic/non-coding RNA features have an authentic role in SUDs, and 2) detailed elucidation of the molecular pathways and processes modulated by candidate genes/variants, particularly for those genes with an unanticipated role in SUDs. This FOA will use the NIH Research Project (R01) award mechanism.
### Program URL

[Link to program URL](#)

### Deadline Dates (ALL)


### Synopsis

National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities. This FOA will use the NIH R34 Planning Grant grant mechanism.

#### 074451 Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional)

<table>
<thead>
<tr>
<th>National Institute on Drug Abuse/NIH/DHHS</th>
<th>PA-18-775</th>
<th>07-May-2020</th>
<th>450,000 USD</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Jacqueline Lloyd, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-8892</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:lloydj2@nida.nih.gov">lloydj2@nida.nih.gov</a></td>
</tr>
</tbody>
</table>

### Program URL

[Link to program URL](#)

### Deadline Dates (ALL)


### Synopsis

National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to misuse or problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving, prevent suicide attempts (nonfatal and fatal), and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and, (b) pre-trial feasibility and acceptability testing for prevention services and systems research. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols. Any intervention development work must be imbedded within a pilot/feasibility study. Of particular interest is prevention research that addresses current public health priorities and priority settings and systems. This FOA will utilize the NIH Planning Grant (R34) award mechanism.

#### 084606 Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)

<table>
<thead>
<tr>
<th>National Institute on Drug Abuse/NIH/DHHS</th>
<th>PAR-19-327</th>
<th>01-May-2020</th>
<th>15,000,000 USD</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Jacqueline Lloyd, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-8892</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:lloydj2@nida.nih.gov">lloydj2@nida.nih.gov</a></td>
</tr>
</tbody>
</table>

### Program URL

[Link to program URL](#)
<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Ivan D. Montoya, M.D., M.P.H.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-827-5936</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:imontoya@mail.nih.gov">imontoya@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>01-May-2020, 01-Sep-2020, 01-Jan-2021, 01-May-2021, 01-Sep-2021, 01-Jan-2022, 01-May-2022, 01-Sep-2022</td>
</tr>
</tbody>
</table>

**Synopsis**
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.

<table>
<thead>
<tr>
<th>079379</th>
<th>Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)</th>
<th>National Institute on Drug Abuse/NIH/DHHS</th>
<th>PAR-19-162</th>
<th>07-May-2020</th>
<th>1,250,000 USD</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Karen Sirocco</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-451-8661</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:siroccok@nida.nih.gov">siroccok@nida.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**
The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).

| 084960 | NIDA Program Project Grant Applications (P01 Clinical Trial Optional) | National Institute on Drug Abuse/NIH/DHHS | PAR-19-345 | 07-May-2020 | Not Specified |
Contact Name: Kevin Walton, Ph.D.
Contact Telephone: 301-827-5980
Contact Email: waltonkm@nida.nih.gov
Sponsor Website: Link to program URL

Synopsis:
This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA.

085474 Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)
National Institute on Drug Abuse/NIH/DHHS
PAR-19-368
07-May-2020
2,499,995 USD

Contact Name: Marsha F. Lopez, Ph.D., M.H.S.
Contact Telephone: 301-443-6504
Contact Email: marsha.lopez@nih.gov
Sponsor Website: Link to program URL

Synopsis:
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV.
<table>
<thead>
<tr>
<th>FOA ID</th>
<th>FOA Title</th>
<th>Agency</th>
<th>PA/Date</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>057394</td>
<td>Drug Abuse Dissertation Research (R36)</td>
<td>National Institute on Drug Abuse/NIH/DHHS</td>
<td>PA-16-443 07-May-2020</td>
<td>100,000 USD</td>
</tr>
<tr>
<td>077346</td>
<td>HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)</td>
<td>National Institute on Drug Abuse/NIH/DHHS</td>
<td>PAS-18-915 07-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>071785</td>
<td>Mechanistic investigations of Psychosocial Stress Effects on Opioid Use Patterns (R01 Clinical Trial Optional)</td>
<td>National Institute on Drug Abuse/NIH/DHHS</td>
<td>PAS-18-624 07-May-2020</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>

### Drug Abuse Dissertation Research (R36)
- **Contact Name**: Will M. Aklin, Ph.D.
- **Contact Telephone**: 301-443-3207
- **Contact Email**: aklinwm@mail.nih.gov
- **Sponsor Website**: Link to program URL
- **Deadline Dates (ALL)**: 07-May-2020
- **Synopsis**: National Institute on Drug Abuse (NIDA) invites applications for support of drug abuse doctoral dissertation research. This FOA will utilize the NIH R36 Dissertation Award mechanism.

### HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)
- **Contact Name**: Richard A. Jenkins, Ph.D.
- **Contact Telephone**: 301-443-1923
- **Contact Email**: jenkinsri@mail.nih.gov
- **Sponsor Website**: Link to program URL
- **Deadline Dates (ALL)**: 07-May-2020, 07-Sep-2020, 07-Jan-2021, 07-May-2021, 07-Sep-2021
- **Synopsis**: National Institute on Drug Abuse (NIDA invites applications for high priority research relevant to drug misuse and HIV/AIDS. This FOA will use the NIH Research Project (R01) award mechanism.

### Mechanistic investigations of Psychosocial Stress Effects on Opioid Use Patterns (R01 Clinical Trial Optional)
- **Contact Name**: Vani Pariyadath, Ph.D.
- **Contact Telephone**: 301-443-3209
- **Contact Email**: vani.pariyadath@nih.gov
- **Sponsor Website**: Link to program URL
- **Deadline Dates (ALL)**: 07-May-2020, 05-Jun-2020, 07-Sep-2020
National Institute on Drug Abuse (NIDA) invites applications for innovative research to characterize the consequences of psychosocial stress on affective/cognitive functioning and/or pain processing as it relates to opioid use disorder (OUD). This FOA encourages research that elucidates mechanisms of action and determinants of vulnerability and/or resilience by which psychosocial stress influence OUD trajectories. Research using basic or clinical approaches is appropriate. This FOA will use the NIH Research Project (R01) award mechanism.

**Synopsis**

The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).

**079380 Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Karen Sirocco</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-451-8661</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:siroccok@nida.nih.gov">siroccok@nida.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**
The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).

**033794 NIH Generic Clone Program (non-ASSIST) (Temporarily Suspended)**

| Contact Name   |  |
|----------------|  |
| Contact Telephone |  |
| Contact Email   |  |
| Sponsor Website |  |
| Program URL     | Link to program URL |
| Deadline Dates (ALL) | 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 |

**Synopsis**
invites applications for This FOA will use the NIH award mechanism.
The BRAIN Initiative and the neuroscience field as a whole are generating massive and diverse research data across different modalities, spatiotemporal scales and species in efforts to advance our understanding of the brain. The data types are being produced through development and application of innovative technologies in high-throughput -omics profiling, optical microscopy, electron microscopy, electrophysiological recording, macroscale neuroimaging, neuromodulation, and others. The BRAIN Initiative has made significant investments in the development of an infrastructure to make data available to the research community in a useful way. This infrastructure includes data archives, data standards, and software for data integration, analysis and machine learning. This Funding Opportunity Announcement (FOA) encourages secondary analysis of the large amounts of existing data related to the BRAIN Initiative. The data do not need to be held in one of the funded BRAIN Initiative data archives, but the data must be held in a data archive that is readily accessible to the research community. Support will be provided for innovative analysis of relevant existing datasets using conventional or novel analytic methods, data science techniques, and machine learning approaches. Support may also be requested to prepare and submit existing data into any of the BRAIN Initiative data archives. Investigators should not underestimate the time and effort that may be necessary to curate or harmonize data. Analyzed data, models and analytical tools generated under this FOA are expected to be deposited into an appropriate data archive. Since the BRAIN Initiative data archives are mostly making the data available to the research community through cloud-based storage, depositing the analyzed data, models and tools are expected to enhance opportunities to create a data sandbox where investigators can easily compare the results of their analysis with those from other research groups. The goal of this FOA is to promote studies that will significantly advance new discoveries and accelerate the pace of research of the BRAIN Initiative through harnessing the big data and machine learning opportunities. Awardees are expected to enhance the value of existing data, improve the overall data integration and analysis capability, and strengthen the statistical power and rigor and reproducibility of BRAIN Initiative related data.
The NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K99/R00 Career Transition Award/Research Transition Award mechanism.

**Synopsis**

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set. This FOA will use the NIH Research Project (R01) award mechanism.
### Research on the Health of Transgender and Gender Nonconforming Populations (R21)

**Contact Name:** Della B. White, PhD  
**Contact Telephone:** 301-435-2712  
**Contact Email:** whitede@mail.nih.gov  

**Program URL:** Link to program URL  

**Synopsis:** National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.

### Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Clinical Trial Not Allowed)

**Contact Telephone:** 301-496-8580  
**Contact Email:** grantinfo@nih.gov  

**Program URL:** Link to program URL  
**Deadline Dates (ALL):** 07-May-2020, 07-Sep-2020, 12-Oct-2020, 07-Jan-2021

**Synopsis:** National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the Mentored Clinical Scientist Research Career Development Award. The award is designed to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This program will use the Mentored Clinical Scientist Research Career Development Award (K08).
### Human Subjects Mechanistic and Minimal Risk Studies (R01 Clinical Trial Optional)

**Contact Name:** Ellen Liberman, Ph.D.  
**Contact Telephone:** 301-451-2020  
**Contact Email:** ellen.liberman@nih.gov  
**Sponsor Website:** [Link to program URL](#)  
**Deadline Dates (ALL):** 07-May-2020, 05-Jun-2020, 07-Sep-2020, 05-Oct-2020, 07-Jan-2021

**Synopsis:** National Eye Institute (NEI) invites applications that seek to conduct studies of the visual system. This FOA will support applications that either involve human subjects, but are not NIH-defined clinical trials (see NOT-OD-15-015); or are NIH-defined clinical trials and are designed to address either: 1) mechanisms underlying human vision in health and disease; or 2) interventions that entail procedures with minimal risk to subjects. A mechanistic trial is defined as "A study designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. "Minimal risk" means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. NIH-defined clinical trial applications that are neither mechanistic nor minimal risk are not eligible for this FOA. Large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials are not appropriate for this FOA. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. This FOA will use the NIH Research Project (R01) award mechanism.

### RFA-HL-18-023 -- Stimulating Access to Research in Residency (StARR) (R38) (Defunct)

**Contact Name:** Neil Aggarwal, M.D.  
**Contact Telephone:** 301-827-7820  
**Contact Email:** neil.aggarwal@nih.gov  
**Sponsor Website:** [Link to program URL](#)  
**Deadline Dates (ALL):** 12-May-2020

**Synopsis:** The purpose of this program is to recruit and retain outstanding, postdoctoral-level health professionals who have demonstrated potential and interest in pursuing careers as clinician-investigators. To address the growing need for this critical component of the research workforce, this funding opportunity seeks applications from institutional programs that
can provide outstanding mentored research opportunities for Resident-Investigators and foster their ability to transition to individual career development research awards. The program will support institutions to provide support for up to 2 years of research conducted by Resident-Investigators in structured programs for clinician-investigators with defined program milestones.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>08-Apr-2020, 07-May-2020, 08-Aug-2020, 07-Sep-2020, 08-Dec-2020, 07-Jan-2021, 08-Apr-2021, 07-May-2021, 08-Aug-2021, 07-Sep-2021, 08-Dec-2021, 07-Jan-2022</td>
<td>The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>07-May-2020, 25-May-2020, 07-Sep-2020, 25-Sep-2020, 07-Jan-2021</td>
<td>NIH and its participating Institutes and Centers invite applications for Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grants from eligible, domestic institutions to develop and/or enhance research training opportunities for predoctoral students interested in careers in biomedical, behavioral, or clinical research.</td>
</tr>
</tbody>
</table>
Many NIH Institutes and Centers (ICs) use this NRSA program exclusively to support intensive, short-term research training experiences for health professional students (medical students, veterinary students, and/or students in other health-professional programs) during the summer. This program is also intended to encourage training of graduate students in the physical or quantitative sciences to pursue research careers by short-term exposure to, and involvement in, the health-related sciences. The training should be of sufficient depth to enable the trainees, upon completion of the program, to have a thorough exposure to the principles underlying the conduct of biomedical research. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor. This program will use the NIH T35 National Research Service Award (NRSA) Short-Term Research Training award mechanism.

The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training, including short-term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda. Programs proposing only short-term research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program (T35) exclusively reserved for predoctoral, short-term research training (see PA-18-404). This Funding Opportunity Announcement (FOA) does not allow appointed trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.
Synopsis

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

078745  
Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)  
National Institutes of Health/DHHS  
PA-19-085  07-May-2020  
Not Specified

Contact Name  
Contact Telephone  
Contact Email  
oer@od.nih.gov  
Sponsor Website  
Link to program URL  
Program URL  
Sign up for email updates

Deadline Dates (ALL)  

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed'
The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

<table>
<thead>
<tr>
<th>079179</th>
<th>Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)</th>
<th>National Institutes of Health/DHHS</th>
<th>PA-19-132</th>
<th>07-May-2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td><a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td>240-627-3566</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td></td>
<td><a href="mailto:tglewis@niaid.nih.gov">tglewis@niaid.nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td></td>
<td>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and &quot;protected time&quot; for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-131).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>078543</th>
<th>Processing and Presentation of Non-Conventional MHC Ligands (R01 Clinical Trial Not Allowed)</th>
<th>National Institutes of Health/DHHS</th>
<th>PA-19-067</th>
<th>07-May-2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td>Timothy A. Gondré-Lewis, Ph.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td>240-627-3566</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td></td>
<td><a href="mailto:tglewis@niaid.nih.gov">tglewis@niaid.nih.gov</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This Funding Opportunity Announcement (FOA) invites applications to characterize antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands presented by classical and non-classical MHC class I and class II molecules, and to determine the contribution of these unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or in the induction/progression or prevention of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.

**Synopsis**

The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-121).

**Synopsis**

The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-121).
The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-132).

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-125).
The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-124).

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Link to program URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Email</td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
</tr>
</tbody>
</table>

**Synopsis**

The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
<table>
<thead>
<tr>
<th>Contact Telephone</th>
<th><a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-122).</td>
</tr>
</tbody>
</table>

| 078546 Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed) | National Institutes of Health/DHHS | PA-19-066 | 07-May-2020 | 275,000 USD |
| Contact Name | Timothy A. Gondré-Lewis, Ph.D. |
| Contact Telephone | 240-627-3566 |
| Contact Email | tglewis@niaid.nih.gov |
| Sponsor Website | Link to program URL |
| Synopsis | This Funding Opportunity Announcement (FOA) invites applications to determine antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and to determine the contribution of these unique antigenic ligands to protective immune responses against infectious disease pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or limit progression or induction of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines. |

| 086663 Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional) | National Institutes of Health/DHHS | PAR-20-036 | 07-May-2020 | Not Specified |
| Contact Name | Robin E. Huebner, Ph.D., M.P.H. |
## Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology, novel tools from data science approaches and m/eHealth, and implementation science research. Data generated through this research will be used to inform and evaluate context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.

### Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>07-May-2020, 07-Sep-2020, 07-Jan-2021, 07-May-2021, 07-Sep-2021, 07-Jan-2022, 07-May-2022, 07-Sep-2022</td>
<td>The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology, novel tools from data science approaches and m/eHealth, and implementation science research. Data generated through this research will be used to inform and evaluate context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.</td>
</tr>
</tbody>
</table>

### Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>08-Apr-2020, 07-May-2020, 07-Aug-2020, 07-Sep-2020, 08-Dec-2020, 07-Jan-2021, 08-Apr-2021, 07-May-2021, 08-Aug-2021, 07-Sep-2021, 08-Dec-2021, 07-Jan-2022</td>
<td>The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce. Through this award program, promising predoctoral students will obtain individualized, mentored research training from outstanding faculty sponsors while conducting well-defined research projects in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</td>
</tr>
</tbody>
</table>
### Synopsis

The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

### Deadline Dates (ALL)

- 08-Apr-2020
- 07-May-2020
- 08-Aug-2020
- 07-Sep-2020
- 08-Dec-2020
- 07-Jan-2021
- 08-Apr-2021
- 07-May-2021
- 08-Aug-2021
- 07-Sep-2021
- 08-Dec-2021
- 07-Jan-2022

### Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)

The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the applicant's dissertation research project and is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></td>
<td></td>
<td>Link to program URL</td>
<td>08-Apr-2020, 07-May-2020, 08-Aug-2020, 07-Sep-2020, 08-Dec-2020, 07-Jan-2021, 08-Apr-2021, 07-May-2021, 08-Aug-2021, 07-Sep-2021, 08-Dec-2021, 07-Jan-2022</td>
</tr>
</tbody>
</table>

**Synopsis**

This Funding Opportunity Announcement (FOA) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g., DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Applicants must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
This Funding Opportunity Announcement (FOA) will support students at institutions with NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g., DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Applicants must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th><a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-127).
The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-126).
workforce diversity. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

**079113**  
**Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)**  
National Institutes of Health/DHHS  
PA-19-118  07-May-2020  
Not Specified

- **Contact Name:**  
- **Contact Telephone:**  
- **Contact Email:** grantinfo@nih.gov  
- **Sponsor Website:**  
- **Program URL:** Link to program URL  

**Synopsis:**  
The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-119).

**079101**  
**Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)**  
National Institutes of Health/DHHS  
PA-19-116  07-May-2020  
Not Specified

- **Contact Name:**  
- **Contact Telephone:** 301-496-8580  
- **Contact Email:** grantinfo@nih.gov  
- **Sponsor Website:**  
- **Program URL:** Link to program URL  

**Synopsis:**  
The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to...
individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-117).

The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Contact Name
Contact Telephone
Contact Email
Sponsor Website
Program URL
Link to program URL

Synopsis
The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-118).

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Award (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-116).
The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-130).
<table>
<thead>
<tr>
<th>SPIN ID</th>
<th>Program Title</th>
<th>Sponsor Name</th>
<th>Sponsor Number</th>
<th>Deadline Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>086667</td>
<td>Support of Competitive Research (SCORE) Pilot Project Award (SC2 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health/DHHS</td>
<td>PAR-20-040</td>
<td>07-May-2020</td>
<td>300,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Irina N. Krasnova, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:irina.krasnova@nih.gov">irina.krasnova@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>086664</td>
<td>Support of Competitive Research (SCORE) Research Advancement Award (SC1 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health/DHHS</td>
<td>PAR-20-039</td>
<td>07-May-2020</td>
<td>1,000,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Irina N. Krasnova, Ph.D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:irina.krasnova@nih.gov">irina.krasnova@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### RFA-NS-20-006 -- BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)

**National Institutes of Health/DHHS**  
RFA-NS-20-006  
24-Mar-2020  
Not Specified

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Sahana N. Kukke, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-496-1447</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:BRAIN-FOAs@nih.gov">BRAIN-FOAs@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**  
A central goal of the BRAIN Initiative is to develop new and improved technologies suitable for recording from as well as controlling specified cell types and circuits to modulate and understand function in the central nervous system. In order to accomplish these goals, further information is needed to understand the function of current technologies used for recording or stimulating the nervous system. This RFA accepts grant applications in two related but distinct areas. The first is to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation technologies. The second is to understand the biological and bioinformatic content of signals recorded from neuronal and non-neuronal cells and circuits. Development of new technologies, therapies and disease models is outside the scope of this FOA. Activities related to enabling the simultaneous use of multiple recording or stimulation technologies are allowed.

### Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)

**National Institutes of Health/DHHS**  
PAR-20-082  
07-May-2020  
275,000 USD

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>David M. Panchision, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-443-5288</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
</tbody>
</table>

**Synopsis**  
This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system...
architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-20-NNN).

**Synopsis**

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities.Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. This FOA is intended to provide support for the further development of projects where preliminary data supports the feasibility of the line of investigation. Applicants without preliminary data may wish to apply to the companion R21 FOA (PAR-20-082).

### Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)

**Contact Name**
David M. Panchision, Ph.D.

**Contact Telephone**
301-443-5288

**Contact Email**
panchisiond@mail.nih.gov

**Sponsor Website**

**Program URL**
[Link to program URL](#)

**Deadline Dates (ALL)**

### Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)

**Contact Name**
Adam Felsenfeld, Ph.D.

**Contact Telephone**
301-480-2269

**Contact Email**
adam_felsenfeld@nih.gov

**Sponsor Website**

**Program URL**
[Link to program URL](#)

**Deadline Dates (ALL)**

**Synopsis**

The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research. Each CEGS award supports a multi-investigator, interdisciplinary team to develop transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science, genomic...
medicine, or computational genomics, proposing a highly innovative solution that would be a major advance. The research will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff. A CEGS will focus on the development of novel technological or computational methods for the production or analysis of comprehensive data sets, on a genome-scale biomedical problem, or on other ways to develop and use genomic approaches for understanding biological systems or furthering the application of genomic knowledge, data, and methods towards clinical applications. Each CEGS will nurture genomics at its institution by facilitating the interaction of investigators from several disciplines. By training new and experienced investigators it will expand the pool of genomics scientists and engineers.

<table>
<thead>
<tr>
<th>NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)</th>
<th>National Institutes of Health/DHHS</th>
<th>PA-18-648</th>
<th>12-Apr-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers. This FOA will utilize the NIH R13 Support for Conferences and Scientific Meetings award mechanisms.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genomic Community Resources (U24 Clinical Trial Not Allowed)</th>
<th>National Institutes of Health/DHHS</th>
<th>PAR-20-100</th>
<th>25-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Christopher Wellington</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-480-3496</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:wellingtonc@mail.nih.gov">wellingtonc@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>To facilitate genomic research and the dissemination of its products, NHGRI supports genomic resources that are crucial for basic research, disease studies, model organism studies, and other biomedical research. Awards under this FOA will support the development and distribution of genomic resources that use cost-effective approaches and will be valuable for the</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
broad research community. Such resources include (but are not limited to) databases and informatics resources (such as human and model organism databases, ontologies, and analysis toolsets), comprehensive identification and collections of genomic features (such as functional genomic elements), and standard data types produced using central sets of samples (such as structural variants in 1000 Genomes or GTEx samples).

<table>
<thead>
<tr>
<th>088091</th>
<th>Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)</th>
<th>National Institutes of Health/DHHS</th>
<th>PAR-20-038</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Enrique Michelotti, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-443-5415</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion FOA PAR-20-037.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>088090</th>
<th>Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)</th>
<th>National Institutes of Health/DHHS</th>
<th>PAR-20-037</th>
<th>07-May-2020</th>
<th>825,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Enrique Michelotti, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-443-5415</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion FOA PAR-20-037.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to FOA PAR-20-038.

<table>
<thead>
<tr>
<th>078396</th>
<th>NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)</th>
<th>National Institutes of Health/DHHS</th>
<th>PA-19-054</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>078391</th>
<th>NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)</th>
<th>National Institutes of Health/DHHS</th>
<th>PA-19-053</th>
<th>07-May-2020</th>
<th>275,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

<table>
<thead>
<tr>
<th>FOA ID</th>
<th>FOA Title</th>
<th>Sponsor</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>RFA-OD-20-010</td>
<td>Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required)</td>
<td>National Institutes of Health/DHHS</td>
<td>09-May-2020, 08-Jul-2020, 10-Dec-2020, 08-Feb-2021, 09-Aug-2021, 08-Oct-2021, 09-May-2022, 08-Jul-2022</td>
<td>The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-OD-20-009).</td>
</tr>
<tr>
<td>RFA-OD-20-009</td>
<td>Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed)</td>
<td>National Institutes of Health/DHHS</td>
<td>09-May-2020, 08-Jul-2020, 08-Feb-2021, 09-Aug-2021, 08-Oct-2021, 09-May-2022, 08-Jul-2022</td>
<td>The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-OD-20-009).</td>
</tr>
</tbody>
</table>
The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (RFA-OD-20-010).
The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (RFA-OD-20-011).

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial or proposing to gain research experience in a clinical trial led by another investigator, must apply to (RFA-OD-20-008).
The purpose of this FOA is to establish expert panels that will select genes and genomic variants associated with diseases or conditions of high priority to participating NIH Institutes and Centers (ICs) and systematically determine their clinical significance for diagnosis and treatment of these diseases or conditions. The Genomic Expert Curation Panels funded through this FOA are required to utilize the NHGRI Clinical Genomics Resource (ClinGen) and the NCBI ClinVar procedures, interfaces, tools and informatics infrastructure to determine the strength of evidence supporting the clinical significance of the selected genes and variants that will support development of clinical practice guidelines.

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
### Synopsis

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

<table>
<thead>
<tr>
<th>Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences (T32 Clinical Trial Not Allowed)</th>
<th>National Institutes of Health/DHHS</th>
<th>PAR-20-076</th>
<th>26-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Nick Gaiano, Ph. D.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>301-827-3420</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:nick.gaiano@nih.gov">nick.gaiano@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
methodology and quantitative reasoning. JSPTPN programs are intended to be 2 years in duration and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare students to be outstanding scientists equipped to pursue careers in neuroscience.

<table>
<thead>
<tr>
<th>078398</th>
<th>NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)</th>
<th>National Institutes of Health/DHHS</th>
<th>PA-19-056</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td>Contact Telephone</td>
<td>Contact Email</td>
<td><a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></td>
<td>Sponsor Website</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>078397</th>
<th>Research Project Grant (Parent R01 Clinical Trial Required)</th>
<th>National Institutes of Health/DHHS</th>
<th>PA-19-055</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td>Contact Telephone</td>
<td>Contact Email</td>
<td><a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></td>
<td>Sponsor Website</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>078383</td>
<td>NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)</td>
<td>National Institutes of Health/DHHS</td>
<td>PA-19-052</td>
<td>07-May-2020</td>
<td>100,000 USD</td>
</tr>
</tbody>
</table>

- **Contact Name**: 
- **Contact Telephone**: 
- **Contact Email**: grantsinfo@nih.gov 
- **Program URL**:
- **Synopsis**: The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

| 089281 | RFA-AG-21-013 -- Prodromal a-Synucleinopathies Consortium (PaSS) (U19 Clinical Trial Optional) | National Institutes of Health/DHHS | RFA-AG-21-013 | 17-May-2020 | 15,000,000 USD |

- **Contact Name**: Miroslaw (Mack) Mackiewicz, Ph.D. 
- **Contact Telephone**: 301-594-7636 
- **Contact Email**: miroslaw.mackiewicz@nih.gov 
- **Program URL**:
- **Deadline Dates (ALL)**: 17-May-2020 [Optional][LOI/Pre-App], 17-Jun-2020 
- **Synopsis**: This funding opportunity announcement (FOA) invites applications to develop a multisite, longitudinal, prospective study of idiopathic REM sleep behavior disorder (iRBD) as a prodromal phase of α-synuclein neurodegenerative disorders.

| 076848 | NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) | National Library of Medicine/NIH/DHHS | PAR-18-896 | 07-May-2020 | 1,000,000 USD |

- **Contact Name**: Dr. Hua-Chuan Sim 
- **Contact Telephone**: 301-594-4882 
- **Contact Email**: simh@mail.nih.gov 
- **Sponsor Website**: 
- **Program URL**:
- **Deadline Dates (ALL)**: 
- **Synopsis**: 

---
National Library of Medicine (NLM) offers support for innovative research and development in biomedical informatics and data science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and approaches to foster data-driven discovery in the biomedical and clinical health sciences as well as domain-independent, reusable approaches to discovery, curation, analysis, organization and management of health-related digital objects. Biomedical informatics and data science draw upon many fields, including mathematics, statistics, information science, computer science and engineering, and social/behavioral sciences. Application domains include health care delivery, basic biomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health information management in disasters, and similar areas. NLM defines biomedical informatics as the science of optimal representation, organization, management, integration and presentation of information relevant to human health and biology. NIH defines data science as the interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are developed and used to extract knowledge and insights from increasingly large and/or complex sets of data. This FOA will use the NIH Research Project (R01) award mechanism.

**Synopsis**

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider and/or healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with emphasis on appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specific research interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that either propose or do not propose a clinical trial(s). This FOA will use the NIH Research Project (R01) award mechanism.
### Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)

- **Contact Name:** Wendy Nilsen, PhD
- **Contact Telephone:** 240-276-6971
- **Contact Email:** nelsonw@mail.nih.gov
- **Sponsor Website Program URL:** Link to program URL
- **Deadline Dates (ALL):** 07-May-2020, 07-Sep-2020, 07-Jan-2021, 07-May-2021

**Synopsis:**
National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider and/or healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with emphasis on appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specific research interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that either propose or do not propose a clinical trial(s). This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

### Limited Competition: Specific Pathogen Free Macaque Colonies (U42 Clinical Trial Not Allowed)

- **Contact Name:** Sheri Hild, Ph.D.
- **Contact Telephone:** 301-594-8937
- **Contact Email:** sheri.hild@nih.gov
- **Sponsor Website Program URL:** Link to program URL
- **Deadline Dates (ALL):** 07-May-2020, 07-Sep-2020, 07-Jan-2021

**Synopsis:**
Office of Research Infrastructure Programs (ORIP) invites applications for continuing support for specific pathogen free (SPF) macaque colonies previously funded under the auspices of PAR-14-066. Breeding colonies are essential to sustain Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) research. Pedigree SPF macaques are free of certain viruses, which can confound the results of AIDS-related investigations or present a risk to the personnel who care for the animals. The SPF macaques are genetically characterized for major histocompatibility (MHC) class I types as defined MHC classes are critical in determining immune responses to HIV/AIDS infections. This FOA will utilize the NIH U42 Animal 

297
<table>
<thead>
<tr>
<th>FOA Number</th>
<th>Title</th>
<th>Agency</th>
<th>PAR</th>
<th>Deadline</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>079634</td>
<td>Methods Development for Cryogenic or Other Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R21 Clinical Trial Not Allowed)</td>
<td>Office of Research Infrastructure Programs/NIH/DHHS</td>
<td>PAR-19-176</td>
<td>07-May-2020</td>
<td>275,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name: Sige Zou, Ph.D. Contact Telephone: 301-435-0749 Contact Email: <a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis: This funding opportunity announcement (FOA) supports exploratory research projects aimed at developing cryogenic or other long-term preservation and revival approaches for Drosophila or zebrafish genetic stocks, which are essential laboratory animal models for biomedical research. The proposed project should address critical knowledge and technology gaps and describe approaches towards the development of reliable, easy-to-use and cost effective cryogenic or other long-term preservation and revival methods for wild-type and mutant strains of Drosophila or zebrafish.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>059951</td>
<td>Limited Competition: National Primate Research Centers (P51)</td>
<td>Office of Research Infrastructure Programs/NIH/DHHS</td>
<td>PAR-17-144</td>
<td>25-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td>Contact Name: Sheri Ann Hild, PhD Contact Telephone: 301-594-8937 Contact Email: <a href="mailto:hildsa@mail.nih.gov">hildsa@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website: <a href="#">Link to program URL</a> Deadline Dates (ALL): 25-May-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis: Office of Research Infrastructure Programs (ORIP) invites grant applications that support the activities of the National Primate Research Centers (NPRCs). Nonhuman primates (NHPs) are most closely related to humans, both physiologically and genetically. Therefore, NHPs are critical animal models for translational research aimed at understanding human biology, both in normal and diseased states. Proper husbandry and management of NHPs require specialized physical and intellectual resources, which are most effectively and economically provided in centralized primate centers, the resources of which are made available to investigators on a national basis. The NPRCs provide these resources to investigators/grantees who utilize</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
NHPs in biomedical research and thereby complement and help enable the missions of the NIH Institutes and Centers. This FOA will utilize the P51 Primate Research Center Grants award mechanism.

**Limited Competition: Small Grant Program for ORIP Special Emphasis Research Career Award (SERCA) K01 Recipients (R03)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Bruce Fuchs, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-402-5225</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:FuchsB@od.nih.gov">FuchsB@od.nih.gov</a></td>
</tr>
</tbody>
</table>

**Synopsis**

Office of Research Infrastructure Programs (ORIP) announces a program that provides ORIP-supported Special Emphasis Research Career Award (SERCA) K01 awardees who have completed the first two years (24 months) of their K01 award the opportunity to apply for Small Grant support. Through the use of this mechanism, ORIP is seeking to enhance the capability of ORIP SERCA K01 awardees to conduct research as they complete their transition to fully independent investigator status. The R03 mechanism supports different types of projects, including but not limited to pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology, and development of new research technology. The R03 is therefore intended to support research projects that can be achieved in a short period of time with limited resources and that provide preliminary data to support a subsequent R01 or equivalent application. This program will use the NIH Small Research Grant (R03) award mechanism.

**Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Sige Zou, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-435-0749</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:zou@nih.gov">zou@nih.gov</a></td>
</tr>
</tbody>
</table>

**Synopsis**

This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of...
Research Infrastructure Programs’ (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC will be considered not acceptable to this FOA.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Stephanie Murphy, VMD, PhD</td>
<td>301-451-7818</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:stephanie.murphy@nih.gov">stephanie.murphy@nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The Office of Research Infrastructure Programs (ORIP) encourages grant applications aimed at developing, characterizing or improving animal models of human diseases; improving access to information about or generated from the use of animal models of human disease; or improving diagnosis and control of diseases of laboratory animals. The animal models and related materials developed must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIP’s trans-NIH mission. Applications must describe the need and potential impact of the proposed resources on broad research areas supported by multiple NIH ICs. Projects that predominantly address the research interests of one NIH IC but are only peripherally related to the research interests of other Institutes and Centers will also not be acceptable for this FOA.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed)</th>
<th>Office of Research Infrastructure Programs/NIH/DHHS</th>
<th>RFA-OD-20-002</th>
<th>07-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Oleg Mirochnitchenko, Ph.D.</td>
<td>301-435-0748</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:oneillr@mail.nih.gov">oneillr@mail.nih.gov</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>This FOA encourages grant applications for national Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals, as well as other resources such as informatics tools, reagents, cultures</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The important mission of the projects described by this FOA is to provide research resources, which are facilitating the optimization and enhancement of scientific rigor, transparency and experimental reproducibility of biomedical research. Proposed Animal and Biological Material Resource Centers must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIP’s trans-NIH mission (https://orip.nih.gov/about-orip). This funding opportunity is designed to support both continuation of existing resources and to develop new ones when appropriate. Prior to preparing an application, all applicants are strongly encouraged to consult with Scientific/Research staff to be advised on appropriateness of the intended resource plans for this program, competitiveness of a potential application, and ORIP’s program priorities.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Sponsor</th>
<th>Code</th>
<th>Start Date</th>
<th>End Date</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>077743</td>
<td>Dear Colleague Letter: Non-Academic Research Internships for Graduate Students (INTERN) Supplemental Funding Opportunity</td>
<td>National Science Foundation</td>
<td>NSF 18-102</td>
<td>01-May-2020</td>
<td>55,000 USD</td>
<td></td>
</tr>
</tbody>
</table>

- **Contact Name**: Elizabeth Blood
- **Contact Telephone**:  
- **Contact Email**: eblood@nsf.gov
- **Sponsor Website**:  
- **Program URL**: [Link to program URL](#)
- **Deadline Dates (ALL)**: 01-May-2020
- **Synopsis**: A supplemental funding opportunity is available in fiscal years FY 2019 and FY 2020 to provide support for non-academic research internships for graduate students to support career opportunities in any sector of the U.S. economy. NSF currently invests in a number of graduate student preparedness activities and has historically encouraged principal investigators (PIs) to include such activities in research proposals to NSF. This Dear Colleague Letter (DCL) describes new funding opportunities at NSF to ensure graduate students are well prepared for the 21st-century STEM workforce.

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Sponsor</th>
<th>Code</th>
<th>Start Date</th>
<th>End Date</th>
<th>Budget</th>
</tr>
</thead>
</table>

- **Contact Name**:  
- **Contact Telephone**: 703-292-5111
- **Contact Email**:  
- **Sponsor Website**:  
- **Program URL**: [Link to program URL](#)
- **Deadline Dates (ALL)**: 01-May-2020
- **Synopsis**: The National Science Foundation (NSF) Strategic Plan "Building the Future: Investing in Discovery and Innovation" (2018 - 2022) states, "NSF must continue to invest in a world-class research enterprise, support the development of a globally competitive scientific and engineering workforce, and foster greater understanding of science and technology among the American public" and "NSF will promote a research culture that is broadly inclusive in its demography and range of intellectual ideas, has access to cutting-edge infrastructure, and is globally engaged, with increased opportunities for exchanging ideas and collaborating on an international scale. NSF will increase opportunities for broadening the training of U.S. graduate students and early-career researchers through international exchanges and partnerships with industry." NSF’s Division of Chemistry seeks to fulfill this vision by advancing research and education in chemistry and ensuring that the U.S. research community remains at the forefront of the field by providing access to the knowledge and resources that exist.
globally. In this context, the Division of Chemistry is inviting requests for supplemental funding from its existing awardees who may wish to add a new, or strengthen an existing, international dimension of their award when such collaboration advances the field of chemistry and enhances the U.S. investigator’s own research and/or education objectives. Principal Investigators supported by NSF Division of Chemistry awards are advised to consult with their cognizant NSF program director prior to submitting a supplemental funding request. Supplemental funding requests must be received by 5 p.m., submitter’s local time on May 1, 2020.
<table>
<thead>
<tr>
<th>FOA ID</th>
<th>FOA Title</th>
<th>Sponsor Agency</th>
<th>Application ID</th>
<th>Application Date</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>057652</td>
<td>Large Health Services Research Demonstration and Dissemination Projects for Prevention of Healthcare-Associated Infections (R18)</td>
<td>Agency for Healthcare Research and Quality/DHHS</td>
<td>PA-17-007</td>
<td>25-May-2020</td>
<td>2,500,000 USD</td>
</tr>
<tr>
<td>058998</td>
<td>Utilizing Health Information Technology to Scale and Spread Successful Practice Models Using Patient-reported Outcomes (R18)</td>
<td>Agency for Healthcare Research and Quality/DHHS</td>
<td>PA-17-077</td>
<td>25-May-2020</td>
<td>1,500,000 USD</td>
</tr>
<tr>
<td>057036</td>
<td>Large Health Services Research Demonstration and Dissemination Projects for Combating Antibiotic-Resistant Bacteria (CARB)(R18)</td>
<td>Agency for Healthcare Research and Quality/DHHS</td>
<td>PA-16-422</td>
<td>25-May-2020</td>
<td>2,500,000 USD</td>
</tr>
</tbody>
</table>
Agency for Healthcare Research and Quality (AHRQ) invites applications to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB). This FOA will use the R18 Research Demonstration and Dissemination Projects award mechanism.

**AHRQ Health Services Research Demonstration and Dissemination Grants (R18)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Kishena Wadhwani, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-427-1556</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Kishena.Wadhwani@ahrq.hhs.gov">Kishena.Wadhwani@ahrq.hhs.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>25-May-2020 , 25-Sep-2020 , 25-Jan-2021</td>
</tr>
<tr>
<td>Synopsis</td>
<td>Agency for Healthcare Research and Quality/DHHS</td>
</tr>
</tbody>
</table>

Agency for Healthcare Research and Quality (AHRQ) invites applications for discrete, specified health services research projects. The project will be performed by the named investigator and study team. The R18 research plan proposed by the applicant institution/organization must be related to the mission and priority research interests of AHRQ. This FOA will use the AHRQ R18 Research Demonstration and Disseminations Projects award mechanism.

**Medication Safety: Advancing the Development of Improvement Strategies and Tools (R18)**

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Deborah Perfetto, Pharm.D., M.S.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>301-427-1295</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Deborah.Perfetto@AHRQ.hhs.gov">Deborah.Perfetto@AHRQ.hhs.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
</tr>
</tbody>
</table>
Despite some progress and improvement, medication errors continue to occur at an alarming rate. The U.S. Food and Drug Administration receives more than 100,000 U.S. reports each year associated with a suspected medication error. Adverse drug events (ADEs) are estimated to account for more than 3.5 million physician office visits and 1 million emergency department visits each year. It is believed that preventable medication errors impact more than 7 million patients and cost almost $21 billion annually across all care settings. Medication errors and ADEs continue to adversely affect patients, providers, and the economy. This funding opportunity continues AHRQ’s support of medication safety investigator-initiated research projects. Medication safety research should not only address the prevention of harm, but also promote standardized and optimized practices and behaviors. AHRQ will focus on funding grants that have strong patient safety impact potential and address significant patient safety problems that result in patient harm or mortality, occur with high frequency, and entail a high cost burden. It is further emphasized that AHRQ is interested in funding grants that will create additional sustainable tools or resources for healthcare providers that can be widely disseminated to promote processes and behaviors that address medication safety events.

**Synopsis**

FDA announces the availability of fiscal year (FY) 2020 funds to support the collection of data on antimicrobial use in companion animals. The funded data collection efforts are intended to 1) provide needed information on antimicrobial use practices in companion animals (specifically, dogs and cats) and 2) provide important information on data collection methodologies to help optimize long-term strategies for collection and reporting of such data. The cooperative agreement will enable the collection of critical information to support the Center for Veterinary Medicine’s goal to foster antimicrobial stewardship in veterinary settings by monitoring antimicrobial use and management practices in companion animals. The data obtained will support efforts to assess potential associations between antimicrobial use practices and antimicrobial resistance.

**Contact Name**

Susan Bright, Veterinary Medical Officer

**Contact Telephone**

240-402-5777

**Contact Email**

patrick.mcdermott@fda.hhs.gov

**Sponsor Website**

[Link to program URL](#)

**Deadline Dates (ALL)**

01-Apr-2020 [Optional][LOI/Pre-App], 01-May-2020

**Synopsis**

ROSES 2020: Health and Air Quality Applied Sciences Team

**Contact Name**

John Haynes
The NASA Earth Science Division (ESD) Applied Sciences Program seeks proposals to form a Health and Air Quality Applied Sciences Team (HAQAST). This team will apply Earth observations to improve and develop decision-making activities and enable transition and adoption by public- and/or private-sector organization(s) for sustained use in decision making and services to end users in the areas of public health and air quality. This team will focus on specific applications and demonstrations required to advance the health and air quality management communities’ uses of Earth science observations and models in decision making. An emphasis of the team is on responsiveness to managerial and end user needs, as well as pursuit of multiple applications of varied durations. Awardees will receive baseline funding to be a team member; a separate amount, representing a significant portion of funds overall, will be allocated to team members for "tiger team" projects during the course of the HAQAST. Submissions to this solicitation shall not propose any "tiger team" activities.

Public Health Surveillance for the Prevention of Complications of Bleeding Disorders

Brandi Dupervil, Project Officer
404-498-6879
bdupervil@cdc.gov

The purpose of this NOFO is to build upon the work currently ongoing in the U.S. Hemophilia Treatment Center Network (USHTCN) under DD15-1507 to prevent and reduce the complications of bleeding disorders by supporting the collection, aggregation and use of data and specimens that are representative of the USHTCN for surveillance for inhibitors and other complications of bleeding disorders, including emerging issues. The recipient or recipients are required to collaborate with HTCs and are expected to build upon the structures, processes and instruments implemented under DD15-1507. The recipient or recipients are expected to implement these five strategies and their corresponding activities: 1) establish collaborations with HTCs; 2) data collection and transfer; 3) specimen collection and transfer; 4) data quality evaluation and improvement; and 5) disseminate information. The data will be used to increase awareness of inhibitors and other complications among stakeholders; monitor trends in complications; identify disparities...
among subpopulations of bleeding disorder patients; identify high risk populations for interventions; assess gaps in data collection; generate hypotheses for research; and, ultimately, prevent the complications of bleeding disorders.

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Eric Cahill, Project Off</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>404-498-0214</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:iib4@cdc.gov">iib4@cdc.gov</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>13-Mar-2020 [Optional][LOI/Pre-App], 07-May-2020</td>
</tr>
</tbody>
</table>

The Centers for Disease Control and Prevention announces availability of funds for notice of funding opportunity (NOFO), Outcomes and Developmental Data Assistance Center for EHDI (ODDACE) Programs. While using intervention and outcomes data can inform decisions and support positive outcomes among children who are deaf or hard of hearing (D/HH), states often lack the capacity to systemically gather this data. The purpose of this NOFO is to establish and support a new outcomes center to coordinate and assist participating states and strategic partners in determining how best to gather, analyze, and use specific intervention and developmental outcomes data. The NOFO involves five key strategies: 1) Surveillance for the identification, standardization, and collection of intervention and developmental outcomes data; 2) Collaboration to engage and align partners; 3) Capacity to strengthen the ability of participating states to gather standardized intervention and outcomes data; 4) Data analysis to analyze data across participating states to assess the provision of intervention services and developmental outcomes; and 5) Translate and disseminate data analysis and other key findings to inform decisions and practices. Expected project outcomes include: Strategic partners have accurate and standardized surveillance data on the outcomes of children who are D/HH. Increased understanding of factors impacting the outcomes of children who are D/HH at the state and national level.
<table>
<thead>
<tr>
<th>ID</th>
<th>Program Name</th>
<th>Sponsor/Description</th>
<th>Deadline Date</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>053725</td>
<td><strong>Agilent Early Career Professor Award</strong></td>
<td>Agilent Technologies</td>
<td>28-Feb-2020</td>
<td>100,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>408-345-8886</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:university_relations@agilent.com">university_relations@agilent.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td><a href="#">Link to sponsor website</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>28-Feb-2020, 29-May-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>The purpose of the Agilent Early Career Professor Award is to: -- Promote and encourage excellent research enabling measurements of importance to Agilent Technologies and the world -- Establish strong collaborative relationships between Agilent researchers and leading professors early in their career -- Build the prominence of Agilent as a sponsor of university research</td>
<td></td>
<td></td>
</tr>
<tr>
<td>004889</td>
<td><strong>Annual Open Grant Program</strong></td>
<td>Alternatives Research and Development Foundation</td>
<td>01-May-2020</td>
<td>40,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>215-887-8076</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:info@ardf-online.org">info@ardf-online.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td><a href="#">Link to sponsor website</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>01-May-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>ARDF’s Annual Open grant program was established to fund research projects that develop alternative methods to advance science and replace or reduce animal use. Proposals are welcome from any nonprofit educational or research institution worldwide, although there is a preference for U.S. applications in order to more quickly advance alternatives here. Proposals are considered in fields of research, testing, or education. The maximum grant is $40,000, with an average 21% funding rate from 2015 to 2019.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>055305</td>
<td><strong>Program to Accelerate Clinical Trials (PACT)</strong></td>
<td>Alzheimer’s Drug Discovery Foundation</td>
<td>10-Apr-2020</td>
<td>3,000,000 USD</td>
</tr>
<tr>
<td></td>
<td>Program Name</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>212-901-8019</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td><a href="mailto:grants@alzdiscovery.org">grants@alzdiscovery.org</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>10-Apr-2020 [LOI/Pre-App], 08-May-2020 , 10-Jul-2020 [LOI/Pre-App], 07-Aug-2020 , 09-Oct-2020 [LOI/Pre-App], 06-Nov-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>10-Apr-2020 [LOI/Pre-App], 08-May-2020 , 10-Jul-2020 [LOI/Pre-App], 07-Aug-2020 , 09-Oct-2020 [LOI/Pre-App], 06-Nov-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The true test for new Alzheimer's drugs is in human clinical trials. Numerous treatments for Alzheimer's disease have been shown to be safe and to have some positive effect when tested in animal models of Alzheimer's disease. However, many of these potentially successful treatments have not been brought to human trials because of the increased cost and risk at this stage of research. The goal of this Request for Proposals (RFP) is to increase the number of innovative treatments tested in humans for Alzheimer's disease, related dementias, and cognitive aging.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 055304 | **Drug Development Program** | Alzheimer's Drug Discovery Foundation | 10-Apr-2020 | 600,000 USD |

| Contact Name | Alessio Travaglia, PhD, Scientific Program Officer |
| Contact Telephone | 212-901-7998 |
| Contact Email | atravaglia@alzdiscovery.org |
| Sponsor Website | Link to sponsor website |
| Program URL | Link to program URL |
| Deadline Dates (ALL) | 10-Apr-2020 , 08-May-2020 , 10-Jul-2020 [LOI/Pre-App], 07-Aug-2020 , 09-Oct-2020 [LOI/Pre-App], 06-Nov-2020 |
| Synopsis | The focus of this request for proposals is to develop therapeutics for Alzheimer’s disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. The proposed studies should have a high probability of reaching IND-enabling studies within two years. |

| 059477 | **Neuromarkers and CSF Biomarker Development Program** | Alzheimer's Drug Discovery Foundation | 10-Apr-2020 | Not Specified |
Given the pathological heterogeneity of Alzheimer's disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology. This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to: Clearly demonstrate target engagement for novel therapeutics. The development of biomarkers that can serve as measures of target engagement for novel targets such as neuroinflammation features (e.g. microglial activity, cytokine production, astrocytic activity), synaptic damage, metabolic activity, mitochondrial dysfunction, vascular health and epigenetic changes, among others, are of particular interest. High priority will be given to projects developing biomarkers that can be used in combination with therapies currently in development and serve as companion biomarkers. Detect signs of disease earlier and monitor progression. We are seeking programs developing sensitive biomarkers that can detect disease earlier than currently available tests. This includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI) or MCI to Alzheimer's disease. We also seek prognostic markers that can predict rates of cognitive decline. More accurately diagnose and distinguish between dementia subtypes. Many types of dementias can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.
<table>
<thead>
<tr>
<th>ID</th>
<th>Program Name</th>
<th>Sponsor</th>
<th>Deadline</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>000570</td>
<td>Junior Investigator Research Grant Program</td>
<td>American Academy of Clinical</td>
<td>01-May-2020</td>
<td>30,000 USD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Toxicology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>045882</td>
<td>Outstanding Investigator Award for Breast Cancer</td>
<td>American Association for Cancer</td>
<td>31-May-2020</td>
<td>15,000 USD</td>
</tr>
<tr>
<td></td>
<td>Research</td>
<td>Research</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Synopsis:**

The AACT is offering a research grant program that supports clinical toxicology research and the development of new investigators’ research skills.

The AACR Outstanding Investigator Award for Breast Cancer Research recognizes an investigator of no more than 50 years of age whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer.

The ADRF seeks to support prevention drug discovery not covered by most research funders or their current RFPs.
<table>
<thead>
<tr>
<th>ID</th>
<th>Program Name</th>
<th>Sponsor Name</th>
<th>Deadline Dates</th>
<th>Award Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>090207</td>
<td><strong>Dale E. Wurster Research Award in Pharmaceutics</strong></td>
<td>American Association of Pharmaceutical Scientists</td>
<td>15-May-2020</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Contact Name</strong></td>
<td><strong>Contact</strong> 703-243-2800</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Contact Email</strong></td>
<td><strong><a href="mailto:awards@aaps.org">awards@aaps.org</a></strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sponsor Website</strong></td>
<td><strong>Link to sponsor website</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Program URL</strong></td>
<td><strong>Link to program URL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Deadline Dates (All)</strong></td>
<td>15-May-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Synopsis</strong></td>
<td>The Dale E. Wurster Research Award in Pharmaceutics recognizes individuals who have made significant research contributions to the pharmaceutical sciences in the specific field of pharmaceutics.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>053501</td>
<td><strong>Rho Chi - AFPE First-Year Graduate School Fellowship</strong></td>
<td>American Foundation for Pharmaceutical Education</td>
<td>01-May-2020</td>
<td>7,500 USD</td>
</tr>
<tr>
<td></td>
<td><strong>Contact Name</strong></td>
<td><strong>Contact Telephone 855-624-9526</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Contact Email</strong></td>
<td><strong><a href="mailto:rhochi@unc.edu">rhochi@unc.edu</a></strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sponsor Website</strong></td>
<td><strong>Link to sponsor website</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Program URL</strong></td>
<td><strong>Link to program URL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Deadline Dates (All)</strong></td>
<td>01-May-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Synopsis</strong></td>
<td>The sponsor provides an award for Rho Chi Honor Society members enrolled in studies leading to a professional degree in pharmacy, and graduate studies in pharmacy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>004764</td>
<td><strong>Phi Lambda Sigma - AFPE First Year Graduate Fellowship</strong></td>
<td>American Foundation for Pharmaceutical Education</td>
<td>15-May-2020</td>
<td>7,500 USD</td>
</tr>
<tr>
<td></td>
<td><strong>Contact Name</strong></td>
<td><strong>Contact Telephone 703-875-3095</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Contact Email</strong></td>
<td><strong><a href="mailto:exec_director@philambdasigma.org">exec_director@philambdasigma.org</a></strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>15-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The Phi Lambda Sigma - AFPE First Year Graduate School Fellowship is awarded to encourage outstanding Phi Lambda Sigma members to pursue the Ph.D. within a college or school of pharmacy graduate program. One fellowship of $7,500 will be awarded in 2020.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>049768</th>
<th>Investigator-Initiated Research Grant Program</th>
<th>American Institute for Cancer Research</th>
<th>15-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td>Contact Telephone 202-600-3004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:research@aicr.org">research@aicr.org</a></td>
<td>Program URL Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>15-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>AICR's Investigator-Initiated Research Grant Program welcomes proposals for research addressing the effects of diet, nutrition, body composition and physical activity on cancer risk and outcomes.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>005022</th>
<th>Investigator-Initiated Research Grants</th>
<th>American Institute for Cancer Research</th>
<th>15-May-2020</th>
<th>75,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td>Contact Telephone 703-237-0159</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:research@aicr.org">research@aicr.org</a></td>
<td>Program URL Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>15-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The Investigator-Initiated Research Grant Program welcomes proposals for research addressing the effects of diet,</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
nutrition, body composition and physical activity on cancer risk and outcomes. The CUP has identified significant gaps in our knowledge and understanding of the mechanisms that mediate the role of diet, nutrition, body composition and physical activity in cancer development and outcomes following a cancer diagnosis. The knowledge gaps directly inform the Investigator Initiated Research Grant Program so that the sponsor can prioritize issues of greatest scientific importance and with the highest potential for translation into effective strategies for cancer prevention and improved outcomes for people living with and beyond cancer.

<table>
<thead>
<tr>
<th>ID</th>
<th>Scholarship/Grant Title</th>
<th>Sponsor</th>
<th>Deadline Dates (ALL)</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>002145</td>
<td>Eight and Forty Lung and Respiratory Nursing Scholarship Fund</td>
<td>American Legion</td>
<td>15-May-2020</td>
<td>3,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td><a href="mailto:lasecretaire@8and40.org">lasecretaire@8and40.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>15-May-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>The Eight and Forty scholarship applicant must attend an accredited school of nursing or a accredited respiratory therapist program. The scholarship amount is $3,000 annually which shall be administered by the college/university or therapist program financial office.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>001991</td>
<td>Association of Nurses in AIDS Care (ANAC) Nursing Research Grant</td>
<td>American Nurses Foundation, Inc.</td>
<td>01-May-2020</td>
<td>5,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Elizabeth Franzino</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-628-5305</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:GiveToNursing@ana.org">GiveToNursing@ana.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>01-May-2020</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The American Nurses Foundation (Foundation) Nursing Research Grants (NRG) Program encourages the research career development of all nurses. ANF provides funds to beginner and experienced nurse researchers working in HIV, HIV comorbidities and HIV-related prevention, care, treatment and/or research.

<table>
<thead>
<tr>
<th>Project Code</th>
<th>Project Title</th>
<th>Sponsor Organization</th>
<th>Deadline Dates</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>090301</td>
<td>Public Service Award</td>
<td>American Society for Cell Biology</td>
<td>15-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>301-347-9300</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:ascbinfo@ascb.org">ascbinfo@ascb.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td>[Link to sponsor website]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td>[Link to program URL]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>15-May-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>The ASCB Public Service Award recognizes outstanding national leadership in support of biomedical research.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>011588</td>
<td>ASH Scholar Award -- Scholar Award for Junior Faculty</td>
<td>American Society of Hematology</td>
<td>01-May-2020 [LOI/Pre-App]</td>
<td>150,000 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>202-776-0544</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:awards@hematology.org">awards@hematology.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td>[Link to sponsor website]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td>[Link to program URL]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>01-May-2020 [LOI/Pre-App], 01-Aug-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>The ASH Scholar Awards are designed to support hematologists who have chosen a career in research by providing partial salary or other support during that critical period required for completion of training and achievement of status as an independent investigator. The Scholar Award for Junior Faculty provides up to $150,000.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>058655</td>
<td>Chronic Pain Medicine Research Grant</td>
<td>American Society of Regional Anesthesia and Pain Medicine</td>
<td>01-May-2020 [LOI/Pre-App]</td>
<td>200,000 USD</td>
</tr>
</tbody>
</table>
### Synopses

**ASRA Chronic Pain Medicine Research Grant**

The ASRA Chronic Pain Medicine Research Grant aims to promote and facilitate high quality research in pain medicine. Results of such research will guide clinical practice for pain physicians and improve patient health care. This research is needed to evaluate the efficacy and safety of pain interventions and treatments.

### Contact Information

- **Contact Name:**
- **Contact Telephone:** 412-471-2718
- **Contact Email:** asraassistant@asra.com
- **Sponsor Website:** [Link to sponsor website](#)
- **Program URL:** [Link to program URL](#)

**Deadline Dates (ALL):** 01-May-2020 [LOI/Pre-App], 01-Sep-2020

### Research Grants

**Australian Collaborative Education Network (ACEN)**

**Synopsis:** The Australian Collaborative Education Network (ACEN) is offering funding for three Work Integrated Learning (WIL) research grants up to $10,000 each and two grants of $5,000 for Emergent and/or Early Career Researchers.

**Contact Name:**
- **Contact Telephone:**
- **Contact Email:** admin@acen.edu.au
- **Sponsor Website:** [Link to sponsor website](#)
- **Program URL:** [Link to program URL](#)

**Deadline Dates (ALL):** 15-May-2020

### Eureka Prize for Promoting Understanding of Science

**Australian Museum**

**Synopsis:**

- **Synopsis:**
- **Contact Name:**
- **Contact Telephone:** (02) 9320 6483
- **Contact Email:** eureka@austmus.gov.au
- **Sponsor Website:** [Link to sponsor website](#)

**Deadline Dates (ALL):** 01-May-2020

---

<table>
<thead>
<tr>
<th>Program Code</th>
<th>Program Name</th>
<th>Sponsor Name</th>
<th>Duration</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>064024</td>
<td>Research Grants</td>
<td>Australian Collaborative Education Network (ACEN)</td>
<td>15-May-2020</td>
<td>6,600 USD</td>
</tr>
<tr>
<td>058686</td>
<td>Eureka Prize for Promoting Understanding of Science</td>
<td>Australian Museum</td>
<td>01-May-2020</td>
<td>6,600 USD</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>---------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>01-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The Celestino Eureka Prize for Promoting Understanding of Science is awarded to an individual scientist who has shared their expertise with a broad audience - informing, enthusing and engaging the public. The prize amount is $10,000.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>066579</th>
<th>Research Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bath Institute for Rheumatic Diseases</td>
<td>31-May-2020</td>
</tr>
<tr>
<td>Contact Name</td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>01225 336363</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:BIRD@birdbath.org.uk">BIRD@birdbath.org.uk</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>31-May-2020 , 30-Nov-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>BIRD funds research and supports the next generation of researchers into bone and joint diseases.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>089251</th>
<th>Medical Education Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biogen, Inc.</td>
<td>15-May-2020</td>
</tr>
<tr>
<td>Contact Name</td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>617-914-1299</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:grantsandgiving@biogen.com">grantsandgiving@biogen.com</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>Biogen provides funding to an eligible institution or organization to support independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>089255</th>
<th>General Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biogen, Inc.</td>
<td>15-May-2020</td>
</tr>
<tr>
<td>Contact Name</td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>Contact Telephone</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
</tr>
<tr>
<td></td>
<td>617-914-1299</td>
</tr>
<tr>
<td></td>
<td>617-914-1299</td>
</tr>
<tr>
<td>Michele Ciapa</td>
<td>301-459-1999</td>
</tr>
</tbody>
</table>
The BMES Diversity Award honors an individual, project, organization, or institution for outstanding contributions to improving gender and racial diversity in biomedical engineering. The award is given for a broad range of activities, including research, education, and service improving diversity in the biomedical engineering industry and/or academia. The award seeks to recognize lifetime achievements as well as innovative and/or high impact activities.

<table>
<thead>
<tr>
<th>ID</th>
<th>Fellowship Name</th>
<th>Sponsor</th>
<th>Contact Name</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>028376</td>
<td><strong>David Phillips Fellowship</strong></td>
<td>Biotechnology &amp; Biological Sciences Research Council</td>
<td>01793 413256</td>
<td><a href="mailto:postdoc.fellowships@bbsrc.ukri.org">postdoc.fellowships@bbsrc.ukri.org</a></td>
<td>Link to sponsor website</td>
<td>Sponsor Website</td>
<td>12-May-2020</td>
<td>1,290,000 USD</td>
<td>David Phillips Fellowships (DPF) provide support for researchers wishing to establish their first independent research group. Awards are for five years and include personal salary and a significant research support grant to enable fellows to establish their own independent research group.</td>
</tr>
<tr>
<td>039790</td>
<td><strong>Discovery Fellowships</strong></td>
<td>Biotechnology &amp; Biological Sciences Research Council</td>
<td>01793 413256</td>
<td><a href="mailto:postdoc.fellowships@bbsrc.ukri.org">postdoc.fellowships@bbsrc.ukri.org</a></td>
<td>Link to sponsor website</td>
<td>Sponsor Website</td>
<td>12-May-2020</td>
<td>387,000 USD</td>
<td>The Discovery Fellowship (DF) will provide support for researchers wishing to undertake independent research and gain leadership skills. The DF will support the transition of early stage researchers to fully independent research</td>
</tr>
</tbody>
</table>
leaders. As such DFs represent part of BBSRC’s commitment to the supply of highly skilled professional scientists to the UK.

<table>
<thead>
<tr>
<th>089230</th>
<th><strong>Strategic Priorities Fund: Centre for Doctoral Training (CDT) in Food Systems</strong></th>
<th>Biotechnology &amp; Biological Sciences Research Council</th>
<th>13-May-2020</th>
<th>6,450,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:food.systems@bbsrc.ukri.org">food.systems@bbsrc.ukri.org</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>13-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>This £5 million call will support one Centre for Doctoral Training (CDT) focused on developing the next generation of interdisciplinary food systems thinkers. This CDT will ensure a pipeline of skilled individuals who are able to apply holistic and critical interdisciplinary food systems thinking to health and sustainability challenges in academia, government, business and civil society organisations, and who will lead the way in transforming the UK food system. It will support three cohorts of doctoral candidates beginning in October 2021 and as a legacy will develop the next generation of food system thinkers.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>052118</th>
<th><strong>Collaborative Training Partnerships (CTP2)</strong></th>
<th>Biotechnology &amp; Biological Sciences Research Council</th>
<th>05-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Name</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:ctp@bbsrc.ukri.org">ctp@bbsrc.ukri.org</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>05-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>UKRI-BBSRC are pleased to announce the second call for BBSRC Collaborative Training Partnerships (CTP2). The UKRI-</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
BBSRC Collaborative Training Partnerships (CTP) scheme is a doctoral training programme directed at industrial research challenges and delivered by consortia led by businesses in collaboration with Research Organisations. Its ambition is to build capacity and address strategic skills challenges in the UK bioeconomy at doctoral level and provide candidates with the research, innovation and transferable skills needed to be competitive for high-quality jobs in the labour markets of the bioeconomy, academia and beyond.

<table>
<thead>
<tr>
<th>036817</th>
<th>Specialist Registrar Travel and Start-Up Grants</th>
<th>British Geriatrics Society</th>
<th>01-May-2020</th>
<th>12,900 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>020 7608 8574</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:scientificofficer@bgs.org.uk">scientificofficer@bgs.org.uk</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>01-May-2020, 30-Nov-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>Specialist Registrar (SpR) Research Start Up grant offers up to four grants a year of up to £10,000 each, to support research-related activities in geriatric medicine. The grant is intended to provide some financial assistance for young doctors which is not already available from other sources. The scheme provides grants to enable SpR’s to follow through ideas at relatively short notice, to enable advantage to be taken of unique or rare opportunities, to provide short-term assistance to speculative and innovative research that may be at an early stage. These grants support a complete project or, where appropriate, support a pilot study to enable an application for external project grant support to be made. If this is the case, the rationale and timescale for such an application should be made clear in the application.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>045337</th>
<th>Travel Awards</th>
<th>British Society for Immunology</th>
<th>01-May-2020</th>
<th>1,290 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Sarah Green</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>+44 (0)20 3019 5901</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:s.green@immunology.org">s.green@immunology.org</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Synopsis
The BSI will support the travel costs for members who wish to attend meetings and congresses, both domestic and international; or, for example, those who wish to visit laboratories for specific short-term activities, such as collaborative research, or in order to learn new techniques. Maximum awards are currently as follows: £500 for travel within the UK; £700 for European travel and £1000 for rest of the World.

### Deadline Dates (ALL)
01-May-2020, 01-Aug-2020, 01-Nov-2020

### Contact Name
Carol Sloan RDN, FAND, Health Research Director

### Contact Telephone
916-932-7070

### Contact Email
csloan@walnuts.org

### Sponsor Website
[Link to sponsor website](#)

### Program URL
[Link to program URL](#)

---

<table>
<thead>
<tr>
<th>074616</th>
<th>Research Grants</th>
<th>California Walnut Commission</th>
<th>02-Mar-2020 [LOI/Pre-App]</th>
<th>500,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Carol Sloan RDN, FAND, Health Research Director</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>916-932-7070</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:csloan@walnuts.org">csloan@walnuts.org</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td><a href="#">Link to sponsor website</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>02-Mar-2020 [LOI/Pre-App], 18-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The California Walnut Commission (CWC) is currently soliciting Letters of Intent (LOI) for human clinical and observational studies in the areas of: walnuts in gut microbiome function and overall health outcomes such as lipid metabolism or other microbial metabolites; and, walnuts in body weight, body composition and/or obesity. In addition CWC is soliciting Letters of Intent (LOI) for a meta-analysis and/or systematic review on walnuts and cognitive health in humans.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>089338</th>
<th>Catalyst Grant : Health Effects of Vaping</th>
<th>Canadian Institutes of Health Research</th>
<th>25-Mar-2020 [LOI/Pre-App]</th>
<th>75,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>613-954-1968</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:support@cihr-irsc.gc.ca">support@cihr-irsc.gc.ca</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Research on vaping will be directly relevant for healthcare workers, policymakers, parents, teachers, and youth, and help to develop the evidence base upon which to build future policies and regulations related to vaping. As a result, CIHR and its Institutes of Circulatory and Respiratory Health; Cancer Research; Human Development, Child and Youth Health; and Neurosciences, Mental Health and Addiction, are launching a one-year catalyst grant opportunity to provide funding for research aimed at further understanding the health effects of vaping.

<table>
<thead>
<tr>
<th>ID</th>
<th>Program Name</th>
<th>Sponsor</th>
<th>Deadline Dates (ALL)</th>
<th>Funding Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>035945</td>
<td>Senior Cancer Research Fellowship</td>
<td>Cancer Research UK</td>
<td>21-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td>095984</td>
<td>Career Establishment Awards</td>
<td>Cancer Research UK</td>
<td>21-May-2020</td>
<td>1,290,000 USD</td>
</tr>
</tbody>
</table>

Contact Name: Dr. Lorenzo de la Rica
Contact Telephone: +44 (0)20 3469 5215
Contact Email: fellowships@cancer.org.uk
Sponsor Website: [Link to sponsor website](#)
Program URL: [Link to program URL](#)
Deadline Dates (ALL): 21-May-2020
Synopsis: The Senior Cancer Research Fellowship supports group leaders to further develop their own research programme and build their reputation as a world-leader in their cancer research field.

Contact Name: [Not Specified]
Contact Telephone: +44 0 20 3469 5215
Contact Email: fellowships@cancer.org.uk
Sponsor Website: [Link to sponsor website](#)
Program URL: [Link to program URL](#)
Deadline Dates (ALL): 21-May-2020
Synopsis: The Career Establishment Award supports new group leaders who have a salaried independent position to establish their own independent research group. Funding support is provided for up to six years, or equivalent duration for part-
<table>
<thead>
<tr>
<th>ID</th>
<th>Fellowship Type</th>
<th>Sponsor</th>
<th>Application Deadline</th>
<th>Funding Available</th>
</tr>
</thead>
<tbody>
<tr>
<td>074272</td>
<td>Career Development Fellowship</td>
<td>Cancer Research UK</td>
<td>21-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td><strong>Contact Name</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Telephone</strong></td>
<td>0203 469 5452</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Email</strong></td>
<td><a href="mailto:fellowships@cancer.org.uk">fellowships@cancer.org.uk</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>21-May-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Synopsis</strong></td>
<td>The Career Development Fellowship supports new group leaders who do not have a salaried independent position to establish their own independent research group. Funding support is provided for up to six years, or equivalent duration for part-time working.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>027490</td>
<td>Travelling Fellowships - Disease Models and Mechanisms</td>
<td>Company of Biologists</td>
<td>06-Mar-2020</td>
<td>3,225 USD</td>
</tr>
<tr>
<td></td>
<td><strong>Contact Name</strong></td>
<td>Charity Administrator</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Telephone</strong></td>
<td>+44 (0) 1223 632850</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Email</strong></td>
<td><a href="mailto:tf@biologists.com">tf@biologists.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Synopsis</strong></td>
<td>The Company of Biologists' journal &quot;Disease Models &amp; Mechanisms&quot; offers fellowships of up to £2,500 or currency equivalent to graduate students and post-doctoral researchers wishing to make collaborative visits to other laboratories.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>000055</td>
<td>Research Fellowship Awards</td>
<td>Crohn's &amp; Colitis Foundation of America</td>
<td>05-May-2020 [LOI/Pre-App]</td>
<td>174,750 USD</td>
</tr>
<tr>
<td></td>
<td><strong>Contact Name</strong></td>
<td>Orlando Green</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Program Name</td>
<td>Sponsor</td>
<td>Deadline Dates (ALL)</td>
<td>Synopsis</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>001440</td>
<td>Career Development Awards</td>
<td>Crohn's &amp; Colitis Foundation of America</td>
<td>05-May-2020 [LOI/Pre-App]</td>
<td>270,000 USD                                                                                                                                                                             The goal of the Career Development Award (CDA) is to encourage a career of independent basic and/or clinical investigation in the area of Crohn's disease and ulcerative colitis research.</td>
</tr>
<tr>
<td>083322</td>
<td>Crohn's &amp; Colitis Foundation/NASPGHAN IBD Young Investigator Award</td>
<td>Crohn's &amp; Colitis Foundation of America</td>
<td>05-May-2020 [LOI/Pre-App]</td>
<td>Not Specified</td>
</tr>
</tbody>
</table>
### Litwin IBD Pioneers Initiative

**Contact Name:**

646-943-7505

**Contact Email:**

grant@crohnscolitisfoundation.org

**Deadline Dates (ALL):**

05-May-2020 [LOI/Pre-App], 20-Jul-2020, 05-Nov-2020 [LOI/Pre-App], 28-Jan-2021

**Synopsis:**

This three-year grant, in partnership with the NASPghan Foundation and the Crohn’s & Colitis Foundation, is available to research fellows or junior faculty. Applications must propose original clinical, translational, epidemiological, or basic scientific research related to pediatric inflammatory bowel disease.

### Clinical Research Scholars Program Award

**Contact Name:**

301-841-2614

**Contact Email:**

grants@cff.org

**Deadline Dates (ALL):**

28-Feb-2020 [LOI/Pre-App], 21-May-2020

**Synopsis:**

The Clinical Research Scholars Program Award (CRSP) Award will enable outstanding early-career pediatricians and
internists to enhance their clinical research proficiency and to develop the necessary clinical research capabilities to become independent investigators who formulate and lead multi-center, clinical research studies. This award provides up to three years of support (up to 20 percent FTE per year), as well as travel support for meetings required as part of the CRSP Award. A limited number of scholars are accepted each year. The scholars will begin the program at the same time and will together attend two one-week sessions based at the CFF TDNCC (in Seattle, WA). Prospective applicants will be required to outline a mentorship plan and identify mentor(s) at their home institution who will continue in this role after they complete the program. Ideally, a mentor (or mentors) along with a mentorship plan will have been in place before applicants apply and program participation begins. Evidence of the institution’s commitment to the applicant’s research and development must be provided in the application. Applications addressing the following areas (in order of prioritization) are particularly encouraged: 1. Respiratory Microorganism Detection and Treatment 2. Gastrointestinal symptoms (including, but not limited to, GERD, DIOS, and Pancreatitis) 3. Reducing Treatment Burden 4. CF-related Diabetes 5. Diet and Nutrition 6. Mental Health 7. CF-related Liver Disease (including cirrhosis and non-cirrhosis, gall stones, hepatic steatosis, and other clinical manifestations of portal hypertension) 8. Exercise 9. Sinus Disease 10. Allergies and Asthma in CF 11. Alternative/Holistic Treatments and Therapies 12. Sexual Reproductive Health 13. Bone/Joint Heath 14. Pain Management

<table>
<thead>
<tr>
<th>011112</th>
<th>Research Project Grants</th>
<th>Dunhill Medical Trust</th>
<th>15-May-2020 [LOI/Pre-App]</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td><a href="mailto:admin@dunhillmedical.org.uk">admin@dunhillmedical.org.uk</a></td>
<td>Link to program URL</td>
<td>Link to sponsor website</td>
<td>Dunhill Medical Trust</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>020 7403 3299</td>
<td>15-May-2020 [LOI/Pre-App], 28-Aug-2020 [LOI/Pre-App]</td>
<td>The Dunhill Medical Trust (DMT) supports high quality research projects which are, perhaps, smaller than can be managed by the Research Councils or fall outside their priority themes but are important to understanding the mechanisms of ageing, treating disease and frailty and identifying and developing new and effective ways to improve the lives of older people.</td>
<td>328</td>
</tr>
<tr>
<td>Code</td>
<td>Program Title</td>
<td>Sponsor</td>
<td>Deadline Dates (ALL)</td>
<td>Contact Name</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------</td>
<td>-----------------------</td>
<td>----------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>089473</td>
<td>Intra-Africa Academic Mobility Scheme</td>
<td>EACEA/07/2020</td>
<td>19-May-2020</td>
<td>Ms María Luisa GARCIA MINGUEZ</td>
</tr>
<tr>
<td>022318</td>
<td>Research Grants</td>
<td>Ekhaga Foundation</td>
<td>20-May-2020</td>
<td></td>
</tr>
<tr>
<td>057143</td>
<td>Young Investigator Travel Scholarships</td>
<td>European Association of Neuro-Oncology</td>
<td>04-May-2020</td>
<td></td>
</tr>
<tr>
<td>Sponsorship</td>
<td>Description</td>
<td>Contact Name</td>
<td>Contact Telephone</td>
<td>Contact Email</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
<td>--------------</td>
<td>------------------</td>
<td>---------------</td>
</tr>
<tr>
<td><strong>001887</strong> One-year Scholarship</td>
<td>European Association of Urology</td>
<td>Angela Terberg</td>
<td>+31(0)26 389 06 80</td>
<td><a href="mailto:eusp@uroweb.org">eusp@uroweb.org</a></td>
</tr>
<tr>
<td><strong>086392</strong> Foundations for Tomorrow’s Industry -- Open Innovation Test Beds for Nano-Pharmaceuticals Production</td>
<td>European Commission</td>
<td>See notes</td>
<td>See notes</td>
<td>Link to sponsor website</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>---------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>14-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>This topic will address the challenge: Open Innovation Test Beds for nano-pharmaceuticals production (IA) The topic is part of the call: Foundations for Tomorrow’s Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>086424</th>
<th>Transforming European Industry -- Biological Scaffolds for Tissue Regeneration and Repair (RIA)</th>
<th>European Commission</th>
<th>NMBP-21-2020</th>
<th>14-May-2020</th>
<th>6,480,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td>See notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>14-May-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>This topic will address the challenge: Biological scaffolds for tissue regeneration and repair (RIA). The topic is part of the call: Transforming European Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>086422</th>
<th>Transforming European Industry -- Next Generation Organ-on-Chip (RIA-LS)</th>
<th>European Commission</th>
<th>DT-NMBP-23-2020</th>
<th>14-May-2020</th>
<th>6,480,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td>See notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>14-May-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Synopsis
This topic will address the challenge: Next generation organ-on-chip (RIA-LS). The topic is part of the call: Transforming European Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.

<table>
<thead>
<tr>
<th>086406</th>
<th>Transforming European Industry -- Multi-Omics for Genotype-Phenotype Associations (RIA)</th>
<th>European Commission</th>
<th>BIOTEC-07-2020</th>
<th>14-May-2020</th>
<th>8,640,000 USD</th>
</tr>
</thead>
</table>

Contact Name
See notes
Contact Telephone
See notes
Contact Email: See notes
Sponsor Website: See notes
Program URL: See notes
Deadline Dates (ALL): 14-May-2020

Synopsis
This topic will address the challenge: Multi-omics for genotype-phenotype associations (RIA). The topic is part of the call: Transforming European Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.

<table>
<thead>
<tr>
<th>089434</th>
<th>ECSEL Joint Undertaking - ECSEL-2020-2-RIA</th>
<th>European Commission</th>
<th>ECSEL-2020-2-RIA</th>
<th>05-May-2020 [LOI/Pre-App]</th>
<th>12,960,000 USD</th>
</tr>
</thead>
</table>

Contact Name
See notes
Contact Telephone: 00 32 2 221 81 02
Contact Email: calls@ecsel.europa.eu
Sponsor Website: See notes
Program URL: See notes
Deadline Dates (ALL): 05-May-2020 [LOI/Pre-App], 16-Sep-2020

Synopsis
An ECSEL Research and Innovation Action (RIA) primarily consists of activities aiming to establish new knowledge and/or to explore the feasibility of a new or improved technology, product, process, service, method, tool or solution. For this purpose they may include applied research, technology development and/or method/tool and integration,
testing and validation on a small-scale prototype in a laboratory or simulated environment. The activities have their centre of gravity at TRL 3-4. Projects on particular topics such as the ones discussed in the Long Term Vision chapter of the MASP naturally have activities in the lower TRLs. A RIA proposal is characterised by: Execution by a consortium that may consist of SMEs, large enterprises, universities, institutes, public organizations; Developing innovative technologies and/or using them in innovative ways; Targeting demonstration of the innovative approach in a relevant product, service or capability, clearly addressing the applications relevant for societal challenges in relation with the ECSEL Strategic Thrusts as outlined in the ECSEL MASP; Demonstrating value and potential in a realistic lab environment reproducing the targeted application; Having a deployment plan showing the valorisation for the ECSEL ecosystem and the contribution to the ECSEL goals and objectives. In order to maximize effective implementation of the ECSEL top-level objectives, the list of RIA proposals to be retained for public funding shall constitute a balanced portfolio of projects developing innovative technologies (as defined in the MASP in the essential technology section) and applying them in different domains as defined in the MASP (as defined in the application trust section).

<p>| OCR confidence level: | 99% |</p>
<table>
<thead>
<tr>
<th>Contact Telephone</th>
<th>Contact Email</th>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>See notes</td>
<td>Link to sponsor website</td>
<td>Link to program URL</td>
<td>14-May-2020</td>
<td>This topic will address the challenge: Reprogrammed microorganisms for biological sensors (IA). The topic is part of the call: Transforming European Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.</td>
</tr>
</tbody>
</table>

**075006 EIC Horizon Prize for ‘Early Warning for Epidemics’**  
European Commission  
31-May-2020  
5,400,000 USD  
**Contact Name**  
**Contact Email**  
EC-EPIDEMICS-EIC-PRIZE@EC.EUROPA.EU  
**Sponsor Website**  
Link to sponsor website  
**Program URL**  
Link to program URL  
**Deadline Dates (ALL)**  
31-May-2020 [LOI/Pre-App], 01-Sep-2020  
**Synopsis**  
The European Commission shall award a prize of 5 Million Euros for a challenge to develop a scalable, reliable and cost-effective early warning system prototype to forecast and monitor vector-borne diseases in order to contribute to the prevention of outbreaks mitigating their impact on local, regional and global scales and providing support to existing elimination efforts.

**086398 Foundations for Tomorrow’s Industry -- Safe by Design, from Science to Regulation: Multi-Component Nanomaterials (RIA)**  
European Commission  
NMBP-16-2020  
14-May-2020  
8,640,000 USD  
**Contact Name**  
**Contact Telephone**
This topic will address the challenge: Safe by design, from science to regulation: multi-component nanomaterials (RIA). The topic is part of the call: Foundations for Tomorrow’s Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.

086427  Industrial Sustainability -- Materials for Off Shore Energy (IA)  European Commission  LC-NMBP-31-2020  14-May-2020  7,560,000 USD

<table>
<thead>
<tr>
<th>Program URL</th>
<th>Link to program URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deadline Dates (ALL)</td>
<td>14-May-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>This topic will address the challenge: Open Innovation Test Beds for materials for building envelopes (IA) The topic is part of the call: Foundations for Tomorrow’s Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.</td>
</tr>
<tr>
<td>086393</td>
<td><strong>Foundations for Tomorrow’s Industry -- Open Innovation Platform for Materials Modelling (RIA)</strong></td>
</tr>
<tr>
<td>Contact Name</td>
<td>See notes</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>See notes</td>
</tr>
<tr>
<td>Contact Email</td>
<td>See notes</td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>14-May-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>This topic will address the challenge: Open Innovation Platform for Materials Modelling (RIA) The topic is part of the call: Foundations for Tomorrow’s Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.</td>
</tr>
<tr>
<td>086396</td>
<td><strong>Foundations for Tomorrow’s Industry -- Creating an Open Market Place for Industrial Data (RIA)</strong></td>
</tr>
<tr>
<td>Contact Name</td>
<td>See notes</td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>See notes</td>
</tr>
<tr>
<td>Contact Email</td>
<td>See notes</td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>14-May-2020</td>
</tr>
<tr>
<td>Synopsis</td>
<td>This topic will address the challenge: Open Innovation Platform for Materials Modelling (RIA) The topic is part of the call: Foundations for Tomorrow’s Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.</td>
</tr>
</tbody>
</table>
Synopsis
This topic will address the challenge: Creating an open market place for industrial data (RIA) The topic is part of the call: Foundations for Tomorrow’s Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.


| Contact Name | See notes |
| Contact Telephone |  |
| Contact Email |  |
| Sponsor Website | Link to sponsor website |
| Program URL | Link to program URL |
| Deadline Dates (ALL) | 14-May-2020 |

Synopsis
This topic will address the challenge: Open Innovation Test Beds for nano-enabled bio-based materials (IA) The topic is part of the call: Foundations for Tomorrow’s Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.


| Contact Name | See notes |
| Contact Telephone |  |
| Contact Email |  |
| Sponsor Website | Link to sponsor website |
| Program URL | Link to program URL |
| Deadline Dates (ALL) | 14-May-2020 |

Synopsis
This topic will address the challenge: Towards harmonised characterisation protocols in NMBP (RIA) The topic is part of the call: Foundations for Tomorrow’s Industry under the The Leadership in Enabling and Industrial Technologies (LEIT) part of Horizon 2020: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology.
<table>
<thead>
<tr>
<th>Program ID</th>
<th>Program Name</th>
<th>Sponsor Organization</th>
<th>Deadline Dates (ALL)</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>022329</td>
<td>Education and Training Bursaries</td>
<td>European Federation for Immunogenetics</td>
<td>01-May-2020</td>
<td>1,620 USD</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>Sandra van Hensbergen</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Telephone</td>
<td>+31(0)71-5265111</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:ajvanhensbergen@lumc.nl">ajvanhensbergen@lumc.nl</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>01-May-2020 , 01-Aug-2020 , 01-Nov-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>The European Federation for Immunogenetics (EFI) offers a fixed number of bursaries to EFI members wishing to visit another laboratory to learn new techniques and to develop research collaborations. The duration of the stay should be between 1 and 4 weeks approximately.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>019315</td>
<td>ESCMID Funded Observerships</td>
<td>European Society of Clinical Microbiology and Infectious Diseases</td>
<td>26-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td>Contact Name</td>
<td>+41 61 5080 153</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contact Email</td>
<td><a href="mailto:observership@escmid.org">observership@escmid.org</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deadline Dates (ALL)</td>
<td>26-May-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synopsis</td>
<td>To facilitate international training and collaboration, ESCMID encourages its Young Scientist Members to visit ESCMID Collaborative Centres (most often departments of infectious diseases and/or clinical microbiology) in other countries for five days to one month under the auspices of ESCMID.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>058307</td>
<td>ETA Research Grants</td>
<td>European Thyroid Association</td>
<td>04-May-2020</td>
<td>21,600 USD</td>
</tr>
</tbody>
</table>
### General Request for Applications (RFA)

**Foundation for Prader-Willi Research**  

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Jessica Bohonowych</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>888-322-5487</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:jessica.bohonowych@fpwr.org">jessica.bohonowych@fpwr.org</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>06-Mar-2020 [LOI/Pre-App], 08-May-2020</td>
</tr>
</tbody>
</table>

**Synopsis**

The Foundation for Prader-Willi Research (FPWR), a nonprofit organization dedicated to supporting research to advance the understanding and treatment of Prader-Willi syndrome (PWS), announces the availability of funds to support innovative PWS research. FPWR is particularly interested in supporting projects that will lead to new treatments to alleviate the symptoms associated with PWS.

---

### Grant Program

**Foundation for Prader-Willi Research**  

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Jessica Bohonowych</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td>888-322-5487</td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:Jessica.Bohonowych@fpwr.org">Jessica.Bohonowych@fpwr.org</a></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>06-Mar-2020 [LOI/Pre-App], 08-May-2020</td>
</tr>
</tbody>
</table>

**Synopsis**

The European Thyroid Association's aims are to promote knowledge in the thyroid field (fundamental and clinical) and improve knowledge of the thyroid gland and its diseases.
<table>
<thead>
<tr>
<th>Sponsor Website</th>
<th>Program URL</th>
<th>Deadline Dates (ALL)</th>
<th>Synopsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Link to sponsor website</td>
<td>Link to program URL</td>
<td>06-Mar-2020 [LOI/Pre-App], 08-May-2020</td>
<td>The Foundation for Prader-Willi Research (FPWR) supports research to advance the understanding and treatment of Prader-Willi syndrome (PWS).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>001921</th>
<th>Bower Award and Prize for Achievement in Science</th>
<th>Franklin Institute</th>
<th>30-Apr-2020 [LOI/Pre-App]</th>
<th>250,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Beth Scheraga, Director of the Awards Program</td>
<td>Contact Telephone</td>
<td>215-448-1329</td>
<td>Contact Email</td>
</tr>
<tr>
<td>Contact Email</td>
<td>Sponsor Website</td>
<td>Program URL</td>
<td>Deadline Dates (ALL)</td>
<td>30-Apr-2020 [LOI/Pre-App], 31-May-2020</td>
</tr>
<tr>
<td>Program URL</td>
<td>The Franklin Institute seeks nominations for the 2021 Bower Award and Prize for Achievement in Science of individuals who have made significant contributions to the scientific understanding of decision-making. The interdisciplinary field of decision-making integrates theory and methods from economics, psychology, neuroscience, computer science, and related areas to understand the mechanisms through which individuals and groups choose among competing possibilities and how these mechanisms guide behavior.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>036255</th>
<th>Kyle Bryant Translational Research Award</th>
<th>Friedreich's Ataxia Research Alliance</th>
<th>15-May-2020 [LOI/Pre-App]</th>
<th>500,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Contact Telephone</td>
<td>Contact Email</td>
<td>Sponsor Website</td>
<td>Program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>Synopsis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-May-2020 [LOI/Pre-App], 15-Jul-2020</td>
<td>The Kyle Bryant Translational Research Award is given to proposals focused on pre-clinical and clinical investigations that will advance treatments for Friedreich's Ataxia.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>086725</th>
<th>Alpha-1 Antitrypsin Laurell's Training Award (ALTA)</th>
<th>Grifols</th>
<th>01-Mar-2020 [LOI/Pre-App]</th>
<th>54,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Contact Telephone</td>
<td>Contact Email</td>
<td>Sponsor Website</td>
<td>Program URL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Link to sponsor website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>Synopsis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01-Mar-2020 [LOI/Pre-App], 31-May-2020</td>
<td>A primary goal of the Alpha-1 Antitrypsin Laurell's Training Award (ALTA) is to identify and engage investigators (both physicians and scientists) who are early in their careers in a longstanding commitment to investigating alpha-1 antitrypsin deficiency (AATD). In awarding 2 grants, the goal/intention is to award one grant for a clinical proposal and a second for a basic research proposal. Another objective of the ALTA award is to strengthen the network between scientists and clinicians working in the field of AATD.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>088138</th>
<th>Healthy Heart Grants</th>
<th>Heart Research UK</th>
<th>24-Feb-2020</th>
<th>12,900 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Contact Telephone</td>
<td>Contact Email</td>
<td>Sponsor Website</td>
<td>Program URL</td>
</tr>
<tr>
<td></td>
<td>0113 234 7474</td>
<td><a href="mailto:info@heartresearch.org.uk">info@heartresearch.org.uk</a></td>
<td>Link to sponsor website</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>Synopsis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24-Feb-2020, 03-Apr-2020, 04-May-2020, 18-May-2020, 01-Jun-2020, 15-Jun-2020, 07-Sep-2020, 28-Sep-2020</td>
<td>HRUK and Subway offer grants of up £10,000 to selected projects that promote heart-healthy lifestyles to help communities to live healthier, happier, longer lives.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Program Name</td>
<td>Sponsor</td>
<td>Application Date</td>
<td>Amount</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>------------------</td>
<td>----------</td>
</tr>
<tr>
<td>022177</td>
<td><strong>Young Investigators Groups</strong></td>
<td>Helmholtz Association</td>
<td>04-May-2020</td>
<td>1,620,000 USD</td>
</tr>
<tr>
<td></td>
<td><em>Synopsis</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Helmholtz Young Investigator Groups offer early scientific</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>independence to international top talents. The funding generally</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>amounts to at least € 300,000 p.a. for five years with an option</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>of a permanent position in case of a positive evaluation.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>011382</td>
<td><strong>Diplomat Specialty Infusion Group/Hemophilia of North Carolina</strong></td>
<td>Hemophilia of North</td>
<td>01-May-2020</td>
<td>3,000 USD</td>
</tr>
<tr>
<td></td>
<td><em>Synopsis</em></td>
<td>Carolina Education</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The sponsor will award at least one scholarship to an applicant</td>
<td>Scholarships</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>pursuing education in a health related field. Scholarships</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>are awarded to persons affected by a bleeding disorder, including</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>anyone who: has been diagnosed with a bleeding disorder; is a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>caregiver of a child or adult affected by a bleeding disorder;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>or has a sibling or a parent in the same household affected by</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a bleeding disorder. <strong>Notes</strong>: See application page for more</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>details on specific criteria and application process.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>091302</td>
<td><strong>HIV Research Award</strong></td>
<td>HIV Medicine Association</td>
<td>08-May-2020</td>
<td>Not Specified</td>
</tr>
<tr>
<td></td>
<td><em>Synopsis</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The sponsor will award at least one scholarship to an applicant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>pursuing education in a health related field. Scholarships</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>are awarded to persons affected by a bleeding disorder, including</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>anyone who: has been diagnosed with a bleeding disorder; is a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>caregiver of a child or adult affected by a bleeding disorder;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>or has a sibling or a parent in the same household affected by</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a bleeding disorder. <strong>Notes</strong>: See application page for more</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>details on specific criteria and application process.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Name</td>
<td>703-299-1215</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:info@hivma.org">info@hivma.org</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>08-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The HIV Research Award recognizes HIVMA members (junior to mid-career, such as an associate professor or its equivalent) who have made outstanding contributions to HIV medicine in clinical or basic research.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 091303 | HIVMA Clinical Educator Award | HIV Medicine Association | 08-May-2020 | Not Specified |
| Contact Name | 703-299-1215 |
| Contact Email | info@hivma.org |
| Sponsor Website | Link to sponsor website |
| Program URL | Link to program URL |
| Deadline Dates (ALL) | 08-May-2020 |
| Synopsis | The Clinical Educator Award recognizes HIVMA members who have demonstrated significant achievement in the area of HIV clinical care and provider education. |

<p>| 024304 | Community Conference Grants: Knowledge Sharing with Families | Hospital for Sick Children Foundation/Sick Kids Foundation | 31-May-2020 | 3,750 USD |
| Contact Name | 416-813-6166 |
| Contact Email | <a href="mailto:national.grants@sickkidsfoundation.com">national.grants@sickkidsfoundation.com</a> |
| Sponsor Website | Link to sponsor website |
| Program URL | Link to program URL |
| Deadline Dates (ALL) | 31-May-2020, 30-Sep-2020 |</p>
<table>
<thead>
<tr>
<th><strong>089126</strong></th>
<th><strong>Innovation Scholars Secondments: Biomedical Sciences</strong></th>
<th>Innovate UK (Technology Strategy Board)</th>
<th>15-Apr-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synopsis</strong></td>
<td>The SickKids Foundation provides support for conferences, workshops, or symposia that are relevant to the health of Canada’s children.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Name</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Telephone</strong></td>
<td>0300 321 4357</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Email</strong></td>
<td><a href="mailto:support@innovateuk.gov.uk">support@innovateuk.gov.uk</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor Website</strong></td>
<td>Link to sponsor website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Program URL</strong></td>
<td>Link to program URL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Deadline Dates (ALL)</strong></td>
<td>15-Apr-2020, 13-May-2020, 01-Jul-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Synopsis</strong></td>
<td>UKRI invites applications for individuals from any discipline wishing to spend up to 36 months (full or part time) on secondment in the biomedical sciences sector.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>099685</strong></th>
<th><strong>Collaborative Activity Grants</strong></th>
<th>Institut de recherche Robert-Sauvé en santé et en sécurité du travail</th>
<th>09-Mar-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synopsis</strong></td>
<td>The Collaborative Activity Grant Program is generally applicable to work defined in collaboration with the IRSST, and whose cost and duration are more limited than for a research project. For the most part, a collaborative activity is work that falls within the IRSST’s priority themes and that is preliminary to or follows a research project. This work takes the form mainly of literature reviews; preliminary, exploratory or feasibility studies; statistical analyses; or expertise activities applying a proven methodology or promoting a technique, approach or product resulting from an</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
IRSST-funded project. Research priorities include: chemical and biological hazard prevention; mechanical and physical risk prevention; occupational rehabilitation; and sustainable prevention and work environment.

<table>
<thead>
<tr>
<th>049569</th>
<th>Clinical Research Program</th>
<th>International Society of Nephrology (ISN)</th>
<th>01-May-2020</th>
<th>20,000 USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td>Thomas Jacob, ISN Clinical Research Program Staff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>+32 2 808 0420</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:crp@theisn.org">crp@theisn.org</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td><a href="#">Link to sponsor website</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>01-May-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The Clinical Research Program funds screening and prevention programs as well as clinical research projects addressing local needs about kidney disease in emerging countries.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>025812</th>
<th>Fellowship Program</th>
<th>International Society of Nephrology (ISN)</th>
<th>01-May-2020</th>
<th>Not Specified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Telephone</td>
<td>+32 2 808 04 20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:fellowship@theisn.org">fellowship@theisn.org</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td><a href="#">Link to sponsor website</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program URL</td>
<td><a href="#">Link to program URL</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>01-May-2020, 01-Oct-2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synopsis</td>
<td>The ISN Fellowship Program provides relevant and contemporary nephrology training to physicians from low resource countries, with the ultimate goal of improving the standards of care in the Fellows' home countries upon their return and to help them become leaders in their fields.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| 081724 | Therapeutic Area Contributions - Infectious Diseases Program | Janssen Pharmaceuticals, Inc. | 31-Mar-2020 | Not Specified |</p>
<table>
<thead>
<tr>
<th>Contact Name</th>
<th>Margery Jacobson</th>
<th>Contact Telephone</th>
<th>908-218-6095</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Synopsis</td>
<td>The sponsor makes charitable contributions to support therapeutic area initiatives. Applications are evaluated competitively with emphasis given to innovative programs with measurable outcomes that address disparities or unmet needs. The Infectious Diseases area of interest supports the following disease states: Hepatitis B; HIV / AIDS; Respiratory Infections; and Vaccines.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ALK-positive Lung Cancer Research Award Program**

**Contact Name**
Margery Jacobson
**Contact Telephone**
312-407-6109
**Contact Email**
mjacobson@LUNGevity.org
**Sponsor Website**
Link to sponsor website
**Program URL**
Link to program URL
**Deadline Dates (ALL)**
01-May-2020
**Synopsis**
The ALK-positive Lung Cancer Research Award Program will fund high-impact research that seeks to transform the future for patients affected by ALK-positive non-small cell lung cancer by transforming advanced ALK-positive lung cancer into a chronic or curable condition. The program has two mechanisms: Transformational Award up to a maximum of $500,000 over two years; and, Clinical Trial Innovation Award up to a maximum of $750,000 over two years. This award is open to researchers at both U.S. and international institutions. Note that, at the time of application, international applicants must name a co-investigator at a U.S. institution.

**Career Development Awards for Translational Research**

**Contact Name**
Margery Jacobson
**Contact Telephone**
312-407-6109
**Contact Email**
mjacobson@LUNGevity.org
**Sponsor Website**
Link to sponsor website
**Program URL**
Link to program URL
**Deadline Dates (ALL)**
01-May-2020
**Synopsis**
The ALK-positive Lung Cancer Research Award Program will fund high-impact research that seeks to transform the future for patients affected by ALK-positive non-small cell lung cancer by transforming advanced ALK-positive lung cancer into a chronic or curable condition. The program has two mechanisms: Transformational Award up to a maximum of $500,000 over two years; and, Clinical Trial Innovation Award up to a maximum of $750,000 over two years. This award is open to researchers at both U.S. and international institutions. Note that, at the time of application, international applicants must name a co-investigator at a U.S. institution.

**Career Development Awards for Translational Research**

**Contact Name**
Margery Jacobson
**Contact Telephone**
312-407-6109
**Contact Email**
mjacobson@LUNGevity.org
**Sponsor Website**
Link to sponsor website
**Program URL**
Link to program URL
**Deadline Dates (ALL)**
01-May-2020
**Synopsis**
The ALK-positive Lung Cancer Research Award Program will fund high-impact research that seeks to transform the future for patients affected by ALK-positive non-small cell lung cancer by transforming advanced ALK-positive lung cancer into a chronic or curable condition. The program has two mechanisms: Transformational Award up to a maximum of $500,000 over two years; and, Clinical Trial Innovation Award up to a maximum of $750,000 over two years. This award is open to researchers at both U.S. and international institutions. Note that, at the time of application, international applicants must name a co-investigator at a U.S. institution.

**Career Development Awards for Translational Research**

**Contact Name**
Margery Jacobson
**Contact Telephone**
312-407-6109
**Contact Email**
mjacobson@LUNGevity.org
**Sponsor Website**
Link to sponsor website
**Program URL**
Link to program URL
**Deadline Dates (ALL)**
01-May-2020
**Synopsis**
The ALK-positive Lung Cancer Research Award Program will fund high-impact research that seeks to transform the future for patients affected by ALK-positive non-small cell lung cancer by transforming advanced ALK-positive lung cancer into a chronic or curable condition. The program has two mechanisms: Transformational Award up to a maximum of $500,000 over two years; and, Clinical Trial Innovation Award up to a maximum of $750,000 over two years. This award is open to researchers at both U.S. and international institutions. Note that, at the time of application, international applicants must name a co-investigator at a U.S. institution.

**Career Development Awards for Translational Research**

**Contact Name**
Margery Jacobson
**Contact Telephone**
312-407-6109
**Contact Email**
mjacobson@LUNGevity.org
**Sponsor Website**
Link to sponsor website
**Program URL**
Link to program URL
**Deadline Dates (ALL)**
01-May-2020
**Synopsis**
The ALK-positive Lung Cancer Research Award Program will fund high-impact research that seeks to transform the future for patients affected by ALK-positive non-small cell lung cancer by transforming advanced ALK-positive lung cancer into a chronic or curable condition. The program has two mechanisms: Transformational Award up to a maximum of $500,000 over two years; and, Clinical Trial Innovation Award up to a maximum of $750,000 over two years. This award is open to researchers at both U.S. and international institutions. Note that, at the time of application, international applicants must name a co-investigator at a U.S. institution.
<table>
<thead>
<tr>
<th>Contact Telephone</th>
<th>312-407-6109</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Email</td>
<td><a href="mailto:mjacobson@LUNGevity.org">mjacobson@LUNGevity.org</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>04-May-2020</td>
</tr>
</tbody>
</table>

**Synopsis**

LUNGevity’s Career Development Awards for Translational Research program was created with one goal: to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Research projects are restricted to translational lung cancer research, and the applicant must demonstrate the translational relevance of the research proposed. The CDAs are mentored awards; a mentoring plan is part of the required submission. The awards may be for a maximum of $100,000 (direct and indirect) per year for three years, for a maximum award of $300,000. The start date of 2020 Career Development Award’s grant term will be November 1, 2020.

<table>
<thead>
<tr>
<th>012474 Research Grants -- Population and Systems Medicine</th>
<th>Medical Research Council of the United Kingdom</th>
<th>20-May-2020</th>
<th>1,290,000 USD</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Contact Name</th>
<th>01793 416200</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Telephone</td>
<td><a href="mailto:RFPD@headoffice.mrc.ac.uk">RFPD@headoffice.mrc.ac.uk</a></td>
</tr>
<tr>
<td>Contact Email</td>
<td><a href="mailto:RFPD@headoffice.mrc.ac.uk">RFPD@headoffice.mrc.ac.uk</a></td>
</tr>
<tr>
<td>Sponsor Website</td>
<td>Link to sponsor website</td>
</tr>
<tr>
<td>Program URL</td>
<td>Link to program URL</td>
</tr>
<tr>
<td>Deadline Dates (ALL)</td>
<td>20-May-2020 , 23-Sep-2020</td>
</tr>
</tbody>
</table>

**Synopsis**

MRC research grants are suitable for focused research projects that may be short- or long-term in nature. In addition, they can be used to support method development or development and continuation of research facilities and may involve more than one research group or institution. Applications in the area of population and systems medicine are assessed by the Population and Systems Medicine Board (PSMB). PSMB supports mechanistic and applied research related to the physiology and pathophysiology of all the major organs and systems with the exception of the brain and the immune system. Its remit also reaches forward to population health and the impact of environmental factors, including the social environment, on health and development across the life course.
<table>
<thead>
<tr>
<th>Programme</th>
<th>Title</th>
<th>Sponsor</th>
<th>Deadline Dates</th>
<th>Contact Telephone</th>
<th>Contact Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>012464</td>
<td>New Investigator Research Grants -- Population and Systems Medicine</td>
<td>Medical Research Council of the United Kingdom</td>
<td>20-May-2020</td>
<td>01793 416200</td>
<td><a href="mailto:RFPD@headoffice.mrc.ac.uk">RFPD@headoffice.mrc.ac.uk</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Link to sponsor website</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Link to program URL</td>
</tr>
<tr>
<td></td>
<td>SYNOPSIS</td>
<td></td>
<td></td>
<td></td>
<td>The New Investigator Research Grant (NIRG) supports researchers towards becoming independent investigators. Applications in the area of population and systems medicine are assessed by the Population and Systems Medicine Board (PSMB). PSMB supports mechanistic and applied research related to the physiology and pathophysiology of all the major organs and systems with the exception of the brain and the immune system. Its remit also reaches forward to population health and the impact of environmental factors, including the social environment, on health and development across the life course.</td>
</tr>
<tr>
<td>032859</td>
<td>Programme Grants -- Population and Systems Medicine</td>
<td>Medical Research Council of the United Kingdom</td>
<td>20-May-2020</td>
<td>01793 416200</td>
<td><a href="mailto:RFPD@headoffice.mrc.ac.uk">RFPD@headoffice.mrc.ac.uk</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Link to sponsor website</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Link to program URL</td>
</tr>
<tr>
<td></td>
<td>SYNOPSIS</td>
<td></td>
<td></td>
<td></td>
<td>The Medical Research Council's Programme Grants provide larger, longer term, renewable programme funding. Applications in the area of population and systems medicine are assessed by the Population and Systems Medicine Board (PSMB). PSMB supports mechanistic and applied research related to the physiology and pathophysiology of all the major organs and systems with the exception of the brain and the immune system. Its remit also reaches forward to population health and the impact of environmental factors, including the social environment, on health and development across the life course.</td>
</tr>
</tbody>
</table>
to population health and the impact of environmental factors, including the social environment, on health and development across the life course.

032865  Partnership Grants -- Population and Systems Medicine  Medical Research Council of the United Kingdom  20-May-2020  Not Specified

Contact Name
Contact Telephone 01793 416200
Contact Email RFPD@headoffice.mrc.ac.uk
Sponsor Website Link to sponsor website
Program URL Link to program URL
Deadline Dates (ALL) 20-May-2020, 23-Sep-2020

Synopsis
Partnership grants provide core funds for one to five years to support partnerships between diverse groupings of researchers and can be used for infrastructure support, platform activities and for bringing together managed consortia or multidisciplinary collaborations. Applications in the area of population and systems medicine are assessed by the Population and Systems Medicine Board (PSMB). PSMB supports mechanistic and applied research related to the physiology and pathophysiology of all the major organs and systems with the exception of the brain and the immune system. Its remit also reaches forward to population health and the impact of environmental factors, including the social environment, on health and development across the life course.

032860  Programme Grants -- Neurosciences and Mental Health  Medical Research Council of the United Kingdom  27-May-2020  Not Specified

Contact Name
Contact Telephone 01793 416200
Contact Email RFPD@headoffice.mrc.ac.uk
Sponsor Website Link to sponsor website
Program URL Link to program URL
Deadline Dates (ALL) 27-May-2020, 30-Sep-2020
The Medical Research Council's Programme Grants provide larger, longer term, renewable programme funding. The Neurosciences and Mental Health Board (NMHB) is responsible for the MRC's investments in disorders of the human nervous system. This includes, and is underpinned, by fundamental research into the human nervous system, its normal development and function, which informs our understanding of the mechanism of disease. The Board’s strategy includes addressing the challenges of mental illness and neurodegenerative diseases as well as exploring what we can learn from the direct study of human brain tissue to gain insight into the human brain.